Scholars@Duke

• Background
• 

  Education, Training, & Certifications

  • Ph.D., University of North Carolina at Chapel Hill 1988
• 

  Duke Appointment History

  • Associate Professor of Biostatistics and Bionformatics, Biostatistics & Bioinformatics, Basic Science Departments 2000 - 2015
  • Associate Professor in Community and Family Medicine, Community and Family Medicine, Clinical Science Departments 2000
  • Assistant Research Professor in Community and Family Medicine, Community and Family Medicine, Clinical Science Departments 1998 - 1999
  • Assistant Professor in Community and Family Medicine, Community and Family Medicine, Clinical Science Departments 1988 - 1998
• Expertise
• 

  Subject Headings

  • Cardiovascular System
  • Cell Membrane
  • Neoplasm Invasiveness
  • Observer Variation
• Research
• 

  Selected Grants

  • Development of a Therapeutic for Brain Tumor Immunotherapy awarded by National Institutes of Health 2018 - 2023
  • Exploiting MTAP deletion for GBM therapeutics awarded by National Institutes of Health 2017 - 2022
  • CCL3 as a Developmental Therapeutic to Enhance Brain Tumor Therapy awarded by National Institutes of Health 2016 - 2021
  • Regional Oncolytic Poliovirus Immunotherapy for Breast Cancer awarded by Department of Defense 2016 - 2021
  • Poliovirus-Instigated APC Responses Against BRaf(V600E) for Pediatric Brain Tumor Immunotherapy awarded by V Foundation for Cancer Research 2018 - 2021
  • Lost and Found: The Bone Marrow as Counterproductive Site of T cell Sequestration in GBM awarded by Sontag Foundation 2015 - 2019
  • EGFRvIII-targeted Bispecific T cell Engagers for brain tumors awarded by National Institutes of Health 2013 - 2019
  • Brain tumors with regulatory T-cells treated with EGFRvIII-specific T-cells awarded by National Institutes of Health 2013 - 2019
  • Systemic EGFRvIII-targeted bispecific antibody as immunotherapy for glioblastoma awarded by National Institutes of Health 2015 - 2019
  • Ph 1/2 trial BMX-001 awarded by BioMimetix JV LLC 2015 - 2018
  • A clinically-relevant anti-CD27 agonist antibody as a vaccine adjuvant for brain tumor immunotherapy awarded by National Institutes of Health 2016 - 2018
  • Therapeutic Vaccine Targeting CMV Antigens in Glioblastoma awarded by Annias Immunotherapeutics, Inc. 2015 - 2018
  • Randomized Trial of Optimal Type of Aerobic Training in Breast Cancer awarded by Memorial Sloan Kettering Cancer Center 2015 - 2018
  • Brain Tumor Targeting Using Tumor-Specific Neuroimmunology awarded by National Institutes of Health 2014 - 2018
  • Improving Adherence to Recommended Surveillance in Breast Cancer Survivors awarded by National Institutes of Health 2010 - 2015
  • Adoptive Immunotherapy for GBM During Hematopoietic Recovery from Temozolomide awarded by National Institutes of Health 2009 - 2014
  • Targeting EGFRvIII in Brain Tumors with Bispecific Antibodies awarded by National Institutes of Health 2013 - 2014
  • (PQA5) 'Dose and Mechanisms of Exercise in Breast Cancer Prevention' awarded by National Institutes of Health 2013 - 2014
  • Aerobic Training During or After Adjuvant Therapy: A Randomized Trial awarded by National Institutes of Health 2012 - 2014
  • Phase II Trial of Aerobic Training in Metastatic Breast Cancer awarded by National Institutes of Health 2010 - 2014
  • Randomized Trial of Optimal Type of Aerobic Training in Breast Cancer awarded by National Institutes of Health 2010 - 2014
  • Modulation of the blood-tumor barrier through targeted suppression of claudin 5 awarded by National Institutes of Health 2011 - 2013
  • Reversal of CMV-specific immune deficits in patients with glioblastoma awarded by National Institutes of Health 2009 - 2013
  • Brain Tumors - Immunological and Biological Studies awarded by National Institutes of Health 2001 - 2013
  • Neuroimmunology of Vaccines in Adoptive T-cell Therapy for Brain Tumor awarded by National Institutes of Health 2010 - 2012
  • Pre-clinical Translation of Regulatory T-cell Inhibition in Brain Tumors awarded by National Institutes of Health 2010 - 2012
  • The Role of OTX2 in Molecular Pathogenesis of Medulloblastoma awarded by National Institutes of Health 2006 - 2012
  • Gene Targeted Therapy of Brain Tumors awarded by National Institutes of Health 2009 - 2012
  • Prospective Validation of Genomic Signatures of Chemosensitivity in NSCLC awarded by National Institutes of Health 2009 - 2010
  • Discovery of Biomarkers for Lung Cancer Metastasis awarded by National Institutes of Health 2005 - 2010
  • Effect on IL-2R Antibody on Regulatory T-cells in Patients with Malignant Gliomas awarded by National Institutes of Health 2008 - 2009
  • Palliative Oxygen for the Relief of Breathlessness awarded by National Institutes of Health 2006 - 2009
  • Serum Biomarkers for Early Diagnosis of NSCLC awarded by Johns Hopkins University 2007 - 2009
  • Stem Cell-Like Glioma Cells in Angiogenesis awarded by National Institutes of Health 2008 - 2009
  • DNA Methylation and GSTP1 Gene Regulation in Gliomas awarded by National Institutes of Health 2002 - 2008
  • Phase I/II Trial of ZD1839 and Celecoxib in Ex-Smokers awarded by National Institutes of Health 2002 - 2007
  • Measurement of Hypoxia in Non-Small Cell Lung Carcinoma awarded by National Institutes of Health 2002 - 2006
  • ACOSOG-Statistics and Data Coordinating Center awarded by National Institutes of Health 2000 - 2005
  • ZD1839 Therapy of Glioblastoma Multiforme awarded by National Institutes of Health 2001 - 2003
  • Using Plasma TGFB1 Levels to Escalate Radiotherapy Doses awarded by National Institutes of Health 2000 - 2003
  • Src On Primary And Matastatic Tumors Of The Cns awarded by National Institutes of Health 1994 - 1999
  • Src On Primary And Metastatic Tumors Of The Cns awarded by National Institutes of Health 1997 - 1999
  • Cancer Center Core Support Grant awarded by National Institutes of Health 1976 - 1998
  • Comprehensive Cancer Center Core Support Grant awarded by National Institutes of Health 1976 - 1998
  • Cancer And Leukemia Group B - Statistical Center awarded by National Institutes of Health 1994 - 1998
  • Cancer And Leukemia Group B Statistical Center awarded by National Institutes of Health 1982 - 1998
  • Src On Malignant Human Gliomas And Medulloblastomas awarded by National Institutes of Health 1992 - 1994
  • Comprehensive Cancer Center Core Support Grant awarded by National Institutes of Health 1992 - 1993
  • Cancer And Leukemia Group B Statistical Center awarded by National Institutes of Health 1992 - 1993
• Publications & Artistic Works
• 

  Selected Publications

  • Conference Papers

    • Affronti, ML, Randazzo, D, Peters, KB, Herndon, SC, Healy, P, II, HJE, Woodring, S, Hawkins, K, Lipp, ES, Kohrman, O, Desjardins, A, Vlahovic, G, Friedman, HS, Kim, J-Y, Miller, ES, and Schneider, S. "PILOT STUDY TO DESCRIBE THE TRAJECTORY OF SYMPTOMS AND ADAPTIVE STRATEGIES OF ADULTS LIVING WITH LOW GRADE GLIOMAS (LGG)." November 2017.  Link to Item
    • Babatunde, O, Kent, C, Mowery, Y, McSherry, F, II, HJE, Wright, A, Clough, R, Sperduto, W, and Kirkpatrick, JP. "LONG-TERM OUTCOMES FOLLOWING SURGERY AND/OR RADIATION THERAPY IN PATIENTS WITH HIGH-GRADE MENINGIOMA." November 2017.  Link to Item
    • Desjardins, A, Randazzo, D, Peters, KB, Johnson, MO, Massey, W, II, HJE, McSherry, F, Lipp, ES, Nadler, P, Horak, ID, and Friedman, HS. "PHASE 2 STUDY OF SYM004 FOR ADULT PATIENTS WITH RECURRENT GLIOBLASTOMA (GBM)." November 2017.  Link to Item
    • Dunn-Pirio, A, Woodring, S, Panta, S, Lipp, ES, Healy, P, II, HJE, Fountain, E, Desjardins, A, Randazzo, D, Friedman, HS, and Peters, KB. "PERAMPANEL FOR TREATMENT OF REFRACTORY SEIZURES IN PATIENTS WITH GLIOMAS." November 2017.  Link to Item
    • Peters, KB, Affronti, ML, Threatt, S, Healy, P, II, HJE, Lipp, ES, Panta, S, Randazzo, D, Friedman, HS, and Desjardins, A. "INCREASED FATIGUE ASSOCIATED WITH TUMOR PROGRESSION IN NEWLY DIAGNOSED GLIOBLASTOMA (GBM) PATIENTS." November 2017.  Link to Item
    • Peters, KB, Affronti, ML, Threatt, S, Healy, P, II, HJE, Lipp, ES, Panta, S, Randazzo, D, Friedman, HS, and Desjardins, A. "MAINTENANCE OF HEALTH RELATED QUALITY OF LIFE (QOL) BEYOND PROGRESSION IN NEWLY DIAGNOSED GLIOBLASTOMA PATIENTS TREATED WITH BEVACIZUMAB." November 2017.  Link to Item
    • Randazzo, D, McSherry, F, II, HJE, Affronti, ML, Healy, P, Lipp, ES, Desjardins, A, Friedman, HS, and Peters, KB. "A SINGLE INSTITUTION'S EXPERIENCE EXPLORING THE ASSOCIATION OF INTEGRATIVE MEDICINE AND SURVIVORSHIP IN GLIOBLASTOMA." November 2017.  Link to Item
    • Weant, MP, Kirkpatrick, J, Johnson, M, Dunn-Pirio, A, Healy, P, II, HJE, Lipp, ES, Fountain, E, Desjardins, A, Randazzo, D, Friedman, HS, and Peters, KB. "PATTERNS OF RELAPSE AFTER SUCCESSFUL COMPLETION OF INITIAL THERAPY IN PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA." November 2017.  Link to Item
    • Desjardins, A, Sampson, JH, Vlahovic, G, Peters, KB, Randazzo, D, Threatt, S, Herndon, JE, Bullock, CA, Miller, ES, Boulton, S, Lally-Goss, D, McSherry, F, Lipp, ES, Friedman, AH, Friedman, HS, Bigner, DD, and Gromeier, M. "Dose finding study of the intratumoral administration of the oncolytic polio/rhinovirus recombinant (PVSRIPO) against WHO grade IV malignant glioma (MG)." May 20, 2017.  Full Text  Link to Item
    • Randazzo, D, and Peters, KB. "Psychosocial distress and its effects on the health-related quality of life of primary brain tumor patients." October 2016.  Full Text
    • Desjardins, A, Sampson, JH, Peters, KB, Vlahovic, G, Randazzo, D, Threatt, S, Herndon, JE, Boulton, S, Lally-Goss, D, McSherry, F, Lipp, ES, Friedman, AH, Friedman, HS, Bigner, DD, and Gromeier, M. "Patient survival on the dose escalation phase of the Oncolytic Polio/Rhinovirus Recombinant (PVSRIPO) against WHO grade IV malignant glioma (MG) clinical trial compared to historical controls." May 20, 2016.  Full Text  Link to Item
    • Vlahovic, G, Archer, GE, Reap, E, Desjardins, R, Peters, KB, Randazzo, D, Healy, P, Herndon, JE, Friedman, AH, Friedman, HS, Bigner, DD, and Sampson, JH. "Phase I trial of combination of antitumor immunotherapy targeted against cytomegalovirus (CMV) plus regulatory T-cell inhibition in patients with newly-diagnosed glioblastoma mult forme (GBM)." May 20, 2016.  Full Text  Link to Item
    • Desjardins, A, Peters, KB, Vlahovic, G, Randazzo, D, Boulton, S, Massey, WC, Lipp, ES, Herndon, JE, Healy, P, Miller, E, Karmali, RA, and Friedman, HS. "Carboxyamidotriazole orotate (CTO) in combination with bevacizumab (BEV) for adult patients with recurrent malignant glioma post-BEV failure: Phase 1." May 20, 2015.  Link to Item
    • Desjardins, A, Sampson, JH, Peters, KB, Vlahovic, G, Randazzo, D, Threatt, S, Herndon, JE, Boulton, S, Lally-Goss, D, McSherry, F, Lipp, ES, Friedman, AH, Friedman, HS, Bigner, DD, and Gromeier, M. "Oncolytic polio/rhinovirus recombinant (PVSRIPO) against recurrent glioblastoma (GBM): Optimal dose determination." May 20, 2015.  Link to Item
    • Friedman, HS, Peters, KB, Vlahovic, G, Randazzo, D, Boulton, S, Woodring, S, Lipp, ES, Herndon, JE, Healy, P, Miller, E, Karmali, RA, and Desjardins, A. "Phase 1 clinical trial of carboxyamidotriazole orotate (CTO) in combination with lomustine (CCNU) for adult patients with recurrent malignant glioma (MG)." May 20, 2015.  Link to Item
    • Ghiaseddin, A, Reardon, DA, Massey, W, Mannerino, A, Lipp, ES, Herndon, JE, McSherry, F, Desjardins, A, Randazzo, DM, Vlahovic, G, Friedman, HS, and Peters, KB. "Phase II study of bevacizumab and vorinostat for recurrent glioblastoma." May 20, 2015.  Link to Item
    • Kim, J-Y, Woodring, S, Affronti, ML, Randazzo, D, McSherry, F, Herndon, JE, Lipp, ES, Desjardins, A, Vlahovic, G, Friedman, HS, and Peters, KB. "Secondary cancers in long-term survivors of primary glioblastoma." May 20, 2015.  Link to Item
    • Vlahovic, G, Archer, GE, Lally-Goss, D, Reap, E, Desjardins, A, Peters, KB, Randazzo, D, Healy, P, Herndon, JE, Friedman, AH, Friedman, HS, Bigner, DD, and Sampson, JH. "Phase I study of combination of antitumor immunotherapy targeted against cytomegalovirus (CMV) plus regulatory T-cell inhibition in patients with newly diagnosed glioblastoma multiforme (GBM)." May 20, 2015.  Link to Item
    • Desjardins, A, Sampson, JH, Peters, KB, Ranjan, T, Vlahovic, G, Threatt, S, Herndon, JE, Boulton, S, Lally-Goss, D, McSherry, F, Friedman, A, Friedman, HS, Bigner, DD, and Gromeier, M. "Abstract CT416: Intratumoral administration of an Oncolytic Polio/Rhinovirus Recombinant (PVSRIPO) in recurrent glioblastoma (GBM): Preliminary results of the Phase I clinical trial." October 1, 2014.  Full Text
    • Desjardins, A, Sampson, JH, Peters, KB, Ranjan, T, Vlahovic, G, Watts, J, Threatt, S, Herndon, JE, Boulton, S, Lally-Goss, D, McSherry, F, Friedman, AH, Friedman, HS, Bigner, DD, and Gromeier, M. "Phase I study of the intratumoral administration of an oncolytic polio/rhinovirus recombinant (PVSRIPO) in recurrent glioblastoma (GBM)." May 20, 2014.  Link to Item
    • Friedman, HS, Herndon, JE, McSherry, F, Ravelo, A, Lipp, ES, Healy, P, Peters, KB, Ranjan, T, Viahovic, G, Watts, J, Sampson, JH, Friedman, AH, and Desjardins, A. "Single-institution retrospective review of newly diagnosed glioblastoma (GBM) patients (pis) treated on bevacizumab (BEV) in clinical practice." May 20, 2014.  Link to Item
    • Peters, KB, Woodring, S, Affronti, ML, McSherry, F, Herndon, JE, Desjardins, A, Ranjan, T, Vlahovic, G, Friedman, AH, and Friedman, HS. "Long-term survivorship in adult primary glioblastoma: Clinical and neurological outcomes of a large, single-center study." May 20, 2014.  Link to Item
    • Vlahovic, G, Archer, GE, Lally-Goss, D, Norman, S, Desjardins, A, Peters, KB, Ranjan, T, Watts, J, Healy, P, Herndon, JE, Friedman, HS, Friedman, AH, Bigner, DD, and Sampson, JH. "Regulatory T-cell inhibition plus antitumor immunotherapy targeted against cytomegalovirus (CMV) in patients with newly diagnosed glioblastoma multiforme (GBM)." May 20, 2014.  Link to Item
    • Desjardins, A, Sampson, JH, Peters, KB, Ranjan, T, Vlahovic, G, Threatt, S, Herndon, JE, Friedman, AH, Friedman, HS, Bigner, DD, and Gromeier, M. "Dose-finding and safety study of an oncolytic polio/rhinovirus recombinant against recurrent glioblastoma." May 20, 2013.  Link to Item
    • Ranjan, T, Peters, KB, Vlahovic, G, Alderson, LM, Herndon, JE, McSherry, F, Threatt, S, Sampson, JH, Friedman, AH, Bigner, DD, Friedman, HS, Vredenburgh, JJ, and Desjardins, A. "Phase II trial for patients with newly diagnosed glioblastoma (GBM) treated with carmustine wafers followed by concurrent radiation therapy (RT), temozolomide (TMZ), and bevacizumab (BV), then followed by TMZ and BV post-RT." May 20, 2013.  Link to Item
    • Gromeier, M, Desjardins, A, Sampson, JH, Threatt, SJE, Herndon, JE, Friedman, A, Friedman, HS, and Bigner, DD. "ONCOLYTIC POLIOVIRUS IMMUNOTHERAPY OF PRIMARY CNS TUMORS." April 2013.  Link to Item
    • Affronti, ML, Woodring, S, Allen, K, II, HJE, McSherry, F, Peters, KB, Friedman, HS, Desjardins, A, Freeman, W, Cheshire, S, Cone, C, Kalinowski, KH, Kim, J-Y, III, LHH, Poillucci, V, Southerland, C, Tetterton, J, Kirkpatrick, J, and Vredenburgh, JJ. "PHASE II STUDY TO EVALUATE THE EFFICACY AND SAFETY OF INTRAVENOUS PALONOSETRON IN PRIMARY MALIGNANT GLIOMA PATIENTS RECEIVING STANDARD RADIOTHERAPY AND CONCOMITANT TEMOZOLOMIDE." October 2012.  Link to Item
    • Affronti, ML, Woodring, S, II, HJE, McSherry, F, Peters, KB, Friedman, HS, Desjardins, A, Freeman, W, Cheshire, S, Cone, C, Kalinowski, KH, Kim, J-Y, III, LHH, Poillucci, V, Southerland, C, Tetterton, J, and Vredenburgh, JJ. "A PHASE II SINGLE-ARM TRIAL OF PALONOSETRON FOR THE PREVENTION OF ACUTE AND DELAYED CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING IN MALIGNANT GLIOMA PATIENTS RECEIVING IRINOTECAN IN COMBINATION WITH BEVACIZUMAB." October 2012.  Open Access Copy  Link to Item
    • Desjardins, A, Peters, KB, II, HJE, Bailey, LA, Alderson, LM, Ranjan, T, Sampson, JH, Friedman, AH, Bigner, DD, Friedman, HS, and Vredenburgh, JJ. "NEWLY DIAGNOSED GLIOBLASTOMA TREATED WITH GLIADEL (R) FOLLOWED BY RADIATION THERAPY (RT), TEMOZOLOMIDE AND BEVACIZUMAB, AND POST-RT BEVACIZUMAB AND TEMOZOLOMIDE: A PHASE II STUDY." October 2012.  Link to Item
    • Peters, KB, Reardon, DA, Vredenburgh, JJ, Desjardins, A, II, HJE, Coan, A, McSherry, F, Lipp, E, Brickhouse, A, Massey, W, and Friedman, HS. "VORINOSTAT, BEVACIZUMAB, AND METRONOMIC TEMOZOLOMIDE FOR RECURRENT HIGH-GRADE GLIOMA: A PHASE I/II CLINICAL TRIAL." October 2012.  Link to Item
    • Peters, KB, Woodring, S, Herndon, JE, McSherry, F, Vredenburgh, JJ, Desjardins, A, and Friedman, HS. "LONG-TERM SURVIVORSHIP IN PRIMARY GLIOBLASTOMA: A FOCUS ON QUALITY OF LIFE." October 2012.  Link to Item
    • Peters, KB, Woodring, S, II, HJE, McSherry, F, Vredenburgh, JJ, Desjardins, A, and Friedman, HS. "LONG-TERM SURVIVORSHIP IN PRIMARY GLIOBLASTOMA: A FOCUS ON NEUROCOGNITION." October 2012.  Link to Item
    • Desjardins, A, Vredenburgh, JJ, Peters, KB, Threatt, S, Herndon, JE, Sampson, JH, Friedman, AH, Friedman, HS, and Reardon, DA. "Phase II study of bevacizumab plus irinotecan and carboplatin for recurrent WHO grade 3 malignant gliomas with no prior bevacizumab failure." May 20, 2012.  Link to Item
    • Friedman, HS, Desjardins, A, Peters, KB, Reardon, DA, Kirkpatrick, J, Herndon, JE, Coan, AD, Bailey, L, Sampson, JH, Friedman, AH, and Vredenburgh, JJ. "The addition of bevacizumab to temozolomide and radiation therapy followed by bevacizumab, temozolomide, and oral topotecan for newly diagnosed glioblastoma multiforme (GBM)." May 20, 2012.  Link to Item
    • Peters, KB, Vredenburgh, JJ, Desjardins, A, Friedman, HS, Herndon, JE, Coan, AD, McSherry, F, Lipp, ES, Brickhouse, A, Massey, WC, and Reardon, DA. "Vorinostat, temozolomide, and bevacizumab for patients with recurrent glioblastoma: A phase I/II trial." May 20, 2012.  Link to Item
    • Vredenburgh, JJ, Desjardins, A, Peters, KB, Reardon, DA, Herndon, JE, Coan, AD, Kirkpatrick, J, Bailey, L, Threatt, S, Sampson, JH, Friedman, AH, and Friedman, HS. "Safety and efficacy of the addition of bevacizumab to temozolomide and radiation therapy followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma multiforme." May 20, 2012.  Link to Item
    • Jiang, X, Reardon, DA, Desjardins, A, Vredenburgh, JJ, Quinn, JA, Austin, AD, Herndon, JE, McLendon, RE, and Friedman, HS. "O6-Methylguanine-DNA Methytransferase (MGMT) Immunohistochemistry as a Predictor of Resistance to Temozolomide in Primary CNS Lymphoma." February 2011.  Link to Item
    • Jiang, X, Reardon, DA, Desjardins, A, Vredenburgh, JJ, Quinn, JA, Austin, AD, Herndon, JE, McLendon, RE, and Friedman, HS. "O6-Methylguanine-DNA Methytransferase (MGMT) Immunohistochemistry as a Predictor of Resistance to Temozolomide in Primary CNS Lymphoma." February 2011.  Link to Item
    • Desjardins, A, Reardon, DA, Peters, KB, II, HJE, Kirkpatrick, JP, Friedman, HS, and Vredenburgh, JJ. "SURVIVAL AND TOXICITY UPDATE OF THE PHASE 2 TRIAL OF BEVACIZUMAB (BV) IN COMBINATION WITH TEMOZOLOMIDE (TMZ) AND RADIATION THERAPY (RT) FOLLOWED BY BV, TMZ, AND IRINOTECAN (CPT-11) FOR NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME (GBM) PATIENTS." November 2010.  Link to Item
    • De Rosa, N, II, HJE, Marcello, J, Tyler, DS, Scheri, RP, Pruitt, SK, Wheeler, JL, and Abernethy, AP. "Patterns of Recurrence in Melanoma and the Impact on Survival." February 2010.  Link to Item
    • Friedman, DR, Dupont, AH, Coan, AD, II, HJE, Rowe, KL, and Abernethy, AP. "Survivorship care planning needs in diffuse large B-cell lymphoma (DLBCL)." May 20, 2009.  Link to Item
    • Heimberger, AB, Archer, GE, Mitchell, DA, Bigner, DD, Schmittling, RJ, II, HJE, Davis, T, Friedman, HS, Keler, T, Reardon, DA, and Sampson, JH. "Epidermal growth factor receptor variant III (EGFRvIII) vaccine ( CDX-110) in GBM." May 20, 2009.  Link to Item
    • Lyerly, HK, Staley, T, II, HJE, Coan, A, Wheeler, JL, Rowe, K, Horne, B, and Abernethy, AP. "Impact of a psychosocial intervention on performance status and coping." May 20, 2009.  Link to Item
    • Peters, K, Desjardins, A, Reardon, DA, Perry, S, II, HJE, Bailey, L, Friedman, AH, Friedman, HS, Bigner, DD, and Vredenburgh, JJ. "Temozolomide (TMZ) and bevacizumab (BV) as initial treatment for unresectable or multifocal glioblastoma multiforme (GBM)." May 20, 2009.  Link to Item
    • Sampson, JH, Archer, GE, Bigner, DD, Schmittling, RJ, II, HJE, Davis, T, Friedman, HS, Keler, T, Reardon, DA, and Mitchell, DA. "Effect of daclizumab on T-Reg counts and EGFRvIII-specific immune responses in GBM." May 20, 2009.  Link to Item
    • Stinchcombe, TE, Hodgson, L, Herndon, JE, Kelley, MJ, Cicchetti, M, Ramnath, N, Niell, HB, Atkins, JN, Green, MR, and Vokes, EE. "Clinical factors predictive of overall survival (OS) and the identification of prognostic groups in patients (pts) with unresectable stage III non-small cell lung cancer (NSCLC) treated with chemoradiotherapy on Cancer and Leukemia and Group B trial (CALGB) 39801." May 20, 2009.  Link to Item
    • Vredenburgh, JJ, Desjardins, A, Reardon, DA, Peters, K, II, HJE, Kirkpatrick, J, Gururangan, S, Bailey, L, Friedman, AH, and Friedman, HS. "Safety and efficacy of the addition of bevacizumab (BV) to temozolomide (TMZ) and radiation therapy (RT) followed by BV, TMZ, and irinotecan (CPT-11) for newly diagnosed glioblastoma multiforme (GBM)." May 20, 2009.  Link to Item
    • Mitchell, DA, Archer, GE, Bigner, DD, Friedman, HS, Lally-Goss, D, Perry, B, II, HJE, McGehee, S, McLendon, RE, Reardon, D, and Sampson, JH. "RNA Transfected Dendritic Cell Vaccines Targeting Human Cytomegalovirus Antigens in Patients with Glioblastoma." May 2009.  Link to Item
    • Scheri, RP, II, HJE, Marcello, J, Wheeler, J, Tyler, DS, and Abernethy, AP. "Mortality burden of melanoma: Metastatic site-specific and temporal trends." May 20, 2008.  Full Text  Link to Item
    • Uronis, HE, II, HJE, Coan, A, Bronson, K, Wheeler, J, Lyerly, HK, Morse, MA, and Abernethy, AP. "E/Tablets to collect research-quality, patient-reported data." May 20, 2008.  Full Text  Link to Item
    • Desjardins, A, Barboriak, D, II, HJE, Reardon, D, Quinn, J, Rich, J, Sathornsumetee, S, Friedman, H, and Vredenburgh, J. "Evaluation of tumor response by dynamic contrast-enhanced magnetic resonance imaging in glioblastoma (gbm) patients treated with bevacizumab (bev) and irinotecan (CPT-11)." October 2007.  Link to Item
    • Anscher, M, Garst, J, Marks, L, Larrier, N, Dunphy, F, Herndon, J, Clough, R, Marino, C, Vujaskovic, Z, and Zhou, S. "2498." November 2006.  Full Text
    • Affronti, ML, Dowell, JM, II, HJE, Cahill, J, Rich, JN, Quinn, JA, Reardon, DA, Vredenburgh, JJ, Desjardins, A, Gururangan, S, and Friedman, HS. "Overall survival of primary glioblastoma (GBM) patients receiving radiation and concurrent temozolomide followed by rotational multi-agent chemotherapy." October 2006.  Link to Item
    • Vredenburgh, J, Desjardins, A, II, HJE, Reardon, D, Quinn, J, Sathornsumetee, S, Gururangan, S, Friedman, A, Bigner, D, and Friedman, H. "Bevacizumab and irinotecan is an effective treatment for malignant gliomas." October 2006.  Link to Item
    • Strauss, GM, II, HJE, Maddaus, MA, Johnstone, DW, Johnson, EA, Watson, DM, Sugarbaker, DJ, Schilsky, RA, Vokes, EE, Green, MR, and CALGB, RTOG. "Adjuvant chemotherapy in stage IB non-small cell lung cancer (NSCLC): Update of Cancer and Leukemia Group B (CALGB) protocol 9633." June 20, 2006.  Link to Item
    • Vredenburgh, JJ, Desjardins, A, II, HJE, Quinn, J, Rich, J, Sathornsumetee, S, Friedman, HS, Reardon, D, Gururangan, S, and Friedman, A. "Bevacizumab, a monoclonal antibody to vascular endothelial growth factor (VEGF), and irinotecan for treatment of malignant gliomas." June 20, 2006.  Link to Item
    • Ali-Osman, F, Herndon, JE, Stephenson, L, Davis, F, McCarthy, B, Reardon, D, Friedman, A, McClendon, R, Friedman, H, and Bigner, DD. "Prevalence and prognostic significance of polymorphisms at the glutathione S-transferase M1, M3, P1, and T1 gene loci in human astrocytomas." July 2005.  Link to Item
    • Lamont, EB, Herndon, JE, Weeks, JC, Henderson, IC, Lilenbaum, R, Schilsky, RL, and Christakis, NA. "Criterion validity of Medicare chemotherapy claims in breast and lung cancer patients." June 1, 2005.  Link to Item
    • Wang, XF, Govindan, R, Herndon, JE, Barrier, RC, Watson, D, Vokes, RFEE, and Green, MR. "A phase II study of carboplatin, etoposide and exisulind in patients with extensive stage small cell lung cancer: CALGB 30104." June 1, 2005.  Link to Item
    • Cornett, WR, Fraker, DL, Ross, MI, Briele, HA, Boddie, AW, Noyes, RD, Sussman, JJ, McCall, LM, Herndon, JE, and Tyler, DS. "Three month follow up for ACOSOG Z0020, a prospective randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone versus melphalan plus tumor necrosis factor." February 2005.  Link to Item
    • Wilke, LG, McCall, LM, Whitworth, PW, Reintgen, DS, Leitch, AM, Gabram, SG, Lucci, A, Cox, CE, Herndon, JE, and Giuliano, AE. "Surgical complications associated with sentinel lymph node biopsy: Results from a prospective international cooperative group trial." February 2005.  Link to Item
    • Strauss, GM, Herndon, JE, Maddaus, MA, Johnstone, DW, Johnson, EA, Harpole, DH, Gillenwater, HH, Watson, DM, Sugarbaker, DJ, Schilsky, RL, Vokes, EE, and CALGB, MRG. "A randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small cell hung cancer (NSCLC): report of cancer and leukemia group b (CALGB) protocol 9633." September 2004.  Link to Item
    • Vokes, EE, Herndon, JE, Kelley, MJ, Watson, D, Cicchetti, MG, and Green, MR. "Induction chemotherapy followed by concomitant chemoradiotherapy (CT/XRT) versus CT/XRT alone for regionally advanced unresectable non-small cell lung cancer (NSCLC): Initial analysis of a randomized phase III trial." July 15, 2004.  Link to Item
    • Strauss, GM, Herndon, JE, Maddaus, MA, Johnstone, DW, Johnson, EA, Harpole, DH, Gillenwater, HH, Watson, DM, Sugarbaker, DJ, Schilsky, RL, Vokes, EE, and Green, MR. "Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small cell lung cancer (NSCLC): Report of Cancer and Leukemia Group B (CALGB) Protocol 9633." 2004.  Link to Item
    • McLendon, RE, Wiltshire, RN, Herndon, JE, Lloyd, A, Friedman, HS, Bigner, DD, and Bigner, SH. "Sub-classification of glioblastoma defined by comparative genomic hybridization alterations." May 2003.  Link to Item
    • Kelley, MJ, Folz, RJ, Glaser, EM, Herndon, JE, Crowell, JA, Perloff, M, Ferdman, E, Gallot, L, Becker, R, and Bergan, RC. "Randomized controlled clinical trial of weekly oltipraz in smokers." October 2002.  Link to Item

  • Journal Articles

    • Peters, KB, Lipp, ES, Miller, E, Herndon, JE, McSherry, F, Desjardins, A, Reardon, DA, and Friedman, HS. "Phase I/II trial of vorinostat, bevacizumab, and daily temozolomide for recurrent malignant gliomas." Journal of neuro-oncology 137, no. 2 (April 2018): 349-356.  Full Text
    • Suryadevara, CM, Desai, R, Abel, ML, Riccione, KA, Batich, KA, Shen, SH, Chongsathidkiet, P, Gedeon, PC, Elsamadicy, AA, Snyder, DJ, Herndon, JE, Healy, P, Archer, GE, Choi, BD, Fecci, PE, Sampson, JH, and Sanchez-Perez, L. "Temozolomide lymphodepletion enhances CAR abundance and correlates with antitumor efficacy against established glioblastoma (Accepted)." OncoImmunology (February 20, 2018).  Full Text
    • Ghiaseddin, A, Reardon, D, Massey, W, Mannerino, A, Lipp, ES, Herndon, JE, McSherry, F, Desjardins, A, Randazzo, D, Friedman, HS, and Peters, KB. "Phase II Study of Bevacizumab and Vorinostat for Patients with Recurrent World Health Organization Grade 4 Malignant Glioma." The oncologist 23, no. 2 (February 2018): 157-e21.  Full Text
    • Reap, EA, Suryadevara, CM, Batich, KA, Sanchez-Perez, L, Archer, GE, Schmittling, RJ, Norberg, PK, Herndon, JE, Healy, P, Congdon, KL, Gedeon, PC, Campbell, OC, Swartz, AM, Riccione, KA, Yi, JS, Hossain-Ibrahim, MK, Saraswathula, A, Nair, SK, Dunn-Pirio, AM, Broome, TM, Weinhold, KJ, Desjardins, A, Vlahovic, G, McLendon, RE, Friedman, AH, Friedman, HS, Bigner, DD, Fecci, PE, Mitchell, DA, and Sampson, JH. "Dendritic Cells Enhance Polyfunctionality of Adoptively Transferred T Cells That Target Cytomegalovirus in Glioblastoma." Cancer research 78, no. 1 (January 2018): 256-264.  Full Text
    • Limon, D, McSherry, F, Herndon, J, Sampson, J, Fecci, P, Adamson, J, Wang, Z, Yin, F-F, Floyd, S, Kirkpatrick, J, and Kim, GJ. "Single fraction stereotactic radiosurgery for multiple brain metastases." Advances in radiation oncology 2, no. 4 (October 2017): 555-563.  Full Text  Open Access Copy
    • Narloch, JL, Farber, SH, Sammons, S, McSherry, F, Herndon, JE, Hoang, JK, Yin, F-F, Sampson, JH, Fecci, PE, Blackwell, KL, Kirkpatrick, JP, and Kim, GJ. "Biopsy of enlarging lesions after stereotactic radiosurgery for brain metastases frequently reveals radiation necrosis." Neuro-oncology 19, no. 10 (October 2017): 1391-1397.  Full Text
    • Randazzo, DM, McSherry, F, Herndon, JE, Affronti, ML, Lipp, ES, Flahiff, C, Miller, E, Woodring, S, Freeman, M, Healy, P, Minchew, J, Boulton, S, Desjardins, A, Vlahovic, G, Friedman, HS, Keir, S, and Peters, KB. "A cross sectional analysis from a single institution's experience of psychosocial distress and health-related quality of life in the primary brain tumor population." Journal of neuro-oncology 134, no. 2 (September 2017): 363-369.  Full Text
    • Campa, MJ, Gottlin, EB, Herndon, JE, and Patz, EF. "Rethinking Autoantibody Signature Panels for Cancer Diagnosis." Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 12, no. 6 (June 2017): 1011-1014.  Full Text
    • Batich, KA, Reap, EA, Archer, GE, Sanchez-Perez, L, Nair, SK, Schmittling, RJ, Norberg, P, Xie, W, Herndon, JE, Healy, P, McLendon, RE, Friedman, AH, Friedman, HS, Bigner, D, Vlahovic, G, Mitchell, DA, and Sampson, JH. "Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination." Clinical cancer research : an official journal of the American Association for Cancer Research 23, no. 8 (April 2017): 1898-1909.  Full Text
    • Affronti, ML, Woodring, S, Peters, KB, Herndon, JE, McSherry, F, Healy, PN, Desjardins, A, Vredenburgh, JJ, and Friedman, HS. "A Phase II single-arm trial of palonosetron for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in malignant glioma patients receiving multidose irinotecan in combination with bevacizumab." Therapeutics and Clinical Risk Management 13 (January 2017): 33-40.  Full Text
    • Kelley, MJ, Jha, G, Shoemaker, D, Herndon, JE, Gu, L, Barry, WT, Crawford, J, and Ready, N. "Phase II Study of Dasatinib in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer." Cancer investigation 35, no. 1 (January 2017): 32-35.  Full Text
    • Affronti, ML, Woodring, S, Allen, K, Kirkpatrick, J, Peters, KB, II, HJE, McSherry, F, Healy, PN, Desjardins, A, Vredenburgh, JJ, and Friedman, HS. "Phase II study to evaluate the safety and efficacy of intravenous palonosetron (PAL) in primary malignant glioma (MG) patients receiving standard radiotherapy (RT) and concomitant temozolomide (TMZ)." SUPPORTIVE CARE IN CANCER 24, no. 10 (October 2016): 4365-4375.  Full Text  Link to Item
    • Weitzel, DH, Tovmasyan, A, Ashcraft, KA, Boico, A, Birer, SR, Roy Choudhury, K, Herndon, J, Rodriguiz, RM, Wetsel, WC, Peters, KB, Spasojevic, I, Batinic-Haberle, I, and Dewhirst, MW. "Neurobehavioral radiation mitigation to standard brain cancer therapy regimens by Mn(III) n-butoxyethylpyridylporphyrin-based redox modifier." Environmental and molecular mutagenesis 57, no. 5 (June 2016): 372-381.  Full Text
    • Saraswathula, A, Reap, EA, Choi, BD, Schmittling, RJ, Norberg, PK, Sayour, EJ, Herndon, JE, Healy, P, Congdon, KL, Archer, GE, Sanchez-Perez, L, and Sampson, JH. "Serum elevation of B lymphocyte stimulator does not increase regulatory B cells in glioblastoma patients undergoing immunotherapy." Cancer immunology, immunotherapy : CII 65, no. 2 (February 2016): 205-211.  Full Text
    • Oldham, M, Yoon, P, Fathi, Z, Beyer, WF, Adamson, J, Liu, L, Alcorta, D, Xia, W, Osada, T, Liu, C, Yang, XY, Dodd, RD, Herndon, JE, Meng, B, Kirsch, DG, Lyerly, HK, Dewhirst, MW, Fecci, P, Walder, H, and Spector, NL. "X-Ray Psoralen Activated Cancer Therapy (X-PACT)." PloS one 11, no. 9 (January 2016): e0162078-.  Full Text  Open Access Copy
    • Robertson, ME, McSherry, F, Herndon, JE, and Peters, KB. "Insomnia and its associations in patients with recurrent glial neoplasms." SpringerPlus 5, no. 1 (January 2016): 823-.  Full Text  Open Access Copy
    • Kwon, W, Howard, BA, Herndon, JE, and Patz, EF. "Reply to "Prognostic Value of Fluorodeoxyglucose-Positron Emission Tomography"." Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 10, no. 10 (October 2015): e102-. (Letter)  Full Text  Open Access Copy
    • Wysham, NG, Miriovsky, BJ, Currow, DC, Herndon, JE, Samsa, GP, Wilcock, A, and Abernethy, AP. "Practical Dyspnea Assessment: Relationship Between the 0-10 Numerical Rating Scale and the Four-Level Categorical Verbal Descriptor Scale of Dyspnea Intensity." Journal of pain and symptom management 50, no. 4 (October 2015): 480-487.  Full Text
    • Peters, KB, Lou, E, Desjardins, A, Reardon, DA, Lipp, ES, Miller, E, Herndon, JE, McSherry, F, Friedman, HS, and Vredenburgh, JJ. "Phase II Trial of Upfront Bevacizumab, Irinotecan, and Temozolomide for Unresectable Glioblastoma." The oncologist 20, no. 7 (July 2015): 727-728.  Full Text
    • Kwon, W, Howard, BA, Herndon, JE, and Patz, EF. "FDG Uptake on Positron Emission Tomography Correlates with Survival and Time to Recurrence in Patients with Stage I Non-Small-Cell Lung Cancer." Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 10, no. 6 (June 2015): 897-902.  Full Text
    • McLendon, RE, Lipp, E, Satterfield, D, Ehinger, M, Austin, A, Fleming, D, Perkinson, K, Lefaivre, M, Zagzag, D, Wiener, B, Gururangan, S, Fuchs, H, Friedman, HS, Herndon, JE, and Healy, P. "Prognostic marker analysis in pediatric intracranial ependymomas." Journal of neuro-oncology 122, no. 2 (April 2015): 255-261.  Full Text
    • Mitchell, DA, Batich, KA, Gunn, MD, Huang, M-N, Sanchez-Perez, L, Nair, SK, Congdon, KL, Reap, EA, Archer, GE, Desjardins, A, Friedman, AH, Friedman, HS, Herndon, JE, Coan, A, McLendon, RE, Reardon, DA, Vredenburgh, JJ, Bigner, DD, and Sampson, JH. "Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients." Nature 519, no. 7543 (March 11, 2015): 366-369.  Full Text  Open Access Copy
    • Tuchman, SA, Lane, A, Hornsby, WE, Bishop, C, Thomas, S, Herndon, JE, Long, G, Gasparetto, C, and Jones, LW. "Quantitative measures of physical functioning after autologous hematopoietic stem cell transplantation in multiple myeloma: a feasibility study." Clinical lymphoma, myeloma & leukemia 15, no. 2 (February 2015): 103-109.  Full Text
    • Kirkpatrick, JP, Wang, Z, Sampson, JH, McSherry, F, Herndon, JE, Allen, KJ, Duffy, E, Hoang, JK, Chang, Z, Yoo, DS, Kelsey, CR, and Yin, F-F. "Defining the optimal planning target volume in image-guided stereotactic radiosurgery of brain metastases: results of a randomized trial." International journal of radiation oncology, biology, physics 91, no. 1 (January 2015): 100-108.  Full Text
    • Weitzel, DH, Tovmasyan, A, Ashcraft, KA, Rajic, Z, Weitner, T, Liu, C, Li, W, Buckley, AF, Prasad, MR, Young, KH, Rodriguiz, RM, Wetsel, WC, Peters, KB, Spasojevic, I, Herndon, JE, Batinic-Haberle, I, and Dewhirst, MW. "Radioprotection of the brain white matter by Mn(III) n-Butoxyethylpyridylporphyrin-based superoxide dismutase mimic MnTnBuOE-2-PyP5+." Molecular cancer therapeutics 14, no. 1 (January 2015): 70-79.  Full Text
    • Peters, KB, West, MJ, Hornsby, WE, Waner, E, Coan, AD, McSherry, F, Herndon, JE, Friedman, HS, Desjardins, A, and Jones, LW. "Impact of health-related quality of life and fatigue on survival of recurrent high-grade glioma patients." Journal of neuro-oncology 120, no. 3 (December 2014): 499-506.  Full Text
    • Kelsey, CR, Scott, JM, Lane, A, Schwitzer, E, West, MJ, Thomas, S, Herndon, JE, Michalski, MG, Horwitz, ME, Hennig, T, and Jones, LW. "Cardiopulmonary exercise testing prior to myeloablative allo-SCT: a feasibility study." Bone marrow transplantation 49, no. 10 (October 2014): 1330-1336.  Full Text
    • Kanaly, CW, Mehta, AI, Ding, D, Hoang, JK, Kranz, PG, Herndon, JE, Coan, A, Crocker, I, Waller, AF, Friedman, AH, Reardon, DA, and Sampson, JH. "A novel, reproducible, and objective method for volumetric magnetic resonance imaging assessment of enhancing glioblastoma." Journal of neurosurgery 121, no. 3 (September 2014): 536-542.  Full Text
    • Kenjale, AA, Hornsby, WE, Crowgey, T, Thomas, S, Herndon, JE, Khouri, MG, Lane, AR, Bishop, CE, Eves, ND, Peppercorn, J, Douglas, PS, and Jones, LW. "Pre-exercise participation cardiovascular screening in a heterogeneous cohort of adult cancer patients." The oncologist 19, no. 9 (September 2014): 999-1005.  Full Text
    • Affronti, ML, Schneider, SM, Herndon, JE, Schlundt, S, and Friedman, HS. "Adherence to antiemetic guidelines in patients with malignant glioma: a quality improvement project to translate evidence into practice." Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 22, no. 7 (July 2014): 1897-1905.  Full Text
    • Desjardins, A, Sampson, JH, Peters, KB, Ranjan, T, Vlahovic, G, Threatt, S, Herndon, JE, Boulton, S, Lally-Goss, D, McSherry, F, Friedman, AH, Friedman, HS, Bigner, DD, and Gromeier, M. "Oncolytic polio/rhinovirus recombinant (pvsripo) in recurrent glioblastoma (gbm): first phase I clinical trial evaluating the intratumoral administration." Neuro Oncol 16 Suppl 3 (July 2014): iii43-.  Full Text  Link to Item
    • Yan, H, Killela, PJ, Reitman, ZJ, Jiao, Y, Bettegowda, C, Agrawal, N, Diaz, LA, Friedman, AH, Friedman, H, Gallia, GL, Giovanella, BC, Grollman, AP, He, TC, He, Y, Hruban, RH, Jallo, GI, Mandahl, N, Meeker, AK, Mertens, F, Netto, GJ, Rasheed, BA, Riggins, GJ, Rosenquist, TA, Schiffman, M, Shih, I, Theodorescu, D, Torbenson, MS, Velculescu, VE, Wang, TL, Wentzensen, N, Wood, LD, Zhang, M, Healy, P, Yang, R, Diplas, B, Wang, ZH, Greer, P, Zhu, HS, Wang, C, Carpenter, A, Herndon, JE, and McLendon, RE et al. "TERT PROMOTER MUTATIONS OCCUR FREQUENTLY IN GLIOMAS AND A SUBSET OF TUMORS DERIVED FROM CELLS WITH LOW RATES OF SELF-RENEWAL." Neuro-oncology 16, no. Suppl 3 (July 2014): iii5-iii6.
    • Crowgey, T, Peters, KB, Hornsby, WE, Lane, A, McSherry, F, Herndon, JE, West, MJ, Williams, CL, and Jones, LW. "Relationship between exercise behavior, cardiorespiratory fitness, and cognitive function in early breast cancer patients treated with doxorubicin-containing chemotherapy: a pilot study." Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme 39, no. 6 (June 2014): 724-729.  Full Text
    • Killela, PJ, Pirozzi, CJ, Healy, P, Reitman, ZJ, Lipp, E, Rasheed, BA, Yang, R, Diplas, BH, Wang, Z, Greer, PK, Zhu, H, Wang, CY, Carpenter, AB, Friedman, H, Friedman, AH, Keir, ST, He, J, He, Y, McLendon, RE, Herndon, JE, Yan, H, and Bigner, DD. "Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas." Oncotarget 5, no. 6 (March 2014): 1515-1525.  Full Text  Open Access Copy
    • Sampson, JH, Choi, BD, Sanchez-Perez, L, Suryadevara, CM, Snyder, DJ, Flores, CT, Schmittling, RJ, Nair, SK, Reap, EA, Norberg, PK, Herndon, JE, Kuan, CT, Morgan, RA, Rosenberg, SA, and Johnson, LA. "EGFRvIII mCAR-modified T-cell therapy cures mice with established intracerebral glioma and generates host immunity against tumor-antigen loss." Clinical Cancer Research 20, no. 4 (February 26, 2014): 972-984.  Full Text
    • Sampson, JH, Choi, BD, Sanchez-Perez, L, Suryadevara, CM, Snyder, DJ, Flores, CT, Schmittling, RJ, Nair, SK, Reap, EA, Norberg, PK, Herndon, JE, Kuan, C-T, Morgan, RA, Rosenberg, SA, and Johnson, LA. "EGFRvIII mCAR-modified T-cell therapy cures mice with established intracerebral glioma and generates host immunity against tumor-antigen loss." Clin Cancer Res 20, no. 4 (February 15, 2014): 972-984.  Full Text  Link to Item
    • Khouri, MG, Hornsby, WE, Risum, N, Velazquez, EJ, Thomas, S, Lane, A, Scott, JM, Koelwyn, GJ, Herndon, JE, Mackey, JR, Douglas, PS, and Jones, LW. "Utility of 3-dimensional echocardiography, global longitudinal strain, and exercise stress echocardiography to detect cardiac dysfunction in breast cancer patients treated with doxorubicin-containing adjuvant therapy." Breast Cancer Res Treat 143, no. 3 (February 2014): 531-539.  Full Text  Link to Item
    • Khouri, MG, Hornsby, WE, Risum, N, Velazquez, EJ, Thomas, S, Lane, A, Scott, JM, Koelwyn, GJ, Herndon, JE, Mackey, JR, Douglas, PS, and Jones, LW. "Utility of 3-dimensional echocardiography, global longitudinal strain, and exercise stress echocardiography to detect cardiac dysfunction in breast cancer patients treated with doxorubicin-containing adjuvant therapy." Breast Cancer Research and Treatment 143, no. 3 (February 1, 2014): 531-539.  Full Text
    • Sampson, JH, Lad, SP, Herndon, JE, Starke, RM, and Kondziolka, D. "SEER insights." J Neurosurg 120, no. 2 (February 2014): 297-298.  Full Text  Link to Item
    • Sampson, JH, Lad, SP, Herndon, JE, Starke, RM, and Kondziolka, D. "SEER insights." Journal of Neurosurgery 120, no. 2 (February 1, 2014): 297-298.  Full Text
    • Affronti, ML, Schneider, SM, Herndon, JE, Schlundt, S, and Friedman, HS. "Adherence to antiemetic guidelines in patients with malignant glioma: A quality improvement project to translate evidence into practice." Supportive Care in Cancer 22, no. 7 (January 1, 2014): 1897-1905.  Full Text
    • Choi, BD, Suryadevara, CM, Gedeon, PC, Herndon, JE, Sanchez-Perez, L, Bigner, DD, and Sampson, JH. "Intracerebral delivery of a third generation EGFRvIII-specific chimeric antigen receptor is efficacious against human glioma." Journal of Clinical Neuroscience 21, no. 1 (January 1, 2014): 189-190.  Full Text
    • Choi, BD, Suryadevara, CM, Gedeon, PC, Herndon, JE, Sanchez-Perez, L, Bigner, DD, and Sampson, JH. "Intracerebral delivery of a third generation EGFRvIII-specific chimeric antigen receptor is efficacious against human glioma." J Clin Neurosci 21, no. 1 (January 2014): 189-190.  Full Text  Link to Item
    • Hornsby, WE, Douglas, PS, West, MJ, Kenjale, AA, Lane, AR, Schwitzer, ER, Ray, KA, Herndon, JE, Coan, A, Gutierrez, A, Hornsby, KP, Hamilton, E, Wilke, LG, Kimmick, GG, Peppercorn, JM, and Jones, LW. "Safety and efficacy of aerobic training in operable breast cancer patients receiving neoadjuvant chemotherapy: a phase II randomized trial." Acta Oncol 53, no. 1 (January 2014): 65-74.  Full Text  Link to Item
    • Jones, LW, Hornsby, WE, Freedland, SJ, Lane, A, West, MJ, Moul, JW, Ferrandino, MN, Allen, JD, Kenjale, AA, Thomas, SM, Herndon, JE, Koontz, BF, Chan, JM, Khouri, MG, Douglas, PS, and Eves, ND. "Effects of nonlinear aerobic training on erectile dysfunction and cardiovascular function following radical prostatectomy for clinically localized prostate cancer." European Urology 65, no. 5 (January 1, 2014): 852-855.  Full Text
    • Kelsey, CR, Scott, JM, Lane, A, Schwitzer, E, West, MJ, Thomas, S, Herndon, JE, Michalski, MG, Horwitz, ME, Hennig, T, and Jones, LW. "Cardiopulmonary exercise testing prior to myeloablative allo-SCT: A feasibility study." Bone Marrow Transplantation 49, no. 10 (January 1, 2014): 1330-1336.  Full Text
    • Miao, H, Choi, BD, Suryadevara, CM, Sanchez-Perez, L, Yang, S, De Leon, G, Sayour, EJ, McLendon, R, Herndon, JE, Healy, P, Archer, GE, Bigner, DD, Johnson, LA, and Sampson, JH. "EGFRvIII-specific chimeric antigen receptor T cells migrate to and kill tumor deposits infiltrating the brain parenchyma in an invasive xenograft model of glioblastoma." PloS one 9, no. 4 (January 2014): e94281-.  Full Text  Open Access Copy
    • Roman, MA, Koelwyn, GJ, Eves, ND, Hornsby, WE, Watson, D, Herndon Ii, JE, Kohman, L, Loewen, G, and Jones, LW. "Comparison of performance status with peak oxygen consumption in operable patients with non-small-cell lung cancer." Respirology (Carlton, Vic.) 19, no. 1 (January 2014): 105-108.  Full Text
    • Denehy, L, Hornsby, WE, Herndon, JE, Thomas, S, Ready, NE, Granger, CL, Valera, L, Kenjale, AA, Eves, ND, and Jones, LW. "Prognostic Validation of the Body Mass Index, Airflow Obstruction, Dyspnea, and Exercise Capacity (BODE) Index in Inoperable Non-Small-Cell Lung Cancer." JOURNAL OF THORACIC ONCOLOGY 8, no. 12 (December 2013): 1545-1550.  Full Text  Link to Item
    • Choi, BD, Gedeon, PC, Herndon, JE, Archer, GE, Reap, EA, Sanchez-Perez, L, Mitchell, DA, Bigner, DD, and Sampson, JH. "Human regulatory T cells kill tumor cells through granzyme-dependent cytotoxicity upon retargeting with a bispecific antibody." Cancer immunology research 1, no. 3 (September 2013): 163-.  Full Text
    • Gururangan, S, Grant, GA, Driscoll, T, Archer, G, Sayour, EJ, II, HJE, Friedman, HS, Kurtzberg, J, Bigner, DD, Sampson, JH, and Mitchell, DA. "ADOPTIVE LYMPHOCYTE THERAPY (ALT) PLUS DENDRITIC CELL VACCINATION (DCV) AFTER MYELOABLATIVE (MA) OR NON-MYELOABLATIVE (NMA) CONDITIONING IN PATIENTS WITH RECURRENT CENTRAL PNET (C-PNET)." PEDIATRIC BLOOD & CANCER 60 (September 2013): 13-13.  Link to Item
    • Patz, EF, Campa, MJ, Gottlin, EB, Trotter, PR, Herndon, JE, Kafader, D, Grant, RP, and Eisenberg, M. "Biomarkers to help guide management of patients with pulmonary nodules." Am J Respir Crit Care Med 188, no. 4 (August 15, 2013): 461-465.  Full Text  Open Access Copy  Link to Item
    • Cabrera, AR, Cuneo, KC, Desjardins, A, Sampson, JH, McSherry, F, Herndon, JE, Peters, KB, Allen, K, Hoang, JK, Chang, Z, Craciunescu, O, Vredenburgh, JJ, Friedman, HS, and Kirkpatrick, JP. "Concurrent stereotactic radiosurgery and bevacizumab in recurrent malignant gliomas: a prospective trial." Int J Radiat Oncol Biol Phys 86, no. 5 (August 1, 2013): 873-879.  Full Text  Link to Item
    • Sanchez-Perez, L, Choi, BD, Reap, EA, Sayour, EJ, Norberg, P, Schmittling, RJ, Archer, GE, Herndon, JE, Mitchell, DA, Heimberger, AB, Bigner, DD, and Sampson, JH. "BLyS levels correlate with vaccine-induced antibody titers in patients with glioblastoma lymphodepleted by therapeutic temozolomide." Cancer Immunol Immunother 62, no. 6 (June 2013): 983-987.  Full Text  Link to Item
    • Lou, E, Peters, KB, Sumrall, AL, Desjardins, A, Reardon, DA, Lipp, ES, Herndon, JE, Coan, A, Bailey, L, Turner, S, Friedman, HS, and Vredenburgh, JJ. "Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma." Cancer Med 2, no. 2 (April 2013): 185-195.  Full Text  Open Access Copy  Link to Item
    • Herndon, JE, Kornblith, AB, Holland, JC, and Paskett, ED. "Effect of socioeconomic status as measured by education level on survival in breast cancer clinical trials." Psychooncology 22, no. 2 (February 2013): 315-323.  Full Text  Open Access Copy  Link to Item
    • Cabrera, AR, Cuneo, KC, Desjardins, A, Sampson, JH, McSherry, F, II, JEH, Peters, KB, Allen, K, Hoang, JK, Chang, Z, Craciunescu, O, Vredenburgh, JJ, Friedman, HS, and Kirkpatrick, JP. "Concurrent stereotactic radiosurgery and bevacizumab in recurrent malignant gliomas: A prospective trial." International Journal of Radiation Oncology Biology Physics 86, no. 5 (2013): 873-879.  Full Text
    • Herndon, JE, Kornblith, AB, Holland, JC, and Paskett, ED. "Effect of socioeconomic status as measured by education level on survival in breast cancer clinical trials." Psycho-Oncology 22, no. 2 (2013): 315-323.  Full Text
    • Jiang, X, Reardon, DA, Desjardins, A, Vredenburgh, JJ, Quinn, JA, Austin, AD, II, JEH, McLendon, RE, and Friedman, HS. "O⁶-methylguanine-DNA methyltransferase (MGMT) immunohistochemistry as a predictor of resistance to temozolomide in primary CNS lymphoma." Journal of Neuro-Oncology 114, no. 1 (2013): 135-140.  Full Text
    • Jones, LW, Hornsby, WE, Freedland, SJ, Lane, A, West, MJ, Moul, JW, Ferrandino, MN, Allen, JD, Kenjale, AA, Thomas, SM, Herndon II, JE, Koontz, BF, Chan, JM, Khouri, MG, Douglas, PS, and Eves, ND. "Effects of Nonlinear Aerobic Training on Erectile Dysfunction and Cardiovascular Function Following Radical Prostatectomy for Clinically Localized Prostate Cancer." European Urology (2013).
    • Lakoski, SG, Barlow, CE, Koelwyn, GJ, Hornsby, WE, Hernandez, J, DeFina, LF, Radford, NB, Thomas, SM, II, JEH, Peppercorn, J, and al, E. "The influence of adjuvant therapy on cardiorespiratory fitness in early-stage breast cancer seven years after diagnosis: the Cooper Center Longitudinal Study." Breast Cancer Research and Treatment (2013): 1-8.  Full Text
    • Lakoski, SG, Barlow, CE, Koelwyn, GJ, Hornsby, WE, Hernandez, J, Defina, LF, Radford, NB, Thomas, SM, II, JEH, Peppercorn, J, Douglas, PS, and Jones, LW. "The influence of adjuvant therapy on cardiorespiratory fitness in early-stage breast cancer seven years after diagnosis: The Cooper Center Longitudinal Study." Breast Cancer Research and Treatment 138, no. 3 (2013): 909-916.  Full Text
    • Salama, AKS, de Rosa, N, Scheri, RP, Pruitt, SK, Herndon, JE, Marcello, J, Tyler, DS, and Abernethy, AP. "Hazard-rate analysis and patterns of recurrence in early stage melanoma: moving towards a rationally designed surveillance strategy." PLoS One 8, no. 3 (2013): e57665-.  Full Text  Open Access Copy  Link to Item
    • Sanchez-Perez, L, Choi, BD, Reap, EA, Sayour, EJ, Norberg, P, Schmittling, RJ, Archer, GE, II, JEH, Mitchell, DA, Heimberger, AB, Bigner, DD, and Sampson, JH. "BLyS levels correlate with vaccine-induced antibody titers in patients with glioblastoma lymphodepleted by therapeutic temozolomide." Cancer Immunology, Immunotherapy 62, no. 6 (2013): 983-987.  Full Text
    • Sanchez-Perez, LA, Choi, BD, Archer, GE, Cui, X, Flores, C, Johnson, LA, Schmittling, RJ, Snyder, D, Herndon, JE, Bigner, DD, Mitchell, DA, and Sampson, JH. "Myeloablative temozolomide enhances CD8⁺ T-cell responses to vaccine and is required for efficacy against brain tumors in mice." PLoS One 8, no. 3 (2013): e59082-.  Full Text  Open Access Copy  Link to Item
    • Zomorodi, A, II, HJE, and Sampson, JH. "Subarachnoid hemorrhage trials." NEUROSURGICAL FOCUS 34, no. 1 (January 2013): 1-2.  Full Text  Link to Item
    • Zomorodi, A, II, HJE, and Sampson, JH. "Subarachnoid hemorrhage trials." JOURNAL OF NEUROSURGERY 118, no. 1 (January 2013): 1-2.  Full Text  Link to Item
    • Salama, AKS, Rosa, ND, Scheri, RP, Herndon, JE, Tyler, DS, Marcello, J, Pruitt, SK, and Abernethy, AP. "The effect of metastatic site and decade of diagnosis on the individual burden of metastatic melanoma: contemporary estimates of average years of life lost." Cancer Invest 30, no. 9 (November 2012): 637-641.  Full Text  Link to Item
    • Reardon, DA, Herndon, JE, Peters, KB, Desjardins, A, Coan, A, Lou, E, Sumrall, AL, Turner, S, Lipp, ES, Sathornsumetee, S, Rich, JN, Sampson, JH, Friedman, AH, Boulton, ST, Bigner, DD, Friedman, HS, and Vredenburgh, JJ. "Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients." Br J Cancer 107, no. 9 (October 23, 2012): 1481-1487.  Full Text  Open Access Copy  Link to Item
    • Pearce, MJ, Coan, AD, Herndon, JE, Koenig, HG, and Abernethy, AP. "Unmet spiritual care needs impact emotional and spiritual well-being in advanced cancer patients." Support Care Cancer 20, no. 10 (October 2012): 2269-2276.  Full Text  Link to Item
    • Reardon, DA, Desjardins, A, Vredenburgh, JJ, Herndon, JE, Coan, A, Gururangan, S, Peters, KB, McLendon, R, Sathornsumetee, S, Rich, JN, Lipp, ES, Janney, D, and Friedman, HS. "Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma." Cancer 118, no. 19 (October 1, 2012): 4759-4767.  Full Text  Link to Item
    • Tcheung, WJ, Selim, MA, Herndon, JE, Abernethy, AP, and Nelson, KC. "Clinicopathologic study of 85 cases of melanoma of the female genitalia." J Am Acad Dermatol 67, no. 4 (October 2012): 598-605.  Full Text  Link to Item
    • Lou, E, Sumrall, AL, Turner, S, Peters, KB, Desjardins, A, Vredenburgh, JJ, McLendon, RE, Herndon, JE, McSherry, F, Norfleet, J, Friedman, HS, and Reardon, DA. "Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series." J Neurooncol 109, no. 1 (August 2012): 63-70.  Full Text  Link to Item
    • Jones, LW, Courneya, KS, Mackey, JR, Muss, HB, Pituskin, EN, Scott, JM, Hornsby, WE, Coan, AD, Herndon, JE, Douglas, PS, and Haykowsky, M. "Cardiopulmonary function and age-related decline across the breast cancer survivorship continuum." J Clin Oncol 30, no. 20 (July 10, 2012): 2530-2537.  Full Text  Link to Item
    • Reardon, DA, Vredenburgh, JJ, Desjardins, A, Peters, KB, Sathornsumetee, S, Threatt, S, Sampson, JH, Herndon, JE, Coan, A, McSherry, F, Rich, JN, McLendon, RE, Zhang, S, and Friedman, HS. "Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma." J Neurooncol 108, no. 3 (July 2012): 499-506.  Full Text  Link to Item
    • Jones, LW, Hornsby, WE, Goetzinger, A, Forbes, LM, Sherrard, EL, Quist, M, Lane, AT, West, M, Eves, ND, Gradison, M, Coan, A, Herndon, JE, and Abernethy, AP. "Prognostic significance of functional capacity and exercise behavior in patients with metastatic non-small cell lung cancer." Lung Cancer 76, no. 2 (May 2012): 248-252.  Full Text  Link to Item
    • Desjardins, A, Reardon, DA, Coan, A, Marcello, J, Herndon, JE, Bailey, L, Peters, KB, Friedman, HS, and Vredenburgh, JJ. "Bevacizumab and daily temozolomide for recurrent glioblastoma." Cancer 118, no. 5 (March 1, 2012): 1302-1312.  Full Text  Link to Item
    • Reardon, DA, Desjardins, A, Peters, KB, Gururangan, S, Sampson, JH, McLendon, RE, Herndon, JE, Bulusu, A, Threatt, S, Friedman, AH, Vredenburgh, JJ, and Friedman, HS. "Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma." J Neurooncol 107, no. 1 (March 2012): 155-164.  Full Text  Link to Item
    • Sampson, JH, Herndon, JE, McLendon, RE, Hasselblad, V, Asher, AL, McGirt, MJ, and Peterson, ED. "Clinical data simplified." J Neurosurg 116, no. 2 (February 2012): 346-348.  Full Text  Link to Item
    • Reardon, DA, Ii, JEH, Peters, K, Desjardins, A, Coan, A, Lou, E, Sumrall, A, Turner, S, Sathornsumetee, S, Rich, JN, Boulton, S, Lipp, ES, Friedman, HS, and Vredenburgh, JJ. "Outcome after bevacizumab clinical trial therapy among recurrent grade III malignant glioma patients." Journal of Neuro-Oncology 107, no. 1 (2012): 213-221.  Full Text
    • Reardon, DA, Norden, AD, Desjardins, A, Vredenburgh, JJ, Herndon, JE, Coan, A, Sampson, JH, Gururangan, S, Peters, KB, McLendon, RE, Norfleet, JA, Lipp, ES, Drappatz, J, Wen, PY, and Friedman, HS. "Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma." J Neurooncol 106, no. 2 (January 2012): 409-415.  Full Text  Link to Item
    • Sampson, JH, Schmittling, RJ, Archer, GE, Congdon, KL, Nair, SK, Reap, EA, Desjardins, A, Friedman, AH, Friedman, HS, Herndon, JE, Coan, A, McLendon, RE, Reardon, DA, Vredenburgh, JJ, Bigner, DD, and Mitchell, DA. "A pilot study of IL-2Rα blockade during lymphopenia depletes regulatory T-cells and correlates with enhanced immunity in patients with glioblastoma." PLoS One 7, no. 2 (2012): e31046-.  Full Text  Open Access Copy  Link to Item
    • Vredenburgh, JJ, Desjardins, A, Kirkpatrick, JP, Reardon, DA, Peters, KB, Herndon, JE, Marcello, J, Bailey, L, Threatt, S, Sampson, J, Friedman, A, and Friedman, HS. "Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme." Int J Radiat Oncol Biol Phys 82, no. 1 (January 1, 2012): 58-66.  Full Text  Link to Item
    • Zalutsky, MR, Boskovitz, A, Kuan, C-T, Pegram, CN, Ayriss, J, Wikstrand, CJ, Buckley, AF, Lipp, ES, Herndon, JE, McLendon, RE, and Bigner, DD. "Radioimmunotargeting of malignant glioma by monoclonal antibody D2C7 reactive against both wild-type and variant III mutant epidermal growth factor receptors." Nucl Med Biol 39, no. 1 (January 2012): 23-34.  Full Text  Link to Item
    • Desjardins, A, Reardon, DA, Peters, KB, Threatt, S, Coan, AD, Herndon, JE, Friedman, AH, Friedman, HS, and Vredenburgh, JJ. "A phase I trial of the farnesyl transferase inhibitor, SCH 66336, with temozolomide for patients with malignant glioma." J Neurooncol 105, no. 3 (December 2011): 601-606.  Full Text  Link to Item
    • Reardon, DA, Desjardins, A, Peters, KB, Vredenburgh, JJ, Gururangan, S, Sampson, JH, McLendon, RE, Herndon, JE, Coan, A, Threatt, S, Friedman, AH, and Friedman, HS. "Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy." Cancer 117, no. 23 (December 1, 2011): 5351-5358.  Full Text  Link to Item
    • Reardon, DA, Vredenburgh, JJ, Coan, A, Desjardins, A, Peters, KB, Gururangan, S, Sathornsumetee, S, Rich, JN, Herndon, JE, and Friedman, HS. "Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma." J Neurooncol 105, no. 3 (December 2011): 621-627.  Full Text  Link to Item
    • Reardon, DA, Vredenburgh, JJ, Coan, A, Desjardins, A, Peters, KB, Gururangan, S, Sathornsumetee, S, Rich, JN, Herndon, JE, and Friedman, HS. "Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma." JOURNAL OF NEURO-ONCOLOGY 105, no. 3 (December 2011): 621-627.  Full Text  Link to Item
    • Desjardins, A, Reardon, DA, Peters, KB, II, HJE, Gururangan, S, Norfleet, J, Friedman, HS, and Vredenburgh, JJ. "PHASE II STUDY OF PANITUMUMAB IN COMBINATION WITH IRINOTECAN FOR MALIGNANT GLIOMA PATIENTS." NEURO-ONCOLOGY 13 (November 2011): 90-90.  Link to Item
    • Kwatra, MM, Porter, TM, Brown, KE, Herndon, JE, and Bigner, DD. "TRUNCATED NEUROKININ 1 RECEPTOR: EXPRESSION IN PRIMARY GLIOBLASTOMAS AND RELATIONSHIP WITH PATIENT SURVIVAL." NEURO-ONCOLOGY 13 (November 2011): 82-82.  Link to Item
    • Mitchell, DA, Archer, GE, Friedman, HS, Herndon, JE, Bigner, DD, and Sampson, JH. "DENDRITIC CELL VACCINES TARGETING CYTOMEGALOVIRUS IN GLIOBLASTOMA." NEURO-ONCOLOGY 13 (November 2011): 39-39.  Link to Item
    • Vredenburgh, JJ, Desjardins, A, Reardon, DA, Peters, KB, Kirkpatrick, JP, II, HJE, Coan, AD, Bailey, L, Janney, D, Lu, C, and Friedman, HS. "THE ADDITION OF BEVACIZUMAB TO TEMOZOLOMIDE AND RADIATION THERAPY FOLLOWED BY BEVACIZUMAB, TEMOZOLOMIDE, AND ORAL TOPOTECAN FOR NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME." NEURO-ONCOLOGY 13 (November 2011): 89-90.  Link to Item
    • Gottlin, EB, Bentley, RC, Campa, MJ, Pisetsky, DS, Herndon, JE, and Patz, EF. "The Association of Intratumoral Germinal Centers with early-stage non-small cell lung cancer." J Thorac Oncol 6, no. 10 (October 2011): 1687-1690.  Full Text  Link to Item
    • Mitchell, DA, Cui, X, Schmittling, RJ, Sanchez-Perez, L, Snyder, DJ, Congdon, KL, Archer, GE, Desjardins, A, Friedman, AH, Friedman, HS, Herndon, JE, McLendon, RE, Reardon, DA, Vredenburgh, JJ, Bigner, DD, and Sampson, JH. "Monoclonal antibody blockade of IL-2 receptor α during lymphopenia selectively depletes regulatory T cells in mice and humans." Blood 118, no. 11 (September 15, 2011): 3003-3012.  Full Text  Link to Item
    • Sampson, JH, Herndon, JE, Friedman, AH, and Abernethy, AP. "Epidemiology." J Neurosurg 115, no. 2 (August 2011): 256-257.  Full Text  Link to Item
    • Ruden, E, Reardon, DA, Coan, AD, Herndon, JE, Hornsby, WE, West, M, Fels, DR, Desjardins, A, Vredenburgh, JJ, Waner, E, Friedman, AH, Friedman, HS, Peters, KB, and Jones, LW. "Exercise behavior, functional capacity, and survival in adults with malignant recurrent glioma." J Clin Oncol 29, no. 21 (July 20, 2011): 2918-2923.  Full Text  Link to Item
    • Kuan, C-T, Wakiya, K, Keir, ST, Li, J, Herndon, JE, Pastan, I, and Bigner, DD. "Affinity-matured anti-glycoprotein NMB recombinant immunotoxins targeting malignant gliomas and melanomas." Int J Cancer 129, no. 1 (July 1, 2011): 111-121.  Full Text  Link to Item
    • Vredenburgh, JJ, Desjardins, A, Reardon, DA, Peters, KB, Herndon, JE, Marcello, J, Kirkpatrick, JP, Sampson, JH, Bailey, L, Threatt, S, Friedman, AH, Bigner, DD, and Friedman, HS. "The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma." Clin Cancer Res 17, no. 12 (June 15, 2011): 4119-4124.  Full Text  Link to Item
    • Reardon, DA, Desjardins, A, Peters, K, Gururangan, S, Sampson, J, Rich, JN, McLendon, R, Herndon, JE, Marcello, J, Threatt, S, Friedman, AH, Vredenburgh, JJ, and Friedman, HS. "Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy." J Neurooncol 103, no. 2 (June 2011): 371-379.  Full Text  Link to Item
    • Cuneo, KC, Cabrera, AR, Sampson, JH, Allen, KJ, Vredenburgh, JJ, Peters, K, Chang, Z, Herndon, JE, Desjardins, A, Reardon, DA, and Kirkpatrick, J. "Safety results from a prospective study of concurrent radiosurgery and bevacizumab for recurrent malignant glioma." Journal of Clinical Oncology 29, no. 15_suppl (May 20, 2011): 2082-2082.  Full Text
    • Desjardins, A, Reardon, DA, Vredenburgh, JJ, Peters, K, Trikha, M, James, J, Gardner, M, Brickhouse, A, Herndon, JE, and Friedman, HS. "A pharmacokinetic (PK) study of AC480 administered twice daily in patients with surgically resectable, recurrent malignant glioma (MG) not on enzyme-inducing antiepileptic drug (EIAED)." Journal of Clinical Oncology 29, no. 15_suppl (May 20, 2011): 2070-2070.  Full Text
    • Lou, E, Reardon, DA, Peters, K, Desjardins, A, Herndon, JE, Coan, AD, Turner, SG, Sumrall, AL, Bailey, L, Friedman, HS, and Vredenburgh, JJ. "Upfront bevacizumab with temozolomide or with temozolomide and irinotecan for unresectable or multifocal glioblastoma." Journal of Clinical Oncology 29, no. 15_suppl (May 20, 2011): 2055-2055.  Full Text
    • Reardon, DA, Vredenburgh, JJ, Desjardins, A, Peters, K, Coan, AD, Herndon, JE, and Friedman, HS. "Bevacizumab (BV) continuation following BV progression: Meta-analysis of five consecutive recurrent glioblastoma (GBM) trials." JOURNAL OF CLINICAL ONCOLOGY 29, no. 15 (May 20, 2011).  Link to Item
    • Cuneo, KC, Cabrera, AR, Sampson, JH, Allen, KJ, Vredenburgh, JJ, Peters, K, Chang, Z, Herndon, JE, Desjardins, A, Reardon, DA, and Kirkpatrick, J. "Safety results from a prospective study of concurrent radiosurgery and bevacizumab for recurrent malignant glioma." Journal of clinical oncology : official journal of the American Society of Clinical Oncology 29, no. 15_suppl (May 2011): 2082-.
    • Desjardins, A, Reardon, DA, Vredenburgh, JJ, Peters, K, Trikha, M, James, J, Gardner, M, Brickhouse, A, Herndon, JE, and Friedman, HS. "A pharmacokinetic (PK) study of AC480 administered twice daily in patients with surgically resectable, recurrent malignant glioma (MG) not on enzyme-inducing antiepileptic drug (EIAED)." Journal of clinical oncology : official journal of the American Society of Clinical Oncology 29, no. 15_suppl (May 2011): 2070-.
    • Lou, E, Reardon, DA, Peters, K, Desjardins, A, Herndon, JE, Coan, AD, Turner, SG, Sumrall, AL, Bailey, L, Friedman, HS, and Vredenburgh, JJ. "Upfront bevacizumab with temozolomide or with temozolomide and irinotecan for unresectable or multifocal glioblastoma." Journal of clinical oncology : official journal of the American Society of Clinical Oncology 29, no. 15_suppl (May 2011): 2055-.
    • Reardon, DA, Vredenburgh, JJ, Desjardins, A, Peters, K, Coan, AD, Herndon, JE, and Friedman, HS. "Bevacizumab (BV) continuation following BV progression: Meta-analysis of five consecutive recurrent glioblastoma (GBM) trials." Journal of clinical oncology : official journal of the American Society of Clinical Oncology 29, no. 15_suppl (May 2011): 2030-.
    • Smith, SK, Herndon, JE, Lyerly, HK, Coan, A, Wheeler, JL, Staley, T, and Abernethy, AP. "Correlates of quality of life-related outcomes in breast cancer patients participating in the Pathfinders pilot study." Psychooncology 20, no. 5 (May 2011): 559-564.  Full Text  Link to Item
    • Reardon, DA, Turner, S, Peters, KB, Desjardins, A, Gururangan, S, Sampson, JH, McLendon, RE, Herndon, JE, Jones, LW, Kirkpatrick, JP, Friedman, AH, Vredenburgh, JJ, Bigner, DD, and Friedman, HS. "A review of VEGF/VEGFR-targeted therapeutics for recurrent glioblastoma." J Natl Compr Canc Netw 9, no. 4 (April 2011): 414-427. (Review)  Link to Item
    • Sampson, JH, Aldape, KD, Archer, GE, Coan, A, Desjardins, A, Friedman, AH, Friedman, HS, Gilbert, MR, Herndon, JE, McLendon, RE, Mitchell, DA, Reardon, DA, Sawaya, R, Schmittling, R, Shi, W, Vredenburgh, JJ, Bigner, DD, and Heimberger, AB. "Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma." Neuro Oncol 13, no. 3 (March 2011): 324-333.  Full Text  Link to Item
    • Heimberger, AB, Bigner, DD, II, JEH, and Sampson, JH. "Reply to M.C. Chamberlain." Journal of Clinical Oncology 29, no. 17 (2011): e519-e520.  Full Text
    • Mehta, AI, Persson, O, II, JEH, Archer, GE, McLendon, R, Heimberger, AB, Mitchell, DA, Bigner, DD, and Sampson, JH. "Reply to M.S. Lesniak." Journal of Clinical Oncology 29, no. 22 (2011): 3105-3106.  Full Text
    • Reardon, DA, Vredenburgh, JJ, Desjardins, A, Peters, K, Gururangan, S, Sampson, JH, Marcello, J, Herndon, JE, McLendon, RE, Janney, D, Friedman, AH, Bigner, DD, and Friedman, HS. "Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma." J Neurooncol 101, no. 1 (January 2011): 57-66.  Full Text  Link to Item
    • Sampson, JH, and II, JEH. "Resection of vestibular schwannomas." Journal of Neurosurgery 114, no. 5 (2011): 1216-1217.  Full Text
    • Sathornsumetee, S, Desjardins, A, Vredenburgh, JJ, McLendon, RE, Marcello, J, Herndon, JE, Mathe, A, Hamilton, M, Rich, JN, Norfleet, JA, Gururangan, S, Friedman, HS, and Reardon, DA. "Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma." Neuro Oncol 12, no. 12 (December 2010): 1300-1310.  Full Text  Link to Item
    • Sampson, JH, Heimberger, AB, Archer, GE, Aldape, KD, Friedman, AH, Friedman, HS, Gilbert, MR, Herndon, JE, McLendon, RE, Mitchell, DA, Reardon, DA, Sawaya, R, Schmittling, RJ, Shi, W, Vredenburgh, JJ, and Bigner, DD. "Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma." J Clin Oncol 28, no. 31 (November 1, 2010): 4722-4729.  Full Text  Link to Item
    • Jones, LW, Watson, D, Herndon, JE, Eves, ND, Haithcock, BE, Loewen, G, and Kohman, L. "Peak oxygen consumption and long-term all-cause mortality in nonsmall cell lung cancer." Cancer 116, no. 20 (October 15, 2010): 4825-4832.  Full Text  Link to Item
    • Jones, LW, Douglas, PS, Eves, ND, Marcom, PK, Kraus, WE, Herndon, JE, Inman, BA, Allen, JD, and Peppercorn, J. "Rationale and design of the Exercise Intensity Trial (EXCITE): A randomized trial comparing the effects of moderate versus moderate to high-intensity aerobic training in women with operable breast cancer. (Published online)" BMC Cancer 10 (October 6, 2010): 531-.  Full Text  Open Access Copy  Link to Item
    • Abernethy, AP, Zafar, SY, Uronis, H, Wheeler, JL, Coan, A, Rowe, K, Shelby, RA, Fowler, R, and Herndon, JE. "Validation of the Patient Care Monitor (Version 2.0): a review of system assessment instrument for cancer patients." J Pain Symptom Manage 40, no. 4 (October 2010): 545-558.  Full Text  Link to Item
    • Ding, D, Kanaly, CW, Cummings, TJ, Herndon, JE, Raghavan, R, and Sampson, JH. "Long-term safety of combined intracerebral delivery of free gadolinium and targeted chemotherapeutic agent PRX321." Neurological research 32, no. 8 (October 2010): 810-815.  Full Text
    • Abernethy, AP, McDonald, CF, Frith, PA, Clark, K, Herndon, JE, Marcello, J, Young, IH, Bull, J, Wilcock, A, Booth, S, Wheeler, JL, Tulsky, JA, Crockett, AJ, and Currow, DC. "Effect of palliative oxygen versus room air in relief of breathlessness in patients with refractory dyspnoea: a double-blind, randomised controlled trial." Lancet 376, no. 9743 (September 4, 2010): 784-793.  Full Text  Link to Item
    • Kuan, C-T, Wakiya, K, Herndon, JE, Lipp, ES, Pegram, CN, Riggins, GJ, Rasheed, A, Szafranski, SE, McLendon, RE, Wikstrand, CJ, and Bigner, DD. "MRP3: a molecular target for human glioblastoma multiforme immunotherapy. (Published online)" BMC Cancer 10 (September 1, 2010): 468-.  Full Text  Open Access Copy  Link to Item
    • Sampson, JH, Archer, G, Pedain, C, Wembacher-Schröder, E, Westphal, M, Kunwar, S, Vogelbaum, MA, Coan, A, Herndon, JE, Raghavan, R, Brady, ML, Reardon, DA, Friedman, AH, Friedman, HS, Rodríguez-Ponce, MI, Chang, SM, Mittermeyer, S, Croteau, D, Puri, RK, and PRECISE Trial Investigators, . "Poor drug distribution as a possible explanation for the results of the PRECISE trial." J Neurosurg 113, no. 2 (August 2010): 301-309.  Full Text  Link to Item
    • Abernethy, AP, Herndon, JE, Coan, A, Staley, T, Wheeler, JL, Rowe, K, Smith, SK, Shaw, H, and Lyerly, HK. "Phase 2 pilot study of Pathfinders: a psychosocial intervention for cancer patients." Support Care Cancer 18, no. 7 (July 2010): 893-898.  Full Text  Link to Item
    • Friedman, DR, Coan, AD, Smith, SK, Herndon, JE, and Abernethy, AP. "Informational needs assessment of non-Hodgkin lymphoma survivors and their physicians." Am J Hematol 85, no. 7 (July 2010): 528-532. (Letter)  Full Text  Link to Item
    • Brickhouse, A, Vredenburgh, JJ, Gururangan, S, Reardon, DA, Desjardins, A, Peters, K, Herndon, JE, Norfleet, J, Marcello, J, and Friedman, HS. "Phase I trial of vandetanib and oral etoposide (VP-16) for recurrent malignant gliomas (MG)." Journal of Clinical Oncology 28, no. 15_suppl (May 20, 2010): 2038-2038.  Full Text
    • Desjardins, A, Vredenburgh, JJ, Reardon, DA, Herndon, JE, Marcello, J, Peters, K, Gururangan, S, Sathornsumetee, S, Rich, JN, and Friedman, HS. "Long-term survival from the initial trial of bevacizumab and irinotecan." JOURNAL OF CLINICAL ONCOLOGY 28, no. 15 (May 20, 2010).  Link to Item
    • Gururangan, S, Vredenburgh, JJ, Desjardins, A, Peters, K, Herndon, JE, McLendon, RE, Janney, D, Friedman, HS, and Reardon, DA. "CYP3A-inducing antiepileptics decrease sorafenib exposures: Results of a phase II study in adults with recurrent glioblastoma." Journal of Clinical Oncology 28, no. 15_suppl (May 20, 2010): 2089-2089.  Full Text
    • Kirkpatrick, J, Vredenburgh, JJ, Reardon, DA, Desjardins, A, Peters, K, Gururangan, S, Herndon, JE, Marcello, J, Woodring, S, and Friedman, HS. "Phase I trial of the addition of oral topotecan to standard 5-day temozolomide for malignant gliomas." Journal of Clinical Oncology 28, no. 15_suppl (May 20, 2010): 2073-2073.  Full Text
    • Sathornsumetee, S, Desjardins, A, Vredenburgh, JJ, McLendon, RE, Marcello, J, Herndon, JE, Norfleet, J, Gururangan, S, Friedman, HS, and Reardon, DA. "Phase II trial of bevacizumab plus erlotinib for patients with recurrent malignant gliomas: Final results." Journal of Clinical Oncology 28, no. 15_suppl (May 20, 2010): 2055-2055.  Full Text
    • Vredenburgh, JJ, Desjardins, A, Reardon, DA, Peters, K, Kirkpatrick, J, Herndon, JE, Marcello, J, Bailey, L, Threatt, S, and Friedman, HS. "Bevacizumab (BEV) in combination with temozolomide (TMZ) and radiation therapy (XRT) followed by BEV, TMZ, and irinotecan for newly diagnosed glioblastoma multiforme (GBM)." Journal of Clinical Oncology 28, no. 15_suppl (May 20, 2010): 2023-2023.  Full Text
    • Ding, D, Kanaly, CW, Bigner, DD, Cummings, TJ, Herndon, JE, Pastan, I, Raghavan, R, and Sampson, JH. "Convection-enhanced delivery of free gadolinium with the recombinant immunotoxin MR1-1." J Neurooncol 98, no. 1 (May 2010): 1-7.  Full Text  Link to Item
    • Jones, LW, Viglianti, BL, Tashjian, JA, Kothadia, SM, Keir, ST, Freedland, SJ, Potter, MQ, Moon, EJ, Schroeder, T, Herndon, JE, and Dewhirst, MW. "Effect of aerobic exercise on tumor physiology in an animal model of human breast cancer." J Appl Physiol (1985) 108, no. 2 (February 2010): 343-348.  Full Text  Link to Item
    • Ding, D, Kanaly, CW, Bigner, DD, Cummings, TJ, II, JEH, Pastan, I, Raghavan, R, and Sampson, JH. "Erratum: Convection-enhanced delivery of free gadolinium with the recombinant immunotoxin MR1-1 (Journal of Neuro-Oncology DOI 10.1007/s11060-009-0046-7)." Journal of Neuro-Oncology 98, no. 1 (2010): 9--.  Full Text
    • Jones, LW, Viglianti, BL, Tashjian, JA, Kothadia, SM, Keir, ST, Freedland, SJ, Potter, MQ, Moon, EJ, Schroeder, T, Herndon, JE, and Dewhirst, MW. "Erratum: Effect of aerobic exercise on tumor physiology in an animal model of human breast cancer (Journal of Applied Physiology (2010) 108: (343-348) DOI: 10.1152/japplphysiol.00424.2009)." Journal of Applied Physiology 108, no. 4 (2010): 1021--.  Full Text
    • Reardon, DA, Desjardins, A, Vredenburgh, JJ, Gururangan, S, Friedman, AH, Herndon, JE, Marcello, J, Norfleet, JA, McLendon, RE, Sampson, JH, and Friedman, HS. "Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma." J Neurooncol 96, no. 2 (January 2010): 219-230.  Full Text  Link to Item
    • Zafar, SY, Marcello, JE, Wheeler, JL, Rowe, KL, Morse, MA, Herndon, JE, and Abernethy, AP. "Treatment-related toxicity and supportive care in metastatic colorectal cancer." J Support Oncol 8, no. 1 (January 2010): 15-20.  Link to Item
    • Reardon, DA, Desjardins, A, Vredenburgh, JJ, Gururangan, S, Sampson, JH, Sathornsumetee, S, McLendon, RE, Herndon, JE, Marcello, JE, Norfleet, J, Friedman, AH, Bigner, DD, and Friedman, HS. "Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study." Br J Cancer 101, no. 12 (December 15, 2009): 1986-1994.  Full Text  Open Access Copy  Link to Item
    • Quinn, JA, Jiang, SX, Reardon, DA, Desjardins, A, Vredenburgh, JJ, Friedman, AH, Sampson, JH, McLendon, RE, Herndon, JE, and Friedman, HS. "Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy." J Neurooncol 95, no. 3 (December 2009): 393-400.  Full Text  Link to Item
    • Quinn, JA, Jiang, SX, Reardon, DA, Desjardins, A, Vredenburgh, JJ, Rich, JN, Gururangan, S, Friedman, AH, Bigner, DD, Sampson, JH, McLendon, RE, Herndon, JE, Walker, A, and Friedman, HS. "Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma." Neuro Oncol 11, no. 5 (October 2009): 556-561.  Full Text  Link to Item
    • Sampson, JH, Archer, GE, Mitchell, DA, Heimberger, AB, Herndon, JE, Lally-Goss, D, McGehee-Norman, S, Paolino, A, Reardon, DA, Friedman, AH, Friedman, HS, and Bigner, DD. "An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme." Mol Cancer Ther 8, no. 10 (October 2009): 2773-2779.  Full Text  Link to Item
    • Stinchcombe, TE, Hodgson, L, Herndon, IIJE, Kelley, M, Cicchetti, MG, Ramnath, N, Niell, H, Atkins, JN, Akerley, W, Green, MR, and Vokes, EE. "Identification of prognostic groups in patients (pts) with unresectable stage III non-small cell lung cancer (NSCLC) treated with chemoradiotherapy on Cancer and Leukemia and Group B trial (CALGB) 39801." JOURNAL OF THORACIC ONCOLOGY 4, no. 9 (September 2009): S522-S523.  Link to Item
    • Stinchcombe, TE, Hodgson, L, Herndon, JE, Kelley, MJ, Cicchetti, MG, Ramnath, N, Niell, HB, Atkins, JN, Akerley, W, Green, MR, Vokes, EE, and Cancer and Leukemia Group B, . "Treatment outcomes of different prognostic groups of patients on cancer and leukemia group B trial 39801: induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for unresectable stage III non-small cell lung cancer." J Thorac Oncol 4, no. 9 (September 2009): 1117-1125.  Full Text  Link to Item
    • Zafar, SY, Marcello, JE, Wheeler, JL, Rowe, KL, Morse, MA, Herndon, JE, and Abernethy, AP. "Longitudinal patterns of chemotherapy use in metastatic colorectal cancer." J Oncol Pract 5, no. 5 (September 2009): 228-233.  Full Text  Link to Item
    • Affronti, ML, Heery, CR, Herndon, JE, Rich, JN, Reardon, DA, Desjardins, A, Vredenburgh, JJ, Friedman, AH, Bigner, DD, and Friedman, HS. "Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy." Cancer 115, no. 15 (August 1, 2009): 3501-3511.  Full Text  Link to Item
    • Abernethy, AP, Herndon, JE, Wheeler, JL, Rowe, K, Marcello, J, and Patwardhan, M. "Poor documentation prevents adequate assessment of quality metrics in colorectal cancer." J Oncol Pract 5, no. 4 (July 2009): 167-174.  Full Text  Link to Item
    • Quinn, JA, Jiang, SX, Reardon, DA, Desjardins, A, Vredenburgh, JJ, Gururangan, S, Sampson, JH, McLendon, RE, Herndon, JE, and Friedman, HS. "Phase 1 trial of temozolomide plus irinotecan plus O6-benzylguanine in adults with recurrent malignant glioma." Cancer 115, no. 13 (July 1, 2009): 2964-2970.  Full Text  Link to Item
    • Abernethy, AP, Barbour, SY, Uronis, H, Zafar, SY, Coan, A, Rowe, K, Pupa, MR, Wheeler, JL, and Herndon, JE. "Quality management of potential chemotherapy-induced neutropenic complications: evaluation of practice in an academic medical center." Support Care Cancer 17, no. 6 (June 2009): 735-744.  Full Text  Link to Item
    • Abernethy, AP, Herndon, JE, Wheeler, JL, Day, JM, Hood, L, Patwardhan, M, Shaw, H, and Lyerly, HK. "Feasibility and acceptability to patients of a longitudinal system for evaluating cancer-related symptoms and quality of life: pilot study of an e/Tablet data-collection system in academic oncology." J Pain Symptom Manage 37, no. 6 (June 2009): 1027-1038.  Full Text  Link to Item
    • Reardon, DA, Egorin, MJ, Desjardins, A, Vredenburgh, JJ, Beumer, JH, Lagattuta, TF, Gururangan, S, Herndon, JE, Salvado, AJ, and Friedman, HS. "Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma." Cancer 115, no. 10 (May 15, 2009): 2188-2198.  Full Text  Link to Item
    • Dupont, A, Wheeler, J, Herndon, JE, Coan, A, Zafar, SY, Hood, L, Patwardhan, M, Shaw, HS, Lyerly, HK, and Abernethy, AP. "Use of tablet personal computers for sensitive patient-reported information." J Support Oncol 7, no. 3 (May 2009): 91-97.  Link to Item
    • Friedman, DR, Dupont, AH, Coan, AD, Herndon, JE, Rowe, KL, and Abernethy, AP. "Survivorship care planning needs in diffuse large B-cell lymphoma (DLBCL)." Journal of clinical oncology : official journal of the American Society of Clinical Oncology 27, no. 15_suppl (May 2009): e20703-.
    • Heimberger, AB, Archer, GE, Mitchell, DA, Bigner, DD, Schmittling, RJ, Herndon, JE, Davis, T, Friedman, HS, Keler, T, Reardon, DA, and Sampson, JH. "Epidermal growth factor receptor variant III (EGFRvIII) vaccine (CDX-110) in GBM." Journal of clinical oncology : official journal of the American Society of Clinical Oncology 27, no. 15_suppl (May 2009): 2021-.
    • Lyerly, HK, Staley, T, Herndon, JE, Coan, A, Wheeler, JL, Rowe, K, Horne, B, and Abernethy, AP. "Impact of a psychosocial intervention on performance status and coping." Journal of clinical oncology : official journal of the American Society of Clinical Oncology 27, no. 15_suppl (May 2009): 9611-.
    • Peters, K, Desjardins, A, Reardon, DA, Perry, S, Herndon, JE, Bailey, L, Friedman, AH, Friedman, HS, Bigner, DD, and Vredenburgh, JJ. "Temozolomide (TMZ) and bevacizumab (BV) as initial treatment for unresectable or multifocal glioblastoma multiforme (GBM)." Journal of clinical oncology : official journal of the American Society of Clinical Oncology 27, no. 15_suppl (May 2009): e13025-.
    • Sampson, JH, Archer, GE, Bigner, DD, Schmittling, RJ, Herndon, JE, Davis, T, Friedman, HS, Keler, T, Reardon, DA, and Mitchell, DA. "Effect of daclizumab on TReg counts and EGFRvIII-specific immune responses in GBM." Journal of clinical oncology : official journal of the American Society of Clinical Oncology 27, no. 15_suppl (May 2009): 2034-.
    • Stinchcombe, TE, Hodgson, L, Herndon, JE, Kelley, MJ, Cicchetti, M, Ramnath, N, Niell, HB, Atkins, JN, Green, MR, and Vokes, EE. "Clinical factors predictive of overall survival (OS) and the identification of prognostic groups in patients (pts) with unresectable stage III non-small cell lung cancer (NSCLC) treated with chemoradiotherapy on Cancer and Leukemia and Group B trial (CALGB) 39801." Journal of clinical oncology : official journal of the American Society of Clinical Oncology 27, no. 15_suppl (May 2009): 7535-.
    • Vredenburgh, JJ, Desjardins, A, Reardon, DA, Peters, K, Herndon, JE, Kirkpatrick, J, Gururangan, S, Bailey, L, Friedman, AH, and Friedman, HS. "Safety and efficacy of the addition of bevacizumab (BV) to temozolomide (TMZ) and radiation therapy (RT) followed by BV, TMZ, and irinotecan (CPT-11) for newly diagnosed glioblastoma multiforme (GBM)." Journal of clinical oncology : official journal of the American Society of Clinical Oncology 27, no. 15_suppl (May 2009): 2015-.
    • Kuan, C-T, Wakiya, K, II, HJE, Wikstrand, CJ, McLendon, RE, Zalutsky, MR, Pastan, IH, and Bigner, DD. "RECOMBINANT ANTIBODY-BASED MOLECULAR THERAPEUTICS FOR BRAIN TUMOR IMMUNOTHERAPY." NEURO-ONCOLOGY 11, no. 2 (April 2009): 224-224.  Link to Item
    • Quinn, JA, Jiang, SX, Reardon, DA, Desjardins, A, Vredenburgh, JJ, Rich, JN, Gururangan, S, Friedman, AH, Bigner, DD, Sampson, JH, McLendon, RE, Herndon, JE, Walker, A, and Friedman, HS. "Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma." J Clin Oncol 27, no. 8 (March 10, 2009): 1262-1267.  Full Text  Link to Item
    • Paskett, E, Herndon, J, Donohue, K, Naughton, M, Grubbs, S, Pavy, M, Hensley, M, Stark, N, Kornblith, A, Bittoni, M, and for Cancer and Leukemia Group B, . "Health-related quality of life in long-term breast cancer survivors: differences by adjuvant chemotherapy dose in Cancer and Leukemia Group B study 8541." Cancer 115, no. 5 (March 1, 2009): 1109-1120.  Full Text  Link to Item
    • Yan, H, Parsons, DW, Jin, G, McLendon, R, Rasheed, BA, Yuan, W, Kos, I, Batinic-Haberle, I, Jones, S, Riggins, GJ, Friedman, H, Friedman, A, Reardon, D, Herndon, J, Kinzler, KW, Velculescu, VE, Vogelstein, B, and Bigner, DD. "IDH1 and IDH2 mutations in gliomas." N Engl J Med 360, no. 8 (February 19, 2009): 765-773.  Full Text  Link to Item
    • Alfano, CM, Day, JM, Katz, ML, Herndon, JE, Bittoni, MA, Oliveri, JM, Donohue, K, and Paskett, ED. "Exercise and dietary change after diagnosis and cancer-related symptoms in long-term survivors of breast cancer: CALGB 79804." Psychooncology 18, no. 2 (February 2009): 128-133.  Full Text  Link to Item
    • Birchard, KR, Hoang, JK, Herndon, JE, and Patz, EF. "Early changes in tumor size in patients treated for advanced stage nonsmall cell lung cancer do not correlate with survival." Cancer 115, no. 3 (February 1, 2009): 581-586.  Full Text  Link to Item
    • Katz, ML, Donohue, KA, Alfano, CM, Day, JM, Herndon, JE, and Paskett, ED. "Cancer surveillance behaviors and psychosocial factors among long-term survivors of breast cancer. Cancer and Leukemia Group B 79804." Cancer 115, no. 3 (February 1, 2009): 480-488.  Full Text  Link to Item
    • Quinn, JA, Jiang, SX, Carter, J, Reardon, DA, Desjardins, A, Vredenburgh, JJ, Rich, JN, Gururangan, S, Friedman, AH, Bigner, DD, Sampson, JH, McLendon, RE, Herndon, JE, Threatt, S, and Friedman, HS. "Phase II trial of Gliadel plus O6-benzylguanine in adults with recurrent glioblastoma multiforme." Clin Cancer Res 15, no. 3 (February 1, 2009): 1064-1068.  Full Text  Link to Item
    • Grunberg, SM, Weeks, J, Magnan, WF, Herndon, J, Naughton, ML, Blackwell, KL, Wood, ME, Christian, DL, Perry, MC, Dees, EC, Reed, E, and Marshall, ME. "Determination of utility scores for control of chemotherapy-induced nausea or vomiting - CALGB 309801." Journal of Supportive Oncology 7, no. 5 (2009): W17-W22.
    • Strauss, GM, II, JEH, Maddaus, MA, Schilsky, RL, Vokes, EE, and Green, MR. "Reply to A. Katz et al." Journal of Clinical Oncology 27, no. 13 (2009): 2301-2302.  Full Text
    • Abernethy, AP, Herndon, JE, Wheeler, JL, Patwardhan, M, Shaw, H, Lyerly, HK, and Weinfurt, K. "Improving health care efficiency and quality using tablet personal computers to collect research-quality, patient-reported data." Health Serv Res 43, no. 6 (December 2008): 1975-1991.  Full Text  Link to Item
    • Oliveri, JM, Day, JM, Alfano, CM, Herndon, JE, Katz, ML, Bittoni, MA, Donohue, K, and Paskett, ED. "Arm/hand swelling and perceived functioning among breast cancer survivors 12 years post-diagnosis: CALGB 79804." J Cancer Surviv 2, no. 4 (December 2008): 233-242.  Full Text  Link to Item
    • Schmittling, RJ, Archer, GE, Mitchell, DA, Heimberger, A, Pegram, C, Herndon, JE, Friedman, HS, Bigner, DD, and Sampson, JH. "Detection of humoral response in patients with glioblastoma receiving EGFRvIII-KLH vaccines." J Immunol Methods 339, no. 1 (November 30, 2008): 74-81.  Full Text  Link to Item
    • Zafar, SY, Abernethy, AP, Abbott, DH, Grambow, SC, Marcello, JE, Herndon, JE, Rowe, KL, Kolimaga, JT, Zullig, LL, Patwardhan, MB, and Provenzale, DT. "Comorbidity, age, race and stage at diagnosis in colorectal cancer: a retrospective, parallel analysis of two health systems. (Published online)" BMC Cancer 8 (November 25, 2008): 345-.  Full Text  Open Access Copy  Link to Item
    • Desjardins, A, Reardon, DA, Herndon, JE, Marcello, J, Quinn, JA, Rich, JN, Sathornsumetee, S, Gururangan, S, Sampson, J, Bailey, L, Bigner, DD, Friedman, AH, Friedman, HS, and Vredenburgh, JJ. "Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas." Clin Cancer Res 14, no. 21 (November 1, 2008): 7068-7073.  Full Text  Link to Item
    • Paskett, ED, Herndon, JE, Day, JM, Stark, NN, Winer, EP, Grubbs, SS, Pavy, MD, Shapiro, CL, List, MA, Hensley, ML, Naughton, MA, Kornblith, AB, Habin, KR, Fleming, GF, Bittoni, MA, and Cancer and Leukemia Group B, . "Applying a conceptual model for examining health-related quality of life in long-term breast cancer survivors: CALGB study 79804." Psychooncology 17, no. 11 (November 2008): 1108-1120.  Full Text  Link to Item
    • Stinchcombe, TE, Mauer, AM, Hodgson, LD, Herndon, JE, Lynch, TJ, Green, MR, Vokes, EE, and Cancer and Leukemia Group B, . "Phase II trial of paclitaxel and cisplatin in patients with extensive stage small cell lung cancer: Cancer and Leukemia Group B Trial 9430." J Thorac Oncol 3, no. 11 (November 2008): 1301-1307.  Full Text  Link to Item
    • Strauss, GM, Herndon, JE, Maddaus, MA, Johnstone, DW, Johnson, EA, Harpole, DH, Gillenwater, HH, Watson, DM, Sugarbaker, DJ, Schilsky, RL, Vokes, EE, and Green, MR. "Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups." J Clin Oncol 26, no. 31 (November 1, 2008): 5043-5051.  Full Text  Link to Item
    • Bogart, JA, Watson, D, McClay, EF, Evans, L, Herndon, JE, Laurie, F, Seagren, SL, Fitzgerald, TJ, Vokes, E, and Green, MR. "Interruptions of once-daily thoracic radiotherapy do not correlate with outcomes in limited stage small cell lung cancer: analysis of CALGB phase III trial 9235." Lung Cancer 62, no. 1 (October 2008): 92-98.  Full Text  Link to Item
    • Burfeind, WR, Tong, BC, O'Branski, E, Herndon, JE, Toloza, EM, D'Amico, TA, Harpole, LH, and Harpole, DH. "Quality of life outcomes are equivalent after lobectomy in the elderly." J Thorac Cardiovasc Surg 136, no. 3 (September 2008): 597-604.  Full Text  Link to Item
    • Herndon, JE, Kornblith, AB, Holland, JC, and Paskett, ED. "Patient education level as a predictor of survival in lung cancer clinical trials." J Clin Oncol 26, no. 25 (September 1, 2008): 4116-4123.  Full Text  Link to Item
    • Greenberg, JA, Shibata, D, Herndon, JE, Steele, GD, Mayer, R, and Bleday, R. "Local excision of distal rectal cancer: an update of cancer and leukemia group B 8984." Dis Colon Rectum 51, no. 8 (August 2008): 1185-1191.  Full Text  Link to Item
    • Reardon, DA, Desjardins, A, Vredenburgh, JJ, Sathornsumetee, S, Rich, JN, Quinn, JA, Lagattuta, TF, Egorin, MJ, Gururangan, S, McLendon, R, Herndon, JE, Friedman, AH, Salvado, AJ, and Friedman, HS. "Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant glioma." Neuro Oncol 10, no. 3 (June 2008): 330-340.  Full Text  Link to Item
    • Sampson, JH, Akabani, G, Archer, GE, Berger, MS, Coleman, RE, Friedman, AH, Friedman, HS, Greer, K, Herndon, JE, Kunwar, S, McLendon, RE, Paolino, A, Petry, NA, Provenzale, JM, Reardon, DA, Wong, TZ, Zalutsky, MR, Pastan, I, and Bigner, DD. "Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors." Neuro Oncol 10, no. 3 (June 2008): 320-329.  Full Text  Link to Item
    • Abernethy, AP, Zafar, Y, Marcello, J, Wheeler, J, Rowe, K, Morse, MA, and Herndon, JE. "Treatment-related toxicity and supportive care in metastatic colorectal cancer (mCRC)." J Clin Oncol 26, no. 15_suppl (May 20, 2008): 15087-.  Link to Item
    • Abernethy, AP, Zafar, Y, Marcello, J, Wheeler, J, Rowe, K, Morse, MA, and II, HJE. "Treatment-related toxicity and supportive care in metastatic colorectal cancer (mCRC)." JOURNAL OF CLINICAL ONCOLOGY 26, no. 15 (May 20, 2008).  Full Text  Link to Item
    • Desjardins, A, Barboriak, DP, II, HJE, Marcello, J, Reardon, DA, Quinn, JA, Rich, JN, Sathornsumetee, S, Friedman, HS, and Vredenburgh, JJ. "Effect of bevacizumab (BEV) and irinotecan (CPT-11) on dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) in glioblastoma (GBM) patients." JOURNAL OF CLINICAL ONCOLOGY 26, no. 15 (May 20, 2008).  Full Text  Link to Item
    • Garst, J, Datto, M, II, HJE, Barry, WT, Shoemaker, D, Bjurstrom, A, Andrews, C, Ginsburg, G, Nevins, JR, and Potti, A. "A phase II prospective study evaluating the role of pemetrexed plus gemcitabine (Pem/Gem) chemotherapy as intial treatment in patients with stage IIIB/IV non-small cell lung cancer (NSCLC) using a genomic predictor of cisplatin-resistance to guide therapy." JOURNAL OF CLINICAL ONCOLOGY 26, no. 15 (May 20, 2008).  Full Text  Link to Item
    • Herndon, JE, Zafar, Y, Marcello, J, Wheeler, J, Rowe, K, Morse, MA, and Abernethy, AP. "Longitudinal patterns of chemotherapy (CT) use in metastatic colorectal cancer (mCRC)." J Clin Oncol 26, no. 15_suppl (May 20, 2008): 15082-.  Link to Item
    • II, HJE, Zafar, Y, Marcello, J, Wheeler, J, Rowe, K, Morse, MA, and Abernethy, AP. "Longitudinal patterns of chemotherapy (CT) use in metastatic colorectal cancer (mCRC)." JOURNAL OF CLINICAL ONCOLOGY 26, no. 15 (May 20, 2008).  Full Text  Link to Item
    • Mitchell, D, Archer, GE, Bigner, DD, Friedman, HS, Lally-Goss, D, II, HJE, McGehee, S, McLendon, R, Reardon, DA, and Sampson, JH. "Efficacy of a phase II vaccine targeting Cytomegalovirus antigens in newly diagnosed GBM." JOURNAL OF CLINICAL ONCOLOGY 26, no. 15 (May 20, 2008).  Link to Item
    • Scheri, RP, Herndon, JE, Marcello, J, Wheeler, J, Tyler, DS, and Abernethy, AP. "Mortality burden of melanoma: Metastatic site-specific and temporal trends." J Clin Oncol 26, no. 15_suppl (May 20, 2008): 9076-.  Link to Item
    • Uronis, HE, Herndon, JE, Coan, A, Bronson, K, Wheeler, J, Lyerly, HK, Morse, MA, and Abernethy, AP. "E/Tablets to collect research-quality, patient-reported data." J Clin Oncol 26, no. 15_suppl (May 20, 2008): 17528-.  Link to Item
    • Wagner, SA, Desjardins, A, Reardon, DA, Marcello, J, II, HJE, Quinn, JA, Rich, JN, Sathornsumetee, S, Friedman, HS, and Vredenburgh, JJ. "Update on survival from the original phase II trial of bevacizumab and irinotecan in recurrent malignant gliomas." JOURNAL OF CLINICAL ONCOLOGY 26, no. 15 (May 20, 2008).  Full Text  Link to Item
    • Arnold, SD, Forman, LM, Brigidi, BD, Carter, KE, Schweitzer, HA, Quinn, HE, Guill, AB, Herndon, JE, and Raynor, RH. "Evaluation and characterization of generalized anxiety and depression in patients with primary brain tumors." Neuro Oncol 10, no. 2 (April 2008): 171-181.  Full Text  Link to Item
    • Reardon, DA, Zalutsky, MR, Akabani, G, Coleman, RE, Friedman, AH, Herndon, JE, McLendon, RE, Pegram, CN, Quinn, JA, Rich, JN, Vredenburgh, JJ, Desjardins, A, Guruangan, S, Boulton, S, Raynor, RH, Dowell, JM, Wong, TZ, Zhao, X-G, Friedman, HS, and Bigner, DD. "A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost." Neuro Oncol 10, no. 2 (April 2008): 182-189.  Full Text  Link to Item
    • Hoang, JK, Hoagland, LF, Coleman, RE, Coan, AD, Herndon, JE, and Patz, EF. "Prognostic value of fluorine-18 fluorodeoxyglucose positron emission tomography imaging in patients with advanced-stage non-small-cell lung carcinoma." J Clin Oncol 26, no. 9 (March 20, 2008): 1459-1464.  Full Text  Link to Item
    • Lamont, EB, Herndon, JE, Weeks, JC, Henderson, IC, Lilenbaum, R, Schilsky, RL, Christakis, NA, and Cancer and Leukemia Group B, . "Measuring clinically significant chemotherapy-related toxicities using Medicare claims from Cancer and Leukemia Group B (CALGB) trial participants." Med Care 46, no. 3 (March 2008): 303-308.  Full Text  Link to Item
    • Graziano, SL, Herndon, JE, Socinski, MA, Wang, X, Watson, D, Vokes, E, Green, MR, and Cancer and Leukemia Group B, . "Phase II trial of weekly dose-dense paclitaxel in extensive-stage small cell lung cancer: cancer and leukemia group B study 39901." J Thorac Oncol 3, no. 2 (February 2008): 158-162.  Full Text  Link to Item
    • Sathornsumetee, S, Cao, Y, Marcello, JE, Herndon, JE, McLendon, RE, Desjardins, A, Friedman, HS, Dewhirst, MW, Vredenburgh, JJ, and Rich, JN. "Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan." J Clin Oncol 26, no. 2 (January 10, 2008): 271-278.  Full Text  Link to Item
    • Bleday, R, Greenberg, JA, Mayer, R, Shibata, D, II, JEH, and Jr, GDS. "The authors reply." Diseases of the Colon and Rectum 51, no. 8 (2008): 1193-1194.  Full Text
    • Ochiai, H, Archer, GE, Herndon, JE, Kuan, C-T, Mitchell, DA, Bigner, DD, Pastan, IH, and Sampson, JH. "EGFRvIII-targeted immunotoxin induces antitumor immunity that is inhibited in the absence of CD4+ and CD8+ T cells." Cancer Immunol Immunother 57, no. 1 (January 2008): 115-121.  Full Text  Link to Item
    • Zafar, SY, Abernethy, AP, Abbott, DH, Grambow, SC, Marcello, JE, 2nd, JEH, Rowe, KL, Kolimaga, JT, Zullig, LL, Patwardhan, MB, and Provenzale, DT. "Comorbidity, age, race and stage at diagnosis in colorectal cancer: a retrospective, parallel analysis of two health systems." BMC cancer 8 (2008): 345--.  Full Text
    • Patz, EF, Campa, MJ, Gottlin, EB, Kusmartseva, I, Guan, XR, and Herndon, JE. "Panel of serum biomarkers for the diagnosis of lung cancer." J Clin Oncol 25, no. 35 (December 10, 2007): 5578-5583.  Full Text  Link to Item
    • Hoagland, LFM, Campa, MJ, Gottlin, EB, Herndon, JE, and Patz, EF. "Haptoglobin and posttranslational glycan-modified derivatives as serum biomarkers for the diagnosis of nonsmall cell lung cancer." Cancer 110, no. 10 (November 15, 2007): 2260-2268.  Full Text  Link to Item
    • Swanson, SJ, Herndon, JE, D'Amico, TA, Demmy, TL, McKenna, RJ, Green, MR, and Sugarbaker, DJ. "Video-assisted thoracic surgery lobectomy: report of CALGB 39802--a prospective, multi-institution feasibility study." J Clin Oncol 25, no. 31 (November 1, 2007): 4993-4997.  Full Text  Link to Item
    • Vredenburgh, JJ, Desjardins, A, Herndon, JE, Marcello, J, Reardon, DA, Quinn, JA, Rich, JN, Sathornsumetee, S, Gururangan, S, Sampson, J, Wagner, M, Bailey, L, Bigner, DD, Friedman, AH, and Friedman, HS. "Bevacizumab plus irinotecan in recurrent glioblastoma multiforme." J Clin Oncol 25, no. 30 (October 20, 2007): 4722-4729.  Full Text  Link to Item
    • Linardic, CM, Naini, S, Herndon, JE, Kesserwan, C, Qualman, SJ, and Counter, CM. "The PAX3-FKHR fusion gene of rhabdomyosarcoma cooperates with loss of p16INK4A to promote bypass of cellular senescence." Cancer Res 67, no. 14 (July 15, 2007): 6691-6699.  Full Text  Link to Item
    • Loewen, GM, Watson, D, Kohman, L, Herndon, JE, Shennib, H, Kernstine, K, Olak, J, Mador, MJ, Harpole, D, Sugarbaker, D, Green, M, and Cancer and Leukemia Group B, . "Preoperative exercise Vo2 measurement for lung resection candidates: results of Cancer and Leukemia Group B Protocol 9238." J Thorac Oncol 2, no. 7 (July 2007): 619-625.  Full Text  Link to Item
    • Sampson, JH, Raghavan, R, Brady, ML, Provenzale, JM, Herndon, JE, Croteau, D, Friedman, AH, Reardon, DA, Coleman, RE, Wong, T, Bigner, DD, Pastan, I, Rodríguez-Ponce, MI, Tanner, P, Puri, R, and Pedain, C. "Clinical utility of a patient-specific algorithm for simulating intracerebral drug infusions." Neuro Oncol 9, no. 3 (July 2007): 343-353.  Full Text  Link to Item
    • Gauger, J, Patz, EF, Coleman, RE, and Herndon, JE. "Clinical stage I non-small cell lung cancer including FDG-PET Imaging: sites and time to recurrence." J Thorac Oncol 2, no. 6 (June 2007): 499-505.  Full Text  Link to Item
    • Riedel, RF, Andrews, C, Garst, J, Dunphy, F, Herndon, JE, Blackwell, S, Barbour, S, and Crawford, J. "A phase II trial of carboplatin/vinorelbine with pegfilgrastim support for the treatment of patients with advanced non-small cell lung cancer." J Thorac Oncol 2, no. 6 (June 2007): 520-525.  Full Text  Link to Item
    • Desjardins, A, Quinn, JA, Vredenburgh, JJ, Sathornsumetee, S, Friedman, AH, Herndon, JE, McLendon, RE, Provenzale, JM, Rich, JN, Sampson, JH, Gururangan, S, Dowell, JM, Salvado, A, Friedman, HS, and Reardon, DA. "Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas." J Neurooncol 83, no. 1 (May 2007): 53-60.  Full Text  Link to Item
    • McLendon, RE, Akabani, G, Friedman, HS, Reardon, DA, Cleveland, L, Cokgor, I, Herndon, JE, Wikstrand, C, Boulton, ST, Friedman, AH, Bigner, DD, and Zalutsky, MR. "Tumor resection cavity administered iodine-131-labeled antitenascin 81C6 radioimmunotherapy in patients with malignant glioma: neuropathology aspects." Nucl Med Biol 34, no. 4 (May 2007): 405-413.  Full Text  Link to Item
    • Vokes, EE, Herndon, JE, Kelley, MJ, Cicchetti, MG, Ramnath, N, Neill, H, Atkins, JN, Watson, DM, Akerley, W, Green, MR, and Cancer and Leukemia Group B, . "Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: Cancer and Leukemia Group B." J Clin Oncol 25, no. 13 (May 1, 2007): 1698-1704.  Full Text  Link to Item
    • Gururangan, S, Fisher, MJ, Allen, JC, Herndon, JE, Quinn, JA, Reardon, DA, Vredenburgh, JJ, Desjardins, A, Phillips, PC, Watral, MA, Krauser, JM, Friedman, AH, and Friedman, HS. "Temozolomide in children with progressive low-grade glioma." Neuro Oncol 9, no. 2 (April 2007): 161-168.  Full Text  Link to Item
    • Vredenburgh, JJ, Desjardins, A, Herndon, JE, Dowell, JM, Reardon, DA, Quinn, JA, Rich, JN, Sathornsumetee, S, Gururangan, S, Wagner, M, Bigner, DD, Friedman, AH, and Friedman, HS. "Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma." Clin Cancer Res 13, no. 4 (February 15, 2007): 1253-1259.  Full Text  Link to Item
    • Rocha-Lima, CM, Herndon, JE, Lee, ME, Atkins, JN, Mauer, A, Vokes, E, Green, MR, and Cancer and Leukemia Group B, . "Phase II trial of irinotecan/gemcitabine as second-line therapy for relapsed and refractory small-cell lung cancer: Cancer and Leukemia Group B Study 39902." Ann Oncol 18, no. 2 (February 2007): 331-337.  Full Text  Link to Item
    • Badruddoja, MA, Penne, K, Desjardins, A, Reardon, DA, Rich, JN, Quinn, JA, Sathornsumetee, S, Friedman, AH, Bigner, DD, Herndon, JE, Cahill, A, Friedman, HS, and Vredenburgh, JJ. "Phase II study of Cloretazine for the treatment of adults with recurrent glioblastoma multiforme." Neuro Oncol 9, no. 1 (January 2007): 70-74.  Full Text  Link to Item
    • Cornett, WR, McCall, LM, Petersen, RP, II, JEH, and Tyler, DS. "In reply [8]." Journal of Clinical Oncology 25, no. 11 (2007): 1450-1451.  Full Text
    • Cornett, WR, McCall, LM, Petersen, RP, II, JEH, and Tyler, DS. "In reply [14]." Journal of Clinical Oncology 25, no. 9 (2007): 1149-1151.  Full Text
    • Jaklitsch, MT, Herndon, JE, DeCamp, MM, Richards, WG, Kumar, P, Krasna, MJ, Green, MR, and Sugarbaker, DJ. "Nodal downstaging predicts survival following induction chemotherapy for stage IIIA (N2) non-small cell lung cancer in CALGB protocol #8935." J Surg Oncol 94, no. 7 (December 1, 2006): 599-606.  Full Text  Link to Item
    • Kornblith, AB, Dowell, JM, Herndon, JE, Engelman, BJ, Bauer-Wu, S, Small, EJ, Morrison, VA, Atkins, J, Cohen, HJ, and Holland, JC. "Telephone monitoring of distress in patients aged 65 years or older with advanced stage cancer: a cancer and leukemia group B study." Cancer 107, no. 11 (December 1, 2006): 2706-2714.  Full Text  Link to Item
    • Riedel, RF, Crawford, J, Dunphy, F, Herndon, JE, Garst, J, and Kelley, MJ. "Phase II study of carboplatin, irinotecan, and thalidomide combination in patients with extensive stage small-cell lung cancer." Lung Cancer 54, no. 3 (December 2006): 431-432. (Letter)  Full Text  Link to Item
    • Vlahovic, G, Rabbani, ZN, Herndon, JE, Dewhirst, MW, and Vujaskovic, Z. "Treatment with Imatinib in NSCLC is associated with decrease of phosphorylated PDGFR-beta and VEGF expression, decrease in interstitial fluid pressure and improvement of oxygenation." Br J Cancer 95, no. 8 (October 23, 2006): 1013-1019.  Full Text  Open Access Copy  Link to Item
    • Anscher, MS, Garst, J, Marks, LB, Larrier, N, Dunphy, F, Herndon, JE, Clough, R, Marino, C, Vujaskovic, Z, Zhou, S, Dewhirst, MW, Shafman, TD, and Crawford, J. "Assessing the ability of the antiangiogenic and anticytokine agent thalidomide to modulate radiation-induced lung injury." Int J Radiat Oncol Biol Phys 66, no. 2 (October 1, 2006): 477-482.  Full Text  Link to Item
    • Maxwell, JA, Johnson, SP, Quinn, JA, McLendon, RE, Ali-Osman, F, Friedman, AH, Herndon, JE, Bierau, K, Bigley, J, Bigner, DD, and Friedman, HS. "Quantitative analysis of O6-alkylguanine-DNA alkyltransferase in malignant glioma." Mol Cancer Ther 5, no. 10 (October 2006): 2531-2539.  Full Text  Link to Item
    • Lamont, EB, Herndon, JE, Weeks, JC, Henderson, IC, Earle, CC, Schilsky, RL, Christakis, NA, and Cancer and Leukemia Group B, . "Measuring disease-free survival and cancer relapse using Medicare claims from CALGB breast cancer trial participants (companion to 9344)." J Natl Cancer Inst 98, no. 18 (September 20, 2006): 1335-1338.  Full Text  Open Access Copy  Link to Item
    • Cornett, WR, McCall, LM, Petersen, RP, Ross, MI, Briele, HA, Noyes, RD, Sussman, JJ, Kraybill, WG, Kane, JM, Alexander, HR, Lee, JE, Mansfield, PF, Pingpank, JF, Winchester, DJ, White, RL, Chadaram, V, Herndon, JE, Fraker, DL, Tyler, DS, and American College of Surgeons Oncology Group Trial Z0020, . "Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020." J Clin Oncol 24, no. 25 (September 1, 2006): 4196-4201.  Full Text  Link to Item
    • Reardon, DA, Zalutsky, MR, Akabani, G, Coleman, RE, Friedman, AH, McLendon, RE, Friedman, HS, II, HJE, Kirkpatrick, J, and Bigner, DD. "Radioimmunotherapy of patients with malignant brain tumors: patient-specific dosing of I-131-labeled anti-tenacin antibody to achieve 44 Gy boost dose to resection cavity margins." EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING 33 (September 2006): S194-S194.  Link to Item
    • Zalutsky, MR, Reardon, DA, Quinn, JA, Coleman, RE, Akabani, G, Friedman, AH, Friedman, HS, II, HJE, McLendon, RE, Wong, TZ, and Bigner, DD. "Chimeric murine/human IgG(2) anti-tenascin 81C6 monoclonal antibody: phase I trial in patients with malignant glioma of a construct with improved stability." EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING 33 (September 2006): S194-S194.  Link to Item
    • Strauss, GM, Herndon, JE, Maddaus, MA, Johnstone, DW, Johnson, EA, Watson, DM, Sugarbaker, DJ, Schilsky, RA, Vokes, EE, Green, MR, CALGB, and Radiation Therapy Oncology Group, . "Adjuvant chemotherapy in stage IB non-small cell lung cancer (NSCLC): Update of Cancer and Leukemia Group B (CALGB) protocol 9633." J Clin Oncol 24, no. 18_suppl (June 20, 2006): 7007-.  Link to Item
    • Vredenburgh, JJ, Desjardins, A, Herndon, JE, Quinn, J, Rich, J, Sathornsumetee, S, Friedman, HS, Reardon, D, Gururangan, S, and Friedman, A. "Bevacizumab, a monoclonal antibody to vascular endothelial growth factor (VEGF), and irinotecan for treatment of malignant gliomas." J Clin Oncol 24, no. 18_suppl (June 20, 2006): 1506-.  Link to Item
    • D'Amico, TA, Brooks, KR, Joshi, M-BM, Conlon, D, Herndon, J, Petersen, RP, and Harpole, DH. "Serum protein expression predicts recurrence in patients with early-stage lung cancer after resection." Ann Thorac Surg 81, no. 6 (June 2006): 1982-1987.  Full Text  Link to Item
    • Reardon, DA, Quinn, JA, Akabani, G, Coleman, RE, Friedman, AH, Friedman, HS, Herndon, JE, McLendon, RE, Pegram, CN, Provenzale, JM, Dowell, JM, Rich, JN, Vredenburgh, JJ, Desjardins, A, Sampson, JH, Gururangan, S, Wong, TZ, Badruddoja, MA, Zhao, X-G, Bigner, DD, and Zalutsky, MR. "Novel human IgG2b/murine chimeric antitenascin monoclonal antibody construct radiolabeled with 131I and administered into the surgically created resection cavity of patients with malignant glioma: phase I trial results." J Nucl Med 47, no. 6 (June 2006): 912-918.  Link to Item
    • Kuan, C-T, Wakiya, K, Dowell, JM, Herndon, JE, Reardon, DA, Graner, MW, Riggins, GJ, Wikstrand, CJ, and Bigner, DD. "Glycoprotein nonmetastatic melanoma protein B, a potential molecular therapeutic target in patients with glioblastoma multiforme." Clin Cancer Res 12, no. 7 Pt 1 (April 1, 2006): 1970-1982.  Full Text  Link to Item
    • Wilke, LG, McCall, LM, Posther, KE, Whitworth, PW, Reintgen, DS, Leitch, AM, Gabram, SGA, Lucci, A, Cox, CE, Hunt, KK, Herndon, JE, and Giuliano, AE. "Surgical complications associated with sentinel lymph node biopsy: results from a prospective international cooperative group trial." Ann Surg Oncol 13, no. 4 (April 2006): 491-500.  Full Text  Link to Item
    • Kemeny, NE, Niedzwiecki, D, Hollis, DR, Lenz, H-J, Warren, RS, Naughton, MJ, Weeks, JC, Sigurdson, ER, Herndon, JE, Zhang, C, and Mayer, RJ. "Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481)." J Clin Oncol 24, no. 9 (March 20, 2006): 1395-1403.  Full Text  Link to Item
    • Fecci, PE, Mitchell, DA, Whitesides, JF, Xie, W, Friedman, AH, Archer, GE, Herndon, JE, Bigner, DD, Dranoff, G, and Sampson, JH. "Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma." Cancer Res 66, no. 6 (March 15, 2006): 3294-3302.  Full Text  Link to Item
    • Allen, MS, Darling, GE, Pechet, TTV, Mitchell, JD, Herndon, JE, Landreneau, RJ, Inculet, RI, Jones, DR, Meyers, BF, Harpole, DH, Putnam, JB, Rusch, VW, and ACOSOG Z0030 Study Group, . "Morbidity and mortality of major pulmonary resections in patients with early-stage lung cancer: initial results of the randomized, prospective ACOSOG Z0030 trial." Ann Thorac Surg 81, no. 3 (March 2006): 1013-1019.  Full Text  Link to Item
    • Kornblith, AB, Dowell, JM, Herndon, JE, Rosenberg, S, Engelman, B, Small, EJ, Morrison, VA, Atkins, J, Muss, H, and Holland, JC. "Telephone monitoring: Early identification of psychological, physical and social distress in older advanced-stage cancer patients." PSYCHO-ONCOLOGY 15, no. 1 (February 2006): S21-S22.  Link to Item
    • Reardon, DA, Quinn, JA, Vredenburgh, JJ, Gururangan, S, Friedman, AH, Desjardins, A, Sathornsumetee, S, Herndon, JE, Dowell, JM, McLendon, RE, Provenzale, JM, Sampson, JH, Smith, RP, Swaisland, AJ, Ochs, JS, Lyons, P, Tourt-Uhlig, S, Bigner, DD, Friedman, HS, and Rich, JN. "Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma." Clin Cancer Res 12, no. 3 Pt 1 (February 1, 2006): 860-868.  Full Text  Link to Item
    • Blackstock, AW, Herndon, JE, Paskett, ED, Miller, AA, Lathan, C, Niell, HB, Socinski, MA, Vokes, EE, Green, MR, and Cancer and Leukemia Group B, . "Similar outcomes between African American and non-African American patients with extensive-stage small-cell lung carcinoma: report from the Cancer and Leukemia Group B." J Clin Oncol 24, no. 3 (January 20, 2006): 407-412.  Full Text  Link to Item
    • Garst, J, Herndon, JE, Shafman, T, Campagna, L, Blackwell, S, Padilla, K, Bjurstrom, T, Andrews, C, Maravich-May, D, Anderson, E, and Crawford, J. "A phase I study of dose-dense topotecan given upfront to standard therapy in patients with small cell lung cancer." Clin Drug Investig 26, no. 5 (2006): 257-266.  Link to Item
    • Reardon, DA, Akabani, G, Coleman, RE, Friedman, AH, Friedman, HS, Herndon, JE, McLendon, RE, Pegram, CN, Provenzale, JM, Quinn, JA, Rich, JN, Vredenburgh, JJ, Desjardins, A, Gururangan, S, Badruddoja, M, Dowell, JM, Wong, TZ, Zhao, X-G, Zalutsky, MR, and Bigner, DD. "Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results." J Clin Oncol 24, no. 1 (January 1, 2006): 115-122.  Full Text  Link to Item
    • Reardon, DA, Egorin, MJ, Quinn, JA, Rich, JN, Gururangan, S, Vredenburgh, JJ, Desjardins, A, Sathornsumetee, S, Provenzale, JM, Herndon, JE, Dowell, JM, Badruddoja, MA, McLendon, RE, Lagattuta, TF, Kicielinski, KP, Dresemann, G, Sampson, JH, Friedman, AH, Salvado, AJ, and Friedman, HS. "Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme." J Clin Oncol 23, no. 36 (December 20, 2005): 9359-9368.  Full Text  Link to Item
    • McLendon, RE, Herndon, JE, West, B, Reardon, D, Wiltshire, R, Rasheed, BKA, Quinn, J, Friedman, HS, Friedman, AH, and Bigner, DD. "Survival analysis of presumptive prognostic markers among oligodendrogliomas." Cancer 104, no. 8 (October 15, 2005): 1693-1699.  Full Text  Link to Item
    • Peppercorn, J, Herndon, J, Kornblith, AB, Peters, W, Ahles, T, Vredenburgh, J, Schwartz, G, Shpall, E, Hurd, DD, Holland, J, and Winer, E. "Quality of life among patients with Stage II and III breast carcinoma randomized to receive high-dose chemotherapy with autologous bone marrow support or intermediate-dose chemotherapy: results from Cancer and Leukemia Group B 9066." Cancer 104, no. 8 (October 15, 2005): 1580-1589.  Full Text  Link to Item
    • Leitch, AM, Beitsch, PD, McCall, LM, Posther, K, Newman, LA, Herndon, JE, Hunt, KK, and Giuliano, AE. "Patterns of participation and successful patient recruitment to American College of Surgeons Oncology Group Z0010, a phase II trial for patients with early-stage breast cancer." Am J Surg 190, no. 4 (October 2005): 539-542.  Full Text  Link to Item
    • Posther, KE, McCall, LM, Blumencranz, PW, Burak, WE, Beitsch, PD, Hansen, NM, Morrow, M, Wilke, LG, Herndon, JE, Hunt, KK, and Giuliano, AE. "Sentinel node skills verification and surgeon performance: data from a multicenter clinical trial for early-stage breast cancer." Ann Surg 242, no. 4 (October 2005): 593-599.  Link to Item
    • Quinn, JA, Desjardins, A, Weingart, J, Brem, H, Dolan, ME, Delaney, SM, Vredenburgh, J, Rich, J, Friedman, AH, Reardon, DA, Sampson, JH, Pegg, AE, Moschel, RC, Birch, R, McLendon, RE, Provenzale, JM, Gururangan, S, Dancey, JE, Maxwell, J, Tourt-Uhlig, S, Herndon, JE, Bigner, DD, and Friedman, HS. "Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma." J Clin Oncol 23, no. 28 (October 1, 2005): 7178-7187.  Full Text  Link to Item
    • Reardon, DA, Quinn, JA, Rich, JN, Desjardins, A, Vredenburgh, J, Gururangan, S, Sathornsumetee, S, Badruddoja, M, McLendon, R, Provenzale, J, Herndon, JE, Dowell, JM, Burkart, JL, Newton, HB, Friedman, AH, and Friedman, HS. "Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma." Cancer 104, no. 7 (October 1, 2005): 1478-1486.  Full Text  Link to Item
    • Lamont, EB, Herndon, JE, Weeks, JC, Henderson, IC, Lilenbaum, R, Schilsky, RL, and Christakis, NA. "Criterion validity of Medicare chemotherapy claims in Cancer and Leukemia Group B breast and lung cancer trial participants." J Natl Cancer Inst 97, no. 14 (July 20, 2005): 1080-1083.  Full Text  Link to Item
    • Akerley, W, Herndon, JE, Lyss, AP, Choy, H, Turrisi, A, Graziano, S, Williams, T, Zhang, C, Vokes, EE, and Green, MR. "Induction paclitaxel/carboplatin followed by concurrent chemoradiation therapy for unresectable stage III non-small-cell lung cancer: a limited-access study--CALGB 9534." Clin Lung Cancer 7, no. 1 (July 2005): 47-53.  Full Text  Link to Item
    • Kindler, HL, Herndon, JE, Zhang, C, Green, MR, and Cancer and Leukemia Group B, . "Irinotecan for malignant mesothelioma A phase II trial by the Cancer and Leukemia Group B." Lung Cancer 48, no. 3 (June 2005): 423-428.  Full Text  Link to Item
    • Miller, AA, Herndon, JE, Gu, L, Green, MR, and Cancer and Leukemia Group B, . "Phase II trial of karenitecin in patients with relapsed or refractory non-small cell lung cancer (CALGB 30004)." Lung Cancer 48, no. 3 (June 2005): 399-407.  Full Text  Link to Item
    • Niell, HB, Herndon, JE, Miller, AA, Watson, DM, Sandler, AB, Kelly, K, Marks, RS, Perry, MC, Ansari, RH, Otterson, G, Ellerton, J, Vokes, EE, Green, MR, and Cancer and Leukemia Group, . "Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732." J Clin Oncol 23, no. 16 (June 1, 2005): 3752-3759.  Full Text  Link to Item
    • D'Cunha, J, Herndon, JE, Herzan, DL, Patterson, GA, Kohman, LJ, Harpole, DH, Kernstine, KH, Kern, JA, Green, MR, Maddaus, MA, Kratzke, RA, and Cancer and Leukemia Group B, . "Poor correspondence between clinical and pathologic staging in stage 1 non-small cell lung cancer: results from CALGB 9761, a prospective trial." Lung Cancer 48, no. 2 (May 2005): 241-246.  Full Text  Link to Item
    • Hensley, ML, Dowell, J, Herndon, JE, Winer, E, Stark, N, Weeks, JC, and Paskett, E. "Economic outcomes of breast cancer survivorship: CALGB study 79804." Breast Cancer Res Treat 91, no. 2 (May 2005): 153-161.  Full Text  Link to Item
    • Clamon, G, Herndon, J, Kern, J, Govindan, R, Garst, J, Watson, D, Green, M, and Cancer and Leukemia Group B, . "Lack of trastuzumab activity in nonsmall cell lung carcinoma with overexpression of erb-B2: 39810: a phase II trial of Cancer and Leukemia Group B." Cancer 103, no. 8 (April 15, 2005): 1670-1675.  Full Text  Link to Item
    • Kelley, MJ, Glaser, EM, Herndon, JE, Becker, F, Bhagat, R, Zhang, Y-J, Santella, RM, Carmella, SG, Hecht, SS, Gallot, L, Schilder, L, Crowell, JA, Perloff, M, Folz, RJ, and Bergan, RC. "Safety and efficacy of weekly oral oltipraz in chronic smokers." Cancer Epidemiol Biomarkers Prev 14, no. 4 (April 2005): 892-899.  Full Text  Link to Item
    • Kim, Y-H, Marom, EM, Herndon, JE, and McAdams, HP. "Pulmonary vein diameter, cross-sectional area, and shape: CT analysis." Radiology 235, no. 1 (April 2005): 43-49.  Full Text  Link to Item
    • Shennib, H, Bogart, J, Herndon, JE, Kohman, L, Keenan, R, Green, M, Sugarbaker, D, Cancer and Leukemia Group B, , and Eastern Cooperative Oncology Group, . "Video-assisted wedge resection and local radiotherapy for peripheral lung cancer in high-risk patients: the Cancer and Leukemia Group B (CALGB) 9335, a phase II, multi-institutional cooperative group study." J Thorac Cardiovasc Surg 129, no. 4 (April 2005): 813-818.  Full Text  Link to Item
    • Govindan, R, Kratzke, RA, Herndon, JE, Niehans, GA, Vollmer, R, Watson, D, Green, MR, Kindler, HL, and Cancer and Leukemia Group B (CALGB 30101), . "Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B." Clin Cancer Res 11, no. 6 (March 15, 2005): 2300-2304.  Full Text  Link to Item
    • Joshi, M-BM, Shirota, Y, Danenberg, KD, Conlon, DH, Salonga, DS, Herndon, JE, Danenberg, PV, and Harpole, DH. "High gene expression of TS1, GSTP1, and ERCC1 are risk factors for survival in patients treated with trimodality therapy for esophageal cancer." Clin Cancer Res 11, no. 6 (March 15, 2005): 2215-2221.  Full Text  Link to Item
    • Dresler, CM, Olak, J, Herndon, JE, Richards, WG, Scalzetti, E, Fleishman, SB, Kernstine, KH, Demmy, T, Jablons, DM, Kohman, L, Daniel, TM, Haasler, GB, Sugarbaker, DJ, Cooperative Groups Cancer and Leukemia Group B, , Eastern Cooperative Oncology Group, , North Central Cooperative Oncology Group, , and Radiation Therapy Oncology Group, . "Phase III intergroup study of talc poudrage vs talc slurry sclerosis for malignant pleural effusion." Chest 127, no. 3 (March 2005): 909-915.  Full Text  Link to Item
    • McClay, EF, Bogart, J, Herndon, JE, Watson, D, Evans, L, Seagren, SL, Green, MR, and Cancer and Leukemia Group B Study (9235), . "A phase III trial evaluating the combination of cisplatin, etoposide, and radiation therapy with or without tamoxifen in patients with limited-stage small cell lung cancer: Cancer and Leukemia Group B Study (9235)." Am J Clin Oncol 28, no. 1 (February 2005): 81-90.  Link to Item
    • Reardon, DA, Quinn, JA, Vredenburgh, J, Rich, JN, Gururangan, S, Badruddoja, M, Herndon, JE, Dowell, JM, Friedman, AH, and Friedman, HS. "Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma." Cancer 103, no. 2 (January 15, 2005): 329-338.  Full Text  Link to Item
    • Jr, EFP, Swensen, SJ, and Herndon, JE. "In reply [4]." Journal of Clinical Oncology 23, no. 9 (2005): 2107-2108.  Full Text
    • Jr, EFP, Swensen, SJ, and II, JEH. "In reply [12]." Journal of Clinical Oncology 23, no. 10 (2005): 2440-2441.  Full Text
    • Lilenbaum, RC, Herndon, JE, List, MA, Desch, C, Watson, DM, Miller, AA, Graziano, SL, Perry, MC, Saville, W, Chahinian, P, Weeks, JC, Holland, JC, and Green, MR. "Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730)." J Clin Oncol 23, no. 1 (January 1, 2005): 190-196.  Full Text  Link to Item
    • Weeks, JC, Romanus, D, Herndon, JE, Schrag, D, Mayer, RJ, and Kemeny, N. "Cost-effectiveness of hepatic artery infusion for metastatic colorectal cancer (CALGB 9481)." VALUE IN HEALTH 8, no. 6 (2005): A37-A37.  Full Text  Link to Item
    • Gururangan, S, Hwang, E, Herndon, JE, Fuchs, H, George, T, and Coleman, RE. "[18F]fluorodeoxyglucose-positron emission tomography in patients with medulloblastoma." Neurosurgery 55, no. 6 (December 2004): 1280-1288.  Link to Item
    • Gururangan, S, Hwang, E, Herndon, JE, Fuchs, H, George, T, and Coleman, RE. "[F-18] fluorodeoxyglucose-positron emission tomography in patients with medulloblastoma." NEUROSURGERY 55, no. 6 (December 2004): 1280-1289.  Full Text  Link to Item
    • Howard, BA, Zheng, Z, Campa, MJ, Wang, MZ, Sharma, A, Haura, E, Herndon, JE, Fitzgerald, MC, Bepler, G, and Patz, EF. "Translating biomarkers into clinical practice: prognostic implications of cyclophilin A and macrophage migratory inhibitory factor identified from protein expression profiles in non-small cell lung cancer." Lung Cancer 46, no. 3 (December 2004): 313-323.  Full Text  Link to Item
    • Ahles, TA, Herndon, JE, Small, EJ, Vogelzang, NJ, Kornblith, AB, Ratain, MJ, Stadler, W, Palchak, D, Marshall, ME, Wilding, G, Petrylak, D, Holland, JC, and Cancer and Leukemia Group B, . "Quality of life impact of three different doses of suramin in patients with metastatic hormone-refractory prostate carcinoma: results of Intergroup O159/Cancer and Leukemia Group B 9480." Cancer 101, no. 10 (November 15, 2004): 2202-2208.  Full Text  Link to Item
    • Marks, LB, Garst, J, Socinski, MA, Sibley, G, Blackstock, AW, Herndon, JE, Zhou, S, Shafman, T, Tisch, A, Clough, R, Yu, X, Turrisi, A, Anscher, M, Crawford, J, Rosenman, J, and Carolina Conformal Therapy Consortium, . "Carboplatin/paclitaxel or carboplatin/vinorelbine followed by accelerated hyperfractionated conformal radiation therapy: report of a prospective phase I dose escalation trial from the Carolina Conformal Therapy Consortium." J Clin Oncol 22, no. 21 (November 1, 2004): 4329-4340.  Full Text  Link to Item
    • Sherman, CA, Herndon, JE, Watson, DM, Green, MR, and Cancer and Leukemia Group B, . "A phase II trial of 6-hydroxymethylacylfulvene (MGI-114, irofulven) in patients with relapsed or refractory non-small cell lung cancer." Lung Cancer 45, no. 3 (September 2004): 387-392.  Full Text  Link to Item
    • Wiltshire, RN, Herndon, JE, Lloyd, A, Friedman, HS, Bigner, DD, Bigner, SH, and McLendon, RE. "Comparative genomic hybridization analysis of astrocytomas: prognostic and diagnostic implications." J Mol Diagn 6, no. 3 (August 2004): 166-179.  Full Text  Link to Item
    • Socinski, MA, Zhang, C, Herndon, JE, Dillman, RO, Clamon, G, Vokes, E, Akerley, W, Crawford, J, Perry, MC, Seagren, SL, and Green, MR. "Combined modality trials of the Cancer and Leukemia Group B in stage III non-small-cell lung cancer: analysis of factors influencing survival and toxicity." Ann Oncol 15, no. 7 (July 2004): 1033-1041.  Full Text  Link to Item
    • Vokes, EE, Herndon, JE, Kelley, MJ, Watson, D, Cicchetti, MG, and Green, MR. "Induction chemotherapy followed by concomitant chemoradiotherapy (CT/XRT) versus CT/XRT alone for regionally advanced unresectable non-small cell lung cancer (NSCLC): Initial analysis of a randomized phase III trial." Journal of clinical oncology : official journal of the American Society of Clinical Oncology 22, no. 14_suppl (July 2004): 7005-.
    • Bogart, JA, Herndon, JE, Lyss, AP, Watson, D, Miller, AA, Lee, ME, Turrisi, AT, Green, MR, and Cancer and Leukemia Group B study 39808, . "70 Gy thoracic radiotherapy is feasible concurrent with chemotherapy for limited-stage small-cell lung cancer: analysis of Cancer and Leukemia Group B study 39808." Int J Radiat Oncol Biol Phys 59, no. 2 (June 1, 2004): 460-468.  Full Text  Link to Item
    • Cheran, SK, Herndon, JE, and Patz, EF. "Comparison of whole-body FDG-PET to bone scan for detection of bone metastases in patients with a new diagnosis of lung cancer." Lung Cancer 44, no. 3 (June 2004): 317-325.  Full Text  Link to Item
    • Patz, EF, Swensen, SJ, and Herndon, JE. "Estimate of lung cancer mortality from low-dose spiral computed tomography screening trials: implications for current mass screening recommendations." J Clin Oncol 22, no. 11 (June 1, 2004): 2202-2206. (Review)  Full Text  Link to Item
    • McLendon, RE, Rasheed, A, Wiltshire, R, and Herndon, J. "Correlation of 1p-19q-defects in human gliomas with the light microscopic appearance of oligodendroglioma." Mod Pathol 17, no. 5 (May 2004): 604-605. (Letter)  Full Text  Link to Item
    • Otterson, GA, Herndon, JE, Watson, D, Green, MR, Kindler, HL, and Cancer and Leukemia Group B, . "Capecitabine in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (39807)." Lung Cancer 44, no. 2 (May 2004): 251-259.  Full Text  Link to Item
    • Quinn, JA, Reardon, DA, Friedman, AH, Rich, JN, Sampson, JH, Vredenburgh, J, Gururangan, S, Provenzale, JM, Walker, A, Schweitzer, H, Bigner, DD, Tourt-Uhlig, S, Herndon, JE, Affronti, ML, Jackson, S, Allen, D, Ziegler, K, Bohlin, C, Lentz, C, and Friedman, HS. "Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant glioma." Neuro Oncol 6, no. 2 (April 2004): 145-153.  Full Text  Link to Item
    • Reardon, DA, Quinn, JA, Rich, JN, Gururangan, S, Vredenburgh, J, Sampson, JH, Provenzale, JM, Walker, A, Badruddoja, M, Tourt-Uhlig, S, Herndon, JE, Dowell, JM, Affronti, ML, Jackson, S, Allen, D, Ziegler, K, Silverman, S, Bohlin, C, Friedman, AH, Bigner, DD, and Friedman, HS. "Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma." Neuro Oncol 6, no. 2 (April 2004): 134-144.  Link to Item
    • Marom, EM, Herndon, JE, Kim, YH, and McAdams, HP. "Variations in pulmonary venous drainage to the left atrium: implications for radiofrequency ablation." Radiology 230, no. 3 (March 2004): 824-829.  Full Text  Link to Item
    • Rocha Lima, CM, Rizvi, NA, Zhang, C, Herndon, JE, Crawford, J, Govindan, R, King, GW, Green, MR, and Cancer Leukemia Group B, . "Randomized phase II trial of gemcitabine plus irinotecan or docetaxel in stage IIIB or stage IV NSCLC." Ann Oncol 15, no. 3 (March 2004): 410-418. (Review)  Link to Item
    • Johnson, E, Lake, D, Herndon, JE, Box, JW, Lynch, TJ, and Green, MR. "Phase II trial of vinorelbine plus doxorubicin in relapsed small-cell lung cancer: CALGB 9332." Am J Clin Oncol 27, no. 1 (February 2004): 19-23.  Link to Item
    • Gururangan, S, Hwang, E, II, JEH, Fuchs, H, George, T, and Coleman, RE. "[¹⁸F]fluorodeoxyglucose-positron emission tomography in patients with medulloblastoma." Neurosurgery 55, no. 6 (2004): 1280-1288.  Full Text
    • Rich, JN, Reardon, DA, Peery, T, Dowell, JM, Quinn, JA, Penne, KL, Wikstrand, CJ, Van Duyn, LB, Dancey, JE, McLendon, RE, Kao, JC, Stenzel, TT, Ahmed Rasheed, BK, Tourt-Uhlig, SE, Herndon, JE, Vredenburgh, JJ, Sampson, JH, Friedman, AH, Bigner, DD, and Friedman, HS. "Phase II trial of gefitinib in recurrent glioblastoma." J Clin Oncol 22, no. 1 (January 1, 2004): 133-142.  Full Text  Link to Item
    • Vollmer, RT, Herndon, JE, D'Cunha, J, Abraham, NZ, Solberg, J, Fatourechi, M, Maruska, A, Kern, JA, Green, MR, Kratzke, RA, Maddaus, MA, and Cancer and Leukemia Group B Trial 9761, . "Immunohistochemical detection of occult lymph node metastases in non-small cell lung cancer: anatomical pathology results from Cancer and Leukemia Group B Trial 9761." Clin Cancer Res 9, no. 15 (November 15, 2003): 5630-5635.  Link to Item
    • Bernacki, SH, Stankovic, AK, Williams, LO, Beck, JC, Herndon, JE, Snow-Bailey, K, Prior, TW, Matteson, KJ, Wasserman, LM, Cole, EC, and Stenzel, TT. "Establishment of stably EBV-transformed cell lines from residual clinical blood samples for use in performance evaluation and quality assurance in molecular genetic testing." J Mol Diagn 5, no. 4 (November 2003): 227-230.  Full Text  Link to Item
    • Sampson, JH, Akabani, G, Archer, GE, Bigner, DD, Berger, MS, Friedman, AH, Friedman, HS, Herndon, JE, Kunwar, S, Marcus, S, McLendon, RE, Paolino, A, Penne, K, Provenzale, J, Quinn, J, Reardon, DA, Rich, J, Stenzel, T, Tourt-Uhlig, S, Wikstrand, C, Wong, T, Williams, R, Yuan, F, Zalutsky, MR, and Pastan, I. "Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors." J Neurooncol 65, no. 1 (October 2003): 27-35.  Link to Item
    • Kornblith, AB, Herndon, JE, Weiss, RB, Zhang, C, Zuckerman, EL, Rosenberg, S, Mertz, M, Payne, D, Jane Massie, M, Holland, JF, Wingate, P, Norton, L, and Holland, JC. "Long-term adjustment of survivors of early-stage breast carcinoma, 20 years after adjuvant chemotherapy." Cancer 98, no. 4 (August 15, 2003): 679-689.  Full Text  Link to Item
    • Anscher, MS, Marks, LB, Shafman, TD, Clough, R, Huang, H, Tisch, A, Munley, M, Herndon, JE, Garst, J, Crawford, J, and Jirtle, RL. "Risk of long-term complications after TFG-beta1-guided very-high-dose thoracic radiotherapy." Int J Radiat Oncol Biol Phys 56, no. 4 (July 15, 2003): 988-995.  Link to Item
    • Brooks, KR, To, K, Joshi, M-BM, Conlon, DH, Herndon, JE, D'Amico, TA, and Harpole, DH. "Measurement of chemoresistance markers in patients with stage III non-small cell lung cancer: a novel approach for patient selection." Ann Thorac Surg 76, no. 1 (July 2003): 187-193.  Link to Item
    • Marom, EM, Palmer, SM, Erasmus, JJ, Herndon, JE, Zhang, C, and McAdams, HP. "Pleural effusions in lung transplant recipients: image-guided small-bore catheter drainage." Radiology 228, no. 1 (July 2003): 241-245.  Full Text  Link to Item
    • Gururangan, S, McLaughlin, C, Quinn, J, Rich, J, Reardon, D, Halperin, EC, Herndon, J, Fuchs, H, George, T, Provenzale, J, Watral, M, McLendon, RE, Friedman, A, Friedman, HS, Kurtzberg, J, Vredenbergh, J, and Martin, PL. "High-dose chemotherapy with autologous stem-cell rescue in children and adults with newly diagnosed pineoblastomas." J Clin Oncol 21, no. 11 (June 1, 2003): 2187-2191.  Full Text  Link to Item
    • Akerley, W, Herndon, JE, Egorin, MJ, Lyss, AP, Kindler, HL, Savarese, DM, Sherman, CA, Rosen, DM, Hollis, D, Ratain, MJ, and Green, MR. "Weekly, high-dose paclitaxel in advanced lung carcinoma: a phase II study with pharmacokinetics by the Cancer and Leukemia Group B." Cancer 97, no. 10 (May 15, 2003): 2480-2486.  Full Text  Link to Item
    • Quinn, JA, Reardon, DA, Friedman, AH, Rich, JN, Sampson, JH, Provenzale, JM, McLendon, RE, Gururangan, S, Bigner, DD, Herndon, JE, Avgeropoulos, N, Finlay, J, Tourt-Uhlig, S, Affronti, ML, Evans, B, Stafford-Fox, V, Zaknoen, S, and Friedman, HS. "Phase II trial of temozolomide in patients with progressive low-grade glioma." J Clin Oncol 21, no. 4 (February 15, 2003): 646-651.  Full Text  Link to Item
    • Vokes, EE, Herndon, JE, Crawford, J, Leopold, KA, Perry, MC, Miller, AA, and Green, MR. "Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: cancer and leukemia group B study 9431." J Clin Oncol 20, no. 20 (October 15, 2002): 4191-4198.  Full Text  Link to Item
    • Elias, AD, Kumar, P, Herndon, J, Skarin, AT, Sugarbaker, DJ, and Green, MR. "Radiotherapy versus chemotherapy plus radiotherapy in surgically treated IIIA N2 non-small-cell lung cancer." Clin Lung Cancer 4, no. 2 (September 2002): 95-103.  Link to Item
    • Gururangan, S, Cavazos, CM, Ashley, D, Herndon, JE, Bruggers, CS, Moghrabi, A, Scarcella, DL, Watral, M, Tourt-Uhlig, S, Reardon, D, and Friedman, HS. "Phase II study of carboplatin in children with progressive low-grade gliomas." J Clin Oncol 20, no. 13 (July 1, 2002): 2951-2958.  Full Text  Link to Item
    • Marom, EM, Erasmus, JJ, Herndon, JE, Zhang, C, and McAdams, HP. "Usefulness of imaging-guided catheter drainage and talc sclerotherapy in patients with metastatic gynecologic malignancies and symptomatic pleural effusions." AJR Am J Roentgenol 179, no. 1 (July 2002): 105-108.  Full Text  Link to Item
    • Kornblith, AB, Herndon, JE, Silverman, LR, Demakos, EP, Odchimar-Reissig, R, Holland, JF, Powell, BL, DeCastro, C, Ellerton, J, Larson, RA, Schiffer, CA, and Holland, JC. "Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study." J Clin Oncol 20, no. 10 (May 15, 2002): 2441-2452.  Full Text  Link to Item
    • Rasheed, A, Herndon, JE, Stenzel, TT, Raetz, JGM, Kendelhardt, J, Friedman, HS, Friedman, AH, Bigner, DD, Bigner, SH, and McLendon, RE. "Molecular markers of prognosis in astrocytic tumors." Cancer 94, no. 10 (May 15, 2002): 2688-2697.  Link to Item
    • Marom, EM, Sarvis, S, Herndon, JE, and Patz, EF. "T1 lung cancers: sensitivity of diagnosis with fluorodeoxyglucose PET." Radiology 223, no. 2 (May 2002): 453-459.  Full Text  Link to Item
    • Naughton, MJ, Herndon, JE, Shumaker, SA, Miller, AA, Kornblith, AB, Chao, D, and Holland, J. "The health-related quality of life and survival of small-cell lung cancer patients: results of a companion study to CALGB 9033." Qual Life Res 11, no. 3 (May 2002): 235-248.  Link to Item
    • Quinn, JA, Pluda, J, Dolan, ME, Delaney, S, Kaplan, R, Rich, JN, Friedman, AH, Reardon, DA, Sampson, JH, Colvin, OM, Haglund, MM, Pegg, AE, Moschel, RC, McLendon, RE, Provenzale, JM, Gururangan, S, Tourt-Uhlig, S, Herndon, JE, Bigner, DD, and Friedman, HS. "Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma." J Clin Oncol 20, no. 9 (May 1, 2002): 2277-2283.  Full Text  Link to Item
    • D'Cunha, J, Corfits, AL, Herndon, JE, Kern, JA, Kohman, LJ, Patterson, GA, Kratzke, RA, and Maddaus, MA. "Molecular staging of lung cancer: real-time polymerase chain reaction estimation of lymph node micrometastatic tumor cell burden in stage I non-small cell lung cancer--preliminary results of Cancer and Leukemia Group B Trial 9761." J Thorac Cardiovasc Surg 123, no. 3 (March 2002): 484-491.  Link to Item
    • Reardon, DA, Akabani, G, Coleman, RE, Friedman, AH, Friedman, HS, Herndon, JE, Cokgor, I, McLendon, RE, Pegram, CN, Provenzale, JM, Quinn, JA, Rich, JN, Regalado, LV, Sampson, JH, Shafman, TD, Wikstrand, CJ, Wong, TZ, Zhao, X-G, Zalutsky, MR, and Bigner, DD. "Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas." J Clin Oncol 20, no. 5 (March 1, 2002): 1389-1397.  Full Text  Link to Item
    • Blackstock, AW, Herndon, JE, Paskett, ED, Perry, MC, Graziano, SL, Muscato, JJ, Kosty, MP, Akerley, WL, Holland, J, Fleishman, S, and Green, MR. "Outcomes among African-American/non-African-American patients with advanced non-small-cell lung carcinoma: report from the Cancer and Leukemia Group B." J Natl Cancer Inst 94, no. 4 (February 20, 2002): 284-290.  Link to Item
    • Lyss, AP, Herndon, JE, Lynch, TJ, Turrisi, AT, Watson, DM, Grethlein, SJ, and Green, MR. "Novel doublets in extensive-stage small-cell lung cancer: a randomized phase II study of topotecan plus cisplatin or paclitaxel (CALGB 9430)." Clin Lung Cancer 3, no. 3 (February 2002): 205-210.  Link to Item
    • Johnson, EA, Klimstra, DS, Herndon, JE, Catalano, E, Canellos, GP, Graziano, SL, Kern, JA, and Green, MR. "Aberrant p53 staining does not predict cisplatin resistance in locally advanced non-small cell lung cancer." Cancer Invest 20, no. 5-6 (2002): 686-692.  Link to Item
    • Rocha Lima, CMS, Herndon, JE, Kosty, M, Clamon, G, and Green, MR. "Therapy choices among older patients with lung carcinoma: an evaluation of two trials of the Cancer and Leukemia Group B." Cancer 94, no. 1 (January 1, 2002): 181-187.  Link to Item
    • Heyneman, LE, Herndon, JE, Goodman, PC, and Patz, EF. "Stage distribution in patients with a small (< or = 3 cm) primary nonsmall cell lung carcinoma. Implication for lung carcinoma screening." Cancer 92, no. 12 (December 15, 2001): 3051-3055.  Link to Item
    • Heyneman, LE, Herndon, JE, Goodman, PC, and Patz, EF. "Stage distribution in patients with a small (." Cancer 92, no. 12 (December 2001): 3051-3055. (Academic Article)
    • Kosty, MP, Herndon, JE, Vogelzang, NJ, Kindler, HL, and Green, MR. "High-dose doxorubicin, dexrazoxane, and GM-CSF in malignant mesothelioma: a phase II study-Cancer and Leukemia Group B 9631." Lung Cancer 34, no. 2 (November 2001): 289-295.  Link to Item
    • Marom, EM, Sarvis, S, Herndon, JE, and Patz, EF. "Accuracy of positron emission tomography with fluorodeoxyglucose in T1 lung cancer." RADIOLOGY 221 (November 2001): 408-408.  Link to Item
    • D'Amico, TA, Aloia, TA, Moore, MB, Conlon, DH, Herndon, JE, Kinch, MS, and Harpole, DH. "Predicting the sites of metastases from lung cancer using molecular biologic markers." Ann Thorac Surg 72, no. 4 (October 2001): 1144-1148.  Link to Item
    • Aloia, TA, Harpole, DH, Reed, CE, Allegra, C, Moore, MB, Herndon, JE, and D'Amico, TA. "Tumor marker expression is predictive of survival in patients with esophageal cancer." Ann Thorac Surg 72, no. 3 (September 2001): 859-866.  Link to Item
    • Anscher, MS, Marks, LB, Shafman, TD, Clough, R, Huang, H, Tisch, A, Munley, M, Herndon, JE, Garst, J, Crawford, J, and Jirtle, RL. "Using plasma transforming growth factor beta-1 during radiotherapy to select patients for dose escalation." J Clin Oncol 19, no. 17 (September 1, 2001): 3758-3765.  Full Text  Link to Item
    • Graziano, SL, Tatum, A, Herndon, JE, Box, J, Memoli, V, Green, MR, and Kern, JA. "Use of neuroendocrine markers, p53, and HER2 to predict response to chemotherapy in patients with stage III non-small cell lung cancer: a Cancer and Leukemia Group B study." Lung Cancer 33, no. 2-3 (August 2001): 115-123.  Link to Item
    • Marom, EM, Aloia, TA, Moore, MB, Hara, M, Herndon, JE, Harpole, DH, Goodman, PC, and Patz, EF. "Correlation of FDG-PET imaging with Glut-1 and Glut-3 expression in early-stage non-small cell lung cancer." Lung Cancer 33, no. 2-3 (August 2001): 99-107.  Link to Item
    • Kornblith, AB, Herndon, JE, Zuckerman, E, Godley, PA, Savarese, D, Vogelzang, NJ, and Cancer and Leukemia Group B (CALGB), . "The impact of docetaxel, estramustine, and low dose hydrocortisone on the quality of life of men with hormone refractory prostate cancer and their partners: a feasibility study." Ann Oncol 12, no. 5 (May 2001): 633-641.  Link to Item
    • Harpole, DH, Moore, MB, Herndon, JE, Aloia, T, D'Amico, TA, Sporn, T, Parr, A, Linoila, I, and Allegra, C. "The prognostic value of molecular marker analysis in patients treated with trimodality therapy for esophageal cancer." Clin Cancer Res 7, no. 3 (March 2001): 562-569.  Link to Item
    • Salgia, R, Harpole, D, Herndon, JE, Pisick, E, Elias, A, and Skarin, AT. "Role of serum tumor markers CA 125 and CEA in non-small cell lung cancer." Anticancer Res 21, no. 2B (March 2001): 1241-1246.  Link to Item
    • Kindler, HL, Millard, F, Herndon, JE, Vogelzang, NJ, Suzuki, Y, and Green, MR. "Gemcitabine for malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B." Lung Cancer 31, no. 2-3 (February 2001): 311-317.  Link to Item
    • Maguire, PD, Marks, LB, Sibley, GS, Herndon, JE, Clough, RW, Light, KL, Hernando, ML, Antoine, PA, and Anscher, MS. "73.6 Gy and beyond: hyperfractionated, accelerated radiotherapy for non-small-cell lung cancer." J Clin Oncol 19, no. 3 (February 1, 2001): 705-711.  Full Text  Link to Item
    • Niell, HB, Perry, MC, Clamon, G, Crawford, J, Miller, AA, Herndon, J, and Green, MR. "Carboplatin/etoposide/paclitaxel in the treatment of patients with extensive small-cell lung cancer." Clin Lung Cancer 2, no. 3 (February 2001): 204-209.  Link to Item
    • Kornblith, AB, Herndon, JE, Zuckerman, E, Viscoli, CM, Horwitz, RI, Cooper, MR, Harris, L, Tkaczuk, KH, Perry, MC, Budman, D, Norton, LC, Holland, J, and Cancer and Leukemia Group B, . "Social support as a buffer to the psychological impact of stressful life events in women with breast cancer." Cancer 91, no. 2 (January 15, 2001): 443-454.  Link to Item
    • Aloia, T, Bepler, G, Harpole, D, Goodman, PC, McAdams, HP, Erasmus, JJ, Herndon, JE, and Patz, EF. "Integration of peripheral blood biomarkers with computed tomography to differentiate benign from malignant pulmonary opacities." Cancer Detect Prev 25, no. 4 (2001): 336-343.  Link to Item
    • Cameron, CL, Cella, D, Herndon, JE, Kornblith, AB, Zuckerman, E, Henderson, E, Weiss, RB, Cooper, MR, Silver, RT, Leone, L, Canellos, GP, Peterson, BA, and Holland, JC. "Persistent symptoms among survivors of Hodgkin's disease: an explanatory model based on classical conditioning." Health Psychol 20, no. 1 (January 2001): 71-75.  Link to Item
    • Salgia, R, Harpole, D, II, JEH, Pisick, E, Elias, A, and Skarin, AT. "Role of serum tumor markers CA 125 and CEA in non-small cell lung cancer." Anticancer Research 21, no. 2 B (2001): 1241-1246.
    • Socinski, MA, Marks, LB, Garst, J, Sibley, GS, Blackstock, W, Turrisi, A, Herndon, J, Zhou, S, Anscher, M, Crawford, J, Shafman, T, and Rosenman, J. "Carboplatin/paclitaxel or carboplatin/vinorelbine followed by accelerated hyperfractionated conformal radiation therapy: a preliminary report of a phase I dose escalation trial from the Carolina Conformal Therapy Consortium." Oncologist 6 Suppl 1 (2001): 20-24.  Link to Item
    • Cokgor, I, Akabani, G, Kuan, CT, Friedman, HS, Friedman, AH, Coleman, RE, McLendon, RE, Bigner, SH, Zhao, XG, Garcia-Turner, AM, Pegram, CN, Wikstrand, CJ, Shafman, TD, Herndon, JE, Provenzale, JM, Zalutsky, MR, and Bigner, DD. "Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas." J Clin Oncol 18, no. 22 (November 15, 2000): 3862-3872.  Full Text  Link to Item
    • Friedman, HS, Pluda, J, Quinn, JA, Ewesuedo, RB, Long, L, Friedman, AH, Cokgor, I, Colvin, OM, Haglund, MM, Ashley, DM, Rich, JN, Sampson, J, Pegg, AE, Moschel, RC, McLendon, RE, Provenzale, JM, Stewart, ES, Tourt-Uhlig, S, Garcia-Turner, AM, Herndon, JE, Bigner, DD, and Dolan, ME. "Phase I trial of carmustine plus O6-benzylguanine for patients with recurrent or progressive malignant glioma." J Clin Oncol 18, no. 20 (October 15, 2000): 3522-3528.  Full Text  Link to Item
    • Farrell, MA, McAdams, HP, Herndon, JE, and Patz, EF. "Non-small cell lung cancer: FDG PET for nodal staging in patients with stage I disease." Radiology 215, no. 3 (June 2000): 886-890.  Full Text  Link to Item
    • Patz, EF, Rossi, S, Harpole, DH, Herndon, JE, and Goodman, PC. "Correlation of tumor size and survival in patients with stage IA non-small cell lung cancer." Chest 117, no. 6 (June 2000): 1568-1571.  Link to Item
    • Perry, MC, Ihde, DC, Herndon, JE, Grossbard, ML, Grethein, SJ, Atkins, JN, Vokes, EE, and Green, MR. "Paclitaxel/ifosfamide or navelbine/ifosfamide chemotherapy for advanced non-small cell lung cancer: CALGB 9532." Lung Cancer 28, no. 1 (April 2000): 63-68.  Link to Item
    • Akabani, G, Cokgor, I, Coleman, RE, González Trotter, D, Wong, TZ, Friedman, HS, Friedman, AH, Garcia-Turner, A, Herndon, JE, DeLong, D, McLendon, RE, Zhao, XG, Pegram, CN, Provenzale, JM, Bigner, DD, and Zalutsky, MR. "Dosimetry and dose-response relationships in newly diagnosed patients with malignant gliomas treated with iodine-131-labeled anti-tenascin monoclonal antibody 81C6 therapy." Int J Radiat Oncol Biol Phys 46, no. 4 (March 1, 2000): 947-958.  Link to Item
    • D'Amico, TA, Aloia, TA, Moore, MB, Herndon, JE, Brooks, KR, Lau, CL, and Harpole, DH. "Molecular biologic substaging of stage I lung cancer according to gender and histology." Ann Thorac Surg 69, no. 3 (March 2000): 882-886.  Link to Item
    • Patz, EF, Connolly, J, and Herndon, J. "Prognostic value of thoracic FDG PET imaging after treatment for non-small cell lung cancer." AJR Am J Roentgenol 174, no. 3 (March 2000): 769-774.  Full Text  Link to Item
    • Kindler, HL, Belani, CP, Herndon, JE, Vogelzang, NJ, Suzuki, Y, and Green, MR. "Edatrexate (10-ethyi-deaza-aminopterin) (NSC 626715) with or without leucovorin rescue for malignant mesothelioma: Sequential Phase II trials by the Cancer and Leukemia Group B." Cancer 86, no. 10 (November 15, 1999): 1985-1991.  Full Text
    • Kindler, HL, Belani, CP, Herndon, JE, Vogelzang, NJ, Suzuki, Y, and Green, MR. "Edatrexate (10-ethyl-deaza-aminopterin) (NSC #626715) with or without leucovorin rescue for malignant mesothelioma. Sequential phase II trials by the cancer and leukemia group B." Cancer 86, no. 10 (November 15, 1999): 1985-1991.  Link to Item
    • Hara, M, McAdams, HP, Vredenburgh, JJ, Herndon, JE, and Patz, EF. "Thymic hyperplasia after high-dose chemotherapy and autologous stem cell transplantation: incidence and significance in patients with breast cancer." AJR Am J Roentgenol 173, no. 5 (November 1999): 1341-1344.  Full Text  Link to Item
    • Marom, EM, McAdams, HP, Erasmus, JJ, Goodman, PC, Culhane, DK, Coleman, RE, Herndon, JE, and Patz, EF. "Staging non-small cell lung cancer with whole-body PET." Radiology 212, no. 3 (September 1999): 803-809.  Full Text  Link to Item
    • Maguire, PD, Sibley, GS, Zhou, SM, Jamieson, TA, Light, KL, Antoine, PA, Herndon, JE, Anscher, MS, and Marks, LB. "Clinical and dosimetric predictors of radiation-induced esophageal toxicity." Int J Radiat Oncol Biol Phys 45, no. 1 (August 1, 1999): 97-103.  Link to Item
    • Patz, EF, Erasmus, JJ, McAdams, HP, Connolly, JE, Marom, EM, Goodman, PC, Leder, RA, Keogan, MT, and Herndon, JE. "Lung cancer staging and management: comparison of contrast-enhanced and nonenhanced helical CT of the thorax." Radiology 212, no. 1 (July 1999): 56-60.  Full Text  Link to Item
    • Steele, GD, Herndon, JE, Bleday, R, Russell, A, Benson, A, Hussain, M, Burgess, A, Tepper, JE, and Mayer, RJ. "Sphincter-sparing treatment for distal rectal adenocarcinoma." Ann Surg Oncol 6, no. 5 (July 1999): 433-441.  Link to Item
    • Vogelzang, NJ, Herndon, JE, Miller, A, Strauss, G, Clamon, G, Stewart, FM, Aisner, J, Lyss, A, Cooper, MR, Suzuki, Y, and Green, MR. "High-dose paclitaxel plus G-CSF for malignant mesothelioma: CALGB phase II study 9234." Ann Oncol 10, no. 5 (May 1999): 597-600.  Link to Item
    • D'Amico, TA, Massey, M, Herndon, JE, Moore, MB, and Harpole, DH. "A biologic risk model for stage I lung cancer: immunohistochemical analysis of 408 patients with the use of ten molecular markers." J Thorac Cardiovasc Surg 117, no. 4 (April 1999): 736-743.  Link to Item
    • Herndon, JE, Fleishman, S, Kornblith, AB, Kosty, M, Green, MR, and Holland, J. "Is quality of life predictive of the survival of patients with advanced nonsmall cell lung carcinoma?." Cancer 85, no. 2 (February 2, 1999): 333-340.  Full Text
    • Herndon, JE, Fleishman, S, Kornblith, AB, Kosty, M, Green, MR, and Holland, J. "Is quality of life predictive of the survival of patients with advanced nonsmall cell lung carcinoma?." Cancer 85, no. 2 (January 15, 1999): 333-340.  Link to Item
    • Clamon, G, Herndon, J, Cooper, R, Chang, AY, Rosenman, J, and Green, MR. "Radiosensitization with carboplatin for patients with unresectable stage III non-small-cell lung cancer: a phase III trial of the Cancer and Leukemia Group B and the Eastern Cooperative Oncology Group." J Clin Oncol 17, no. 1 (January 1999): 4-11.  Full Text  Link to Item
    • Clamon, G, Herndon, J, Cooper, R, Chang, AY, Rosenman, J, and Green, MR. "Radiosensitization with Carboplatin for patients with unresectable stage III non-small-cell lung cancer: A phase III trial of the Cancer and Leukemia Group B and the Eastern Cooperative Oncology Group." Pneumologie 53, no. 5 (1999): M10-.
    • Marom, EM, Patz, EF, Erasmus, JJ, McAdams, HP, Goodman, PC, and Herndon, JE. "Malignant pleural effusions: treatment with small-bore-catheter thoracostomy and talc pleurodesis." Radiology 210, no. 1 (January 1999): 277-281.  Full Text  Link to Item
    • Patz, E, Adams, HM, Erasmus, J, Goodman, P, Culhane, D, Gilkeson, R, and Herndon, J. "Sclerotherapy for malignant pleural effusions." Pneumologie 53, no. 1 (1999): 44--.
    • Patz, E, McAdams, H, Erasmus, J, Goodman, P, Culhane, D, Gilkeson, R, and Herndon, J. "Sclerotherapy for malignant pleural effusions." Pneumologie 53, no. 2 (1999): 112--.
    • Perry, MC, III, JEH, Eaton, WL, and Green, MK. "Thoracic radiation therapy added to chemotherapy for small-cell lung cancer: An update of cancer and leukemia group B study 8083." Pneumologie 53, no. 2 (1999): 105--.
    • Shieh, DB, Godleski, J, Herndon, JE, Azuma, T, Mercer, H, Sugarbaker, DJ, and Kwiatkowski, DJ. "Cell motility as a prognostic factor in stage I nonsmall cell lung carcinoma: The role of gelsolin expression." Cancer 85, no. 1 (January 1, 1999): 47-57.  Full Text
    • Shieh, DB, Godleski, J, Herndon, JE, Azuma, T, Mercer, H, Sugarbaker, DJ, and Kwiatkowski, DJ. "Cell motility as a prognostic factor in Stage I nonsmall cell lung carcinoma: the role of gelsolin expression." Cancer 85, no. 1 (January 1, 1999): 47-57.  Link to Item
    • Choi, NC, Herndon, JE, Rosenman, J, Carey, RW, Chung, CT, Bernard, S, Leone, L, Seagren, S, and Green, M. "Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer." J Clin Oncol 16, no. 11 (November 1998): 3528-3536.  Full Text  Link to Item
    • Friedman, HS, Kokkinakis, DM, Pluda, J, Friedman, AH, Cokgor, I, Haglund, MM, Ashley, DM, Rich, J, Dolan, ME, Pegg, AE, Moschel, RC, McLendon, RE, Kerby, T, Herndon, JE, Bigner, DD, and Schold, SC. "Phase I trial of O6-benzylguanine for patients undergoing surgery for malignant glioma." J Clin Oncol 16, no. 11 (November 1998): 3570-3575.  Full Text  Link to Item
    • Herndon, JE. "A design alternative for two-stage, phase II, multicenter cancer clinical trials." Control Clin Trials 19, no. 5 (October 1998): 440-450.  Link to Item
    • Ahuja, V, Coleman, RE, Herndon, J, and Patz, EF. "The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with nonsmall cell lung carcinoma." Cancer 83, no. 5 (September 1, 1998): 918-924.  Link to Item
    • Ahuja, V, Edward Coleman, R, Herndon, J, and Patz, EF. "The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with nonsmall cell lung carcinoma." Cancer 83, no. 5 (September 1, 1998): 918-924.  Full Text
    • Graziano, SL, Kern, JA, Herndon, JE, Tatum, A, Brisson, ML, Memoli, V, Sugarbaker, D, Skarin, AT, Kreisman, H, and Green, MR. "Analysis of neuroendocrine markers, HER2 and CEA before and after chemotherapy in patients with stage IIIA non-small cell lung cancer: a Cancer and Leukemia Group B study." Lung Cancer 21, no. 3 (September 1998): 203-211.  Link to Item
    • Mehdi, SA, Perry, MC, Herndon, JE, Crawford, J, Young, R, and Graziano, SL. "A study of filgrastim (rG-CSF) priming of etoposide/cisplatin in advanced non-small cell lung cancer." J Interferon Cytokine Res 18, no. 8 (August 1998): 623-627.  Full Text  Link to Item
    • Kwiatkowski, DJ, Harpole, DH, Godleski, J, Herndon, JE, Shieh, DB, Richards, W, Blanco, R, Xu, HJ, Strauss, GM, and Sugarbaker, DJ. "Molecular pathologic substaging in 244 stage I non-small-cell lung cancer patients: clinical implications." J Clin Oncol 16, no. 7 (July 1998): 2468-2477.  Full Text  Link to Item
    • Perry, MC, Herndon, JE, Eaton, WL, and Green, MR. "Thoracic radiation therapy added to chemotherapy for small-cell lung cancer: an update of Cancer and Leukemia Group B Study 8083." J Clin Oncol 16, no. 7 (July 1998): 2466-2467.  Full Text  Link to Item
    • Bigner, DD, Brown, MT, Friedman, AH, Coleman, RE, Akabani, G, Friedman, HS, Thorstad, WL, McLendon, RE, Bigner, SH, Zhao, XG, Pegram, CN, Wikstrand, CJ, Herndon, JE, Vick, NA, Paleologos, N, Cokgor, I, Provenzale, JM, and Zalutsky, MR. "Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results." J Clin Oncol 16, no. 6 (June 1998): 2202-2212.  Full Text  Link to Item
    • Ahles, TA, Silberfarb, PM, Herndon, J, Maurer, LH, Kornblith, AB, Aisner, J, Perry, MC, Eaton, WL, Zacharski, LL, Green, MR, and Holland, JC. "Psychologic and neuropsychologic functioning of patients with limited small-cell lung cancer treated with chemotherapy and radiation therapy with or without warfarin: a study by the Cancer and Leukemia Group B." J Clin Oncol 16, no. 5 (May 1998): 1954-1960.  Full Text  Link to Item
    • Assi, Z, Caruso, JL, Herndon, J, and Patz, EF. "Cytologically proved malignant pleural effusions: distribution of transudates and exudates." Chest 113, no. 5 (May 1998): 1302-1304.  Link to Item
    • Graham, ML, Asselin, BL, Herndon, JE, Casey, JR, Chaffee, S, Ciocci, GH, Daeschner, CW, Davis, AR, Gold, S, Halperin, EC, Laughlin, MJ, Martin, PL, Olson, JF, and Kurtzberg, J. "Toxicity, pharmacology and feasibility of administration of PEG-L-asparaginase as consolidation therapy in patients undergoing bone marrow transplantation for acute lymphoblastic leukemia." Bone Marrow Transplant 21, no. 9 (May 1998): 879-885.  Full Text  Link to Item
    • Patz, EF, McAdams, HP, Erasmus, JJ, Goodman, PC, Culhane, DK, Gilkeson, RC, and Herndon, J. "Sclerotherapy for malignant pleural effusions: a prospective randomized trial of bleomycin vs doxycycline with small-bore catheter drainage." Chest 113, no. 5 (May 1998): 1305-1311.  Link to Item
    • Samuels, BL, Herndon, JE, Harmon, DC, Carey, R, Aisner, J, Corson, JM, Suzuki, Y, Green, MR, and Vogelzang, NJ. "Dihydro-5-azacytidine and cisplatin in the treatment of malignant mesothelioma: A Phase II study by the Cancer and Leukemia Group B." Cancer 82, no. 8 (April 15, 1998): 1578-1584.  Full Text
    • Samuels, BL, Herndon, JE, Harmon, DC, Carey, R, Aisner, J, Corson, JM, Suzuki, Y, Green, MR, and Vogelzang, NJ. "Dihydro-5-azacytidine and cisplatin in the treatment of malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B." Cancer 82, no. 8 (April 15, 1998): 1578-1584.  Link to Item
    • Herndon, JE, Green, MR, Chahinian, AP, Corson, JM, Suzuki, Y, and Vogelzang, NJ. "Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B." Chest 113, no. 3 (March 1998): 723-731.  Link to Item
    • Kornblith, AB, Herndon, JE, Zuckerman, E, Cella, DF, Cherin, E, Wolchok, S, Weiss, RB, Diehl, LF, Henderson, E, Cooper, MR, Schiffer, C, Canellos, GP, Mayer, RJ, Silver, RT, Schilling, A, Peterson, BA, Greenberg, D, and Holland, JC. "Comparison of psychosocial adaptation of advanced stage Hodgkin's disease and acute leukemia survivors. Cancer and Leukemia Group B." Ann Oncol 9, no. 3 (March 1998): 297-306.  Link to Item
    • Clamon, G, Herndon, J, Akerley, W, and Green, M. "Subcutaneous interleukin-2 as initial therapy for patients with extensive small cell lung cancer: a phase II trial of Cancer and Leukemia Group B." Lung Cancer 19, no. 1 (January 1998): 25-29.  Link to Item
    • Ryan, CW, Herndon, J, and Vogelzang, NJ. "A review of chemotherapy trials for malignant mesothelioma." Chest 113, no. 1 Suppl (January 1998): 66S-73S. (Review)  Link to Item
    • Ryan, CW, Herndon, J, and Vogelzang, NJ. "A review of chemotherapy trials for malignant mesothelioma." Chest 113, no. 1 SUPPL. (1998): 66S-73S.
    • Greenberg, DB, Kornblith, AB, Herndon, JE, Zuckerman, E, Schiffer, CA, Weiss, RB, Mayer, RJ, Wolchok, SM, and Holland, JC. "Quality of life for adult leukemia survivors treated on clinical trials of cancer and leukemia group b during the period 1971-1988: Predictors for later psychologic distress." Cancer 80, no. 10 (November 15, 1997): 1936-1944.  Full Text
    • Greenberg, DB, Kornblith, AB, Herndon, JE, Zuckerman, E, Schiffer, CA, Weiss, RB, Mayer, RJ, Wolchok, SM, and Holland, JC. "Quality of life for adult leukemia survivors treated on clinical trials of Cancer and Leukemia Group B during the period 1971-1988: predictors for later psychologic distress." Cancer 80, no. 10 (November 15, 1997): 1936-1944.  Link to Item
    • Maurer, LH, Herndon, JE, Hollis, DR, Aisner, J, Carey, RW, Skarin, AT, Perry, MC, Eaton, WL, Zacharski, LL, Hammond, S, and Green, MR. "Randomized trial of chemotherapy and radiation therapy with or without warfarin for limited-stage small-cell lung cancer: a Cancer and Leukemia Group B study." J Clin Oncol 15, no. 11 (November 1997): 3378-3387.  Full Text  Link to Item
    • Herndon, JE, Fleishman, S, Kosty, MP, and Green, MR. "A longitudinal study of quality of life in advanced non-small cell lung cancer: Cancer and Leukemia Group B (CALGB) 8931." Control Clin Trials 18, no. 4 (August 1997): 286-300.  Link to Item
    • Vogelzang, NJ, Herndon, JE, Cirrincione, C, Harmon, DC, Antman, KH, Corson, JM, Suzuki, Y, Citron, ML, and Green, MR. "Dihydro-5-azacytidine in malignant mesothelioma: A Phase II trial demonstrating activity accompanied by cardiac toxicity." Cancer 79, no. 11 (June 1, 1997): 2237-2242.  Full Text
    • Vokes, EE, Leopold, KA, Herndon, J, and Green, MR. "Investigations of new drugs in combination with cisplatin in stage III non-small cell lung cancer." Semin Oncol 24, no. 3 Suppl 8 (June 1997): S8-42-S8-45-. (Review)  Link to Item
    • Yogelzang, NJ, Herndon, JE, Cirrincione, C, Harmon, DC, Antman, KH, Corson, JM, Suzuki, Y, Citron, ML, and Green, MR. "Dihydro-5-azacytidine in malignant mesothelioma. A phase II trial demonstrating activity accompanied by cardiac toxicity. Cancer and Leukemia Group B." Cancer 79, no. 11 (June 1, 1997): 2237-2242.  Link to Item
    • Erasmus, JJ, Patz, EF, McAdams, HP, Murray, JG, Herndon, J, Coleman, RE, and Goodman, PC. "Evaluation of adrenal masses in patients with bronchogenic carcinoma using 18F-fluorodeoxyglucose positron emission tomography." AJR Am J Roentgenol 168, no. 5 (May 1997): 1357-1360.  Full Text  Link to Item
    • Graham, ML, Herndon, JE, Casey, JR, Chaffee, S, Ciocci, GH, Krischer, JP, Kurtzberg, J, Laughlin, MJ, Longee, DC, Olson, JF, Paleologus, N, Pennington, CN, and Friedman, HS. "High-dose chemotherapy with autologous stem-cell rescue in patients with recurrent and high-risk pediatric brain tumors." J Clin Oncol 15, no. 5 (May 1997): 1814-1823.  Full Text  Link to Item
    • Luikart, SD, Herndon, JE, Hollis, DR, MacDonald, M, Maurer, LH, Crawford, J, Clamon, GH, Wright, J, Perry, MC, Ozer, H, and Green, MR. "Phase I trial of etoposide, carboplatin, and GM-CSF in extensive small-cell lung cancer: a Cancer and Leukemia Group B study (CALGB 8832)." Am J Clin Oncol 20, no. 1 (February 1997): 24-30.  Link to Item
    • Vokes, EE, Leopold, KA, Herndon, J, and Green, MR. "Investigations of new drugs in combination with cisplatin in stage III non-small cell lung cancer." Seminars in Oncology 24, no. 3 SUPPL. 8 (1997): S842-S845.
    • Dillman, RO, Herndon, J, Seagren, SL, Eaton, WL, and Green, MR. "Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial." J Natl Cancer Inst 88, no. 17 (September 4, 1996): 1210-1215.  Link to Item
    • Mitchell, EP, Perry, MC, Luikart, SD, Cirrincione, CT, Van Echo, DA, Herndon, JE, Maurer, LH, Clamon, G, and Green, MR. "A phase I/II trial of etoposide and cisplatin in extensive small cell lung cancer: a cancer and leukemia group B study." Lung Cancer 15, no. 2 (September 1996): 215-223.  Link to Item
    • Brown, MT, Coleman, RE, Friedman, AH, Friedman, HS, McLendon, RE, Reiman, R, Felsberg, GJ, Tien, RD, Bigner, SH, Zalutsky, MR, Zhao, XG, Wikstrand, CJ, Pegram, CN, Herndon, JE, Vick, NA, Paleologos, N, Fredericks, RK, Schold, SC, and Bigner, DD. "Intrathecal 131I-labeled antitenascin monoclonal antibody 81C6 treatment of patients with leptomeningeal neoplasms or primary brain tumor resection cavities with subarachnoid communication: phase I trial results." Clin Cancer Res 2, no. 6 (June 1996): 963-972.  Link to Item
    • Graziano, SL, Valone, FH, Herndon, JE, Crawford, J, Richards, F, Rege, VB, Clamon, G, and Green, MR. "A randomized phase II study of ifosfamide/mesna/cisplatin plus G-CSF or etoposide/cisplatin plus G-CSF in advanced non-small cell lung cancer: a Cancer and Leukemia Group B study." Lung Cancer 14, no. 2-3 (June 1996): 315-329.  Link to Item
    • Kumar, P, Herndon, J, Langer, M, Kohman, LJ, Elias, AD, Kass, FC, Eaton, WL, Seagren, SL, Green, MR, and Sugarbaker, DJ. "Patterns of disease failure after trimodality therapy of nonsmall cell lung carcinoma pathologic Stage IIIA (N2): Analysis of Cancer and Leukemia Group B Protocol 8935." Cancer 77, no. 11 (June 1, 1996): 2393-2399.  Full Text
    • Kumar, P, Herndon, J, Langer, M, Kohman, LJ, Elias, AD, Kass, FC, Eaton, WL, Seagren, SL, Green, MR, and Sugarbaker, DJ. "Patterns of disease failure after trimodality therapy of nonsmall cell lung carcinoma pathologic stage IIIA (N2). Analysis of Cancer and Leukemia Group B Protocol 8935." Cancer 77, no. 11 (June 1, 1996): 2393-2399.  Full Text  Link to Item
    • Tross, S, Herndon, J, Korzun, A, Kornblith, AB, Cella, DF, Holland, JF, Raich, P, Johnson, A, Kiang, DT, Perloff, M, Norton, L, Wood, W, and Holland, JC. "Psychological symptoms and disease-free and overall survival in women with stage II breast cancer. Cancer and Leukemia Group B." J Natl Cancer Inst 88, no. 10 (May 15, 1996): 661-667.  Link to Item
    • Harpole, DH, Richards, WG, Herndon, JE, and Sugarbaker, DJ. "Angiogenesis and molecular biologic substaging in patients with stage I non-small cell lung cancer." Ann Thorac Surg 61, no. 5 (May 1996): 1470-1476.  Full Text  Link to Item
    • Halperin, EC, Herndon, J, Schold, SC, Brown, M, Vick, N, Cairncross, JG, Macdonald, DR, Gaspar, L, Fischer, B, Dropcho, E, Rosenfeld, S, Morowitz, R, Piepmeier, J, Hait, W, Byrne, T, Salter, M, Imperato, J, Khandekar, J, Paleologos, N, Burger, P, Bentel, GC, and Friedman, A. "A phase III randomized prospective trial of external beam radiotherapy, mitomycin C, carmustine, and 6-mercaptopurine for the treatment of adults with anaplastic glioma of the brain. CNS Cancer Consortium." Int J Radiat Oncol Biol Phys 34, no. 4 (March 1, 1996): 793-802.  Link to Item
    • Bogart, JA, U'Afson, D, McClay, EF, Evans, L, and Herndon, JE. "Interruptions of modest dose once-daily (QD) thoracic radiotherapy (TRT) do not correlate with outcome in limited small cell lung cancer (L-SCLC): Analysis of CALGB 9235." Cancer Journal 9, no. 6 (1996): 504--.
    • Tross, S, II, JH, Korzun, A, Kornblith, AB, Cella, DF, Holland, JF, Raich, P, Johnson, A, Kiang, DT, Perloff, M, Norton, L, Wood, W, and Holland, JC. "Psychological symptoms and disease-free and overall survival in women with stage II breast cancer." Journal of the National Cancer Institute 88, no. 10 (1996): 661-667.  Full Text
    • Bigner, DD, Archer, GE, McLendon, RE, Friedman, HS, Fuchs, HE, Pai, LH, Herndon, JE, and Pastan, IH. "Efficacy of compartmental administration of immunotoxin LMB-1 (B3-LysPE38) in a rat model of carcinomatous meningitis." Clin Cancer Res 1, no. 12 (December 1995): 1545-1555.  Link to Item
    • Muscato, JJ, Cirrincione, C, Clamon, G, Perry, MC, Omura, G, Berkowitz, I, Reid, T, Herndon, JE, and Green, MR. "Etoposide (VP-16) and cisplatin at maximum tolerated dose in non-small cell lung carcinoma: a Cancer and Leukemia Group B study." Lung Cancer 13, no. 3 (December 1995): 285-294.  Link to Item
    • Patz, EF, Lowe, VJ, Goodman, PC, and Herndon, J. "Thoracic nodal staging with PET imaging with 18FDG in patients with bronchogenic carcinoma." Chest 108, no. 6 (December 1995): 1617-1621.  Link to Item
    • Herndon, JE, and Harrell, FE. "The restricted cubic spline as baseline hazard in the proportional hazards model with step function time-dependent covariables." Stat Med 14, no. 19 (October 15, 1995): 2119-2129.  Link to Item
    • Harpole, DH, Herndon, JE, Young, WG, Wolfe, WG, and Sabiston, DC. "Stage I nonsmall cell lung cancer. A multivariate analysis of treatment methods and patterns of recurrence." Cancer 76, no. 5 (September 1, 1995): 787-796.  Link to Item
    • Miller, AA, Herndon, JE, Hollis, DR, Ellerton, J, Langleben, A, Richards, F, and Green, MR. "Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive-stage small-cell lung cancer: a randomized phase III study of the Cancer and Leukemia Group B." J Clin Oncol 13, no. 8 (August 1995): 1871-1879.  Full Text  Link to Item
    • Harpole, DH, Marks, JR, Richards, WG, Herndon, JE, and Sugarbaker, DJ. "Localized adenocarcinoma of the lung: oncogene expression of erbB-2 and p53 in 150 patients." Clin Cancer Res 1, no. 6 (June 1995): 659-664.  Link to Item
    • Kosty, MP, Herndon, JE, Green, MR, and McIntyre, OR. "Placebo-controlled randomized study of hydrazine sulfate in lung cancer." J Clin Oncol 13, no. 6 (June 1995): 1529-1530. (Letter)  Full Text  Link to Item
    • Pastan, IH, Archer, GE, McLendon, RE, Friedman, HS, Fuchs, HE, Wang, QC, Pai, LH, Herndon, J, and Bigner, DD. "Intrathecal administration of single-chain immunotoxin, LMB-7 [B3(Fv)-PE38], produces cures of carcinomatous meningitis in a rat model." Proc Natl Acad Sci U S A 92, no. 7 (March 28, 1995): 2765-2769.  Link to Item
    • Sugarbaker, DJ, Herndon, J, Kohman, LJ, Krasna, MJ, and Green, MR. "Results of cancer and leukemia group B protocol 8935. A multiinstitutional phase II trimodality trial for stage IIIA (N2) non-small-cell lung cancer. Cancer and Leukemia Group B Thoracic Surgery Group." J Thorac Cardiovasc Surg 109, no. 3 (March 1995): 473-483.  Link to Item
    • Bitran, JD, Green, M, Perry, M, Hollis, DR, and Herndon, JE. "A phase II study of recombinant interferon-gamma following combination chemotherapy for patients with extensive small cell lung cancer. CALGB." Am J Clin Oncol 18, no. 1 (February 1995): 67-70.  Link to Item
    • Harpole, DH, Herndon, JE, Wolfe, WG, Iglehart, JD, and Marks, JR. "A prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation, histopathology, and oncoprotein expression." Cancer Res 55, no. 1 (January 1, 1995): 51-56.  Link to Item
    • Harpole, DH, Herndon, JE, Young, WG, Wolfe, WG, and Sabiston, DC. "Stage I nonsmall cell lung cancer. A multivariate analysis of treatment methods and patterns of recurrence." Cancer 76, no. 5 (January 1, 1995): 787-796.  Full Text
    • Sugarbaker, DJ, Herndon, J, Kohman, LJ, Krasna, MJ, and Green, MR. "Results of cancer and leukemia group B protocol 8935. A multiinstitutional phase II trimodality trial for stage IIIa (N2) non-small-cell lung cancer." The Journal of Thoracic and Cardiovascular Surgery 109, no. 3 (1995): 473-485.  Full Text
    • Deutsch, M, Crawford, J, Leopold, K, Wolfe, W, Foster, W, Herndon, J, Blackwell, S, and Yost, R. "Phase II study of neoadjuvant chemotherapy and radiation therapy with thoracotomy in the treatment of clinically staged IIIA non-small cell lung cancer." Cancer 74, no. 4 (August 15, 1994): 1243-1252.  Link to Item
    • Seagren, SL, Herndon, JE, Baeker, JR, Boles, M, Chung, C, and Green, MR. "Alternating irradiation and chemotherapy in stage III A and B nonsmall cell lung cancer: report of a cancer and Leukemia Group B phase II study 8636." Int J Radiat Oncol Biol Phys 29, no. 5 (July 30, 1994): 1085-1088.  Link to Item
    • Vogelzang, NJ, Weissman, LB, Herndon, JE, Antman, KH, Cooper, MR, Corson, JM, and Green, MR. "Trimetrexate in malignant mesothelioma: A Cancer and Leukemia Group B Phase II study." J Clin Oncol 12, no. 7 (July 1994): 1436-1442.  Full Text  Link to Item
    • Green, MR, Kosty, MP, Muscato, JJ, Graziano, S, Dillman, RO, Clamon, GH, and Herndon, J. "Nonoperative management of non-small cell lung cancer: the current cancer and leukemia group B experience." Semin Oncol 21, no. 3 Suppl 6 (June 1994): 60-65. (Review)  Link to Item
    • Kosty, MP, Fleishman, SB, Herndon, JE, Coughlin, K, Kornblith, AB, Scalzo, A, Morris, JC, Mortimer, J, and Green, MR. "Cisplatin, vinblastine, and hydrazine sulfate in advanced, non-small-cell lung cancer: a randomized placebo-controlled, double-blind phase III study of the Cancer and Leukemia Group B." J Clin Oncol 12, no. 6 (June 1994): 1113-1120.  Full Text  Link to Item
    • Wheeler, RH, Herndon, JE, Clamon, GH, and Green, MR. "A phase II study of recombinant beta-interferon at maximum tolerated dose in patients with advanced non-small cell lung cancer: a cancer and leukemia group B study." J Immunother Emphasis Tumor Immunol 15, no. 3 (April 1994): 212-216.  Link to Item
    • Rasheed, BK, McLendon, RE, Herndon, JE, Friedman, HS, Friedman, AH, Bigner, DD, and Bigner, SH. "Alterations of the TP53 gene in human gliomas." Cancer Res 54, no. 5 (March 1, 1994): 1324-1330.  Link to Item
    • Clamon, G, Herndon, J, Eaton, W, Rosenman, J, Maurer, LH, Cooper, MR, and Green, MR. "A feasibility study of extended chemotherapy for locally advanced non-small cell lung cancer: a phase II trial of cancer and leukemia group B." Cancer Invest 12, no. 3 (1994): 273-282.  Link to Item
    • Green, MR, Kosty, MP, Muscato, JJ, Graziano, S, Dillman, RO, Clamon, GH, and II, JH. "Nonoperative management of non-small cell lung cancer: The current Cancer and Leukemia Group B experience." Seminars in Oncology 21, no. 3 SUPPL. 6 (1994): 60-65.
    • Kornblith, AB, Hollis, DR, Zuckerman, E, Lyss, AP, Canellos, GP, Cooper, MR, Herndon, JE, Phillips, CA, Abrams, J, and Aisner, J. "Effect of megestrol acetate on quality of life in a dose-response trial in women with advanced breast cancer. The Cancer and Leukemia Group B." J Clin Oncol 11, no. 11 (November 1993): 2081-2089.  Full Text  Link to Item
    • Chahinian, AP, Antman, K, Goutsou, M, Corson, JM, Suzuki, Y, Modeas, C, Herndon, JE, Aisner, J, Ellison, RR, and Leone, L. "Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B." J Clin Oncol 11, no. 8 (August 1993): 1559-1565.  Full Text  Link to Item
    • Halperin, EC, Gaspar, L, Imperato, J, Salter, M, Herndon, J, and Dowling, S. "An analysis of radiotherapy data from the CNS cancer consortium's randomized prospective trial comparing AZQ to BCNU in the treatment of patients with primary malignant brain tumors. The CNS cancer consortium." Am J Clin Oncol 16, no. 4 (August 1993): 277-283.  Link to Item
    • Graziano, SL, Herndon, JE, Richards, F, DiFino, S, Modeas, C, Duggan, DB, and Green, MR. "A phase I trial of ifosfamide, mesna, and cisplatin in advanced non-small cell lung cancer. A cancer and leukemia group B study." Cancer 72, no. 1 (July 1, 1993): 62-68.  Link to Item
    • Clamon, G, Herndon, J, Perry, MC, Ozer, H, Kreisman, H, Maher, T, Ellerton, J, and Green, MR. "Interleukin-2 activity in patients with extensive small-cell lung cancer: a phase II trial of Cancer and Leukemia Group B." J Natl Cancer Inst 85, no. 4 (February 17, 1993): 316-320.  Link to Item
    • Graziano, SL, Herndon, JE, Richards, F, Difino, S, Modeas, C, Duggan, DB, and Green, MR. "A phase I trial of ifosfamide, mesna, and cisplatin in advanced non‐small cell lung cancer a cancer and leukemia group B study." Cancer 72, no. 1 (January 1, 1993): 62-68.  Full Text
    • Schold, SC, Herndon, JE, Burger, PC, Halperin, EC, Vick, NA, Cairncross, JG, Macdonald, DR, Dropcho, EJ, Morawetz, R, and Bigner, DD. "Randomized comparison of diaziquone and carmustine in the treatment of adults with anaplastic glioma." J Clin Oncol 11, no. 1 (January 1993): 77-83.  Full Text  Link to Item
    • Vokes, EE, Lyss, AP, Herndon, JE, Cooper, B, Perry, MC, Vinciguerra, V, Mason-Coughlin, K, and Green, MR. "Intravenous 6-thioguanine or cisplatin, fluorouracil and leucovorin for advanced non-small cell lung cancer: a randomized phase II study of the cancer and leukemia group B." Ann Oncol 3, no. 9 (November 1992): 727-732.  Link to Item
    • Vokes, EF, Lyss, AP, Herndon, JE, Cooper, B, Perry, MC, Vinciguerra, V, Mason-coughlin, K, and Green, MR. "Original article: Intravenous 6-thioguanine or cisplatin, fluorouracil and leucovorin for advanced non-small cell lung cancer: A randomized phase II study of the cancer and leukemia group B." Annals of Oncology 3, no. 9 (November 1, 1992): 727-732.
    • Lyss, AP, Perry, MC, Goutsou, M, Propert, K, Herndon, JE, Mason-Coughlin, K, and Green, MR. "Intensive etoposide and carboplatin chemotherapy for advanced non-small-cell lung cancer. A phase II trial of the Cancer and Leukemia Group B." Am J Clin Oncol 15, no. 5 (October 1992): 399-404.  Link to Item
    • Sketch, MH, Quigley, PJ, Perez, JA, Davidson, CJ, Muhlestein, JB, Herndon, JE, Glower, DD, Phillips, HR, Califf, RM, and Stack, RS. "Angiographic follow-up after internal mammary artery graft angioplasty." Am J Cardiol 70, no. 3 (August 1, 1992): 401-403.  Link to Item
    • Strauss, GM, Herndon, JE, Sherman, DD, Mathisen, DJ, Carey, RW, Choi, NC, Rege, VB, Modeas, C, and Green, MR. "Neoadjuvant chemotherapy and radiotherapy followed by surgery in stage IIIA non-small-cell carcinoma of the lung: report of a Cancer and Leukemia Group B phase II study." J Clin Oncol 10, no. 8 (August 1992): 1237-1244.  Full Text  Link to Item
    • Panella, TJ, Smith, DC, Schold, SC, Rogers, MP, Winer, EP, Fine, RL, Crawford, J, Herndon, JE, and Trump, DL. "Modulation of O6-alkylguanine-DNA alkyltransferase-mediated carmustine resistance using streptozotocin: a phase I trial." Cancer Res 52, no. 9 (May 1, 1992): 2456-2459.  Link to Item
    • Glantz, MJ, Burger, PC, Herndon, JE, Friedman, AH, Cairncross, JG, Vick, NA, and Schold, SC. "Influence of the type of surgery on the histologic diagnosis in patients with anaplastic gliomas." Neurology 41, no. 11 (November 1991): 1741-1744.  Link to Item
    • Nelson, CL, Herndon, JE, Mark, DB, Pryor, DB, Califf, RM, and Hlatky, MA. "Relation of clinical and angiographic factors to functional capacity as measured by the Duke Activity Status Index." Am J Cardiol 68, no. 9 (October 1, 1991): 973-975.  Link to Item
    • Davidoff, AM, Herndon, JE, Glover, NS, Kerns, BJ, Pence, JC, Iglehart, JD, and Marks, JR. "Relation between p53 overexpression and established prognostic factors in breast cancer." Surgery 110, no. 2 (August 1991): 259-264.  Link to Item
    • Glantz, MJ, Hoffman, JM, Coleman, RE, Friedman, AH, Hanson, MW, Burger, PC, Herndon, JE, Meisler, WJ, and Schold, SC. "Identification of early recurrence of primary central nervous system tumors by [18F]fluorodeoxyglucose positron emission tomography." Ann Neurol 29, no. 4 (April 1991): 347-355.  Full Text  Link to Item
    • Doll, D, Goutsou, M, Graziano, S, Ellerton, J, Bitran, J, Modeas, C, Herndon, J, Perry, M, and Green, M. "Carboplatin and vinblastine in advanced non-small-cell lung cancer: a phase II study." Cancer Chemother Pharmacol 29, no. 1 (1991): 71-74.  Link to Item
    • HERNDON, JE, and HARRELL, FE. "THE RESTRICTED CUBIC SPLINE HAZARD MODEL." COMMUNICATIONS IN STATISTICS-THEORY AND METHODS 19, no. 2 (1990): 639-663.  Full Text  Link to Item
    • Gururangan, S, Cokgor, L, Rich, JN, Edwards, S, Affronti, ML, Quinn, JA, Herndon, JE, Provenzale, JM, McLendon, RE, Tourt-Uhlig, S, Sampson, JH, Stafford-Fox, V, Zaknoen, S, Early, M, Friedman, AH, and Friedman, HS. "Phase I study of Gliadel wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas." Neuro Oncol 3, no. 4: 246-250.  Link to Item

  • Other Articles

    • Abernethy, AP, II, JEH, Coan, A, Staley, T, Wheeler, JL, Rowe, K, Smith, SK, Shaw, H, and Lyerly, HK. "Erratum: Phase 2 pilot study of Pathfinders: A psychosocial intervention for cancer patients (Support Care Center DOI 10.1007/s00520-010-0823-z)." Supportive Care in Cancer 19, no. 3 (2011): 439--.  Full Text
    • Kwiatkowski, DJ, Jr, DHH, Godlewski, J, II, JEH, Shieh, D-B, Richards, W, Blanco, R, Xu, H-J, Strauss, GM, and Sugarbaker, DJ. "Molecular pathologic substaging in 244 stage I non-small-cell lung cancer patients: Clinical implications." Pneumologie 53, no. 2 (1999): 105--.

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.